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Abstract 
Resistance to β-lactam antibiotics by pathogenic bacteria is a global concern. 
Typically arising between 2 and 3 years after the introduction of the antibiotic into 
clinical use, it is usually due to β-lactamase activity. The gene for IMP-1, a metallo-β-
lactamase with two catalytic metal ions, is located on an extremely mobile integron 
element, enabling the rapid horizontal transfer of β-lactam resistance between bacterial 
species, including genera of pathogenically relevant bacteria. Along with the absence of 
any viable metallo-β-lactamase inhibitors, this gene mobility makes IMP-1 particularly 
problematic in the clinical environment. Chapter two of this thesis reports nuclear 
magnetic resonance (NMR) analysis of IMP-1. 90% of the backbone amide resonances 
of IMP-1 were assigned using conventional 3D NMR experiments along with selective 
isotope labelling using cell-free methods. IMP-1 was found to have a high affinity for 
iron through the course of this study. The iron form was structurally and biochemically 
characterised using several techniques. A 1.8 Å crystal structure of the iron variant was 
solved, showing a tertiary structure almost identical to the previously solved X-ray 
structures of the di-zinc form. NMR analysis suggested subtle differences in structure 
and/or mobility between the two species.  
Observed paramagnetic NMR effects induced by the iron centre included 
paramagnetic relaxation enhancement (PRE), which located the metal centre in the 
active site. Pseudocontact shifts (PCS) were also evident and a magnetic susceptibility 
anisotropy (Δχ) tensor was calculated. Paramagnetic NMR methods concurred with 
anomalous X-ray scattering experiments, locating the metal-binding site of the iron ion. 
A protocol for the use of paramagnetic effects from the iron centre in a high-throughput 
drug screening is proposed. 
A novel method of generating perdeuterated proteins using cell-free protein 
synthesis with isotope-labelled amino acids is described in chapter three. Performing the 
cell-free reaction in H2O-based buffers avoids the need for back-exchange of protons 
onto the backbone amides, which would be required following expressions in D2O. This 
is particularly useful for cases where protein refolding is impossible, such as the IMP-1 
metallo-β-lactamase. For proteins that can be expressed in good yields, the cost 
 X 
difference compared to conventional isotope-labelling methods is minimal. This chapter 
includes a reproduction of the application note produced for Cambridge Isotope 
Laboratories. 
The use of hyperpolarising agents such as para-hydrogen has recently 
engendered much interest in the NMR community. This methodology promises up to 
350-fold signal-to-noise improvements over conventional experiments that start with a 
Boltzmann thermal population. Chapter four of this thesis briefly documents the 
establishment of an in-house built para-hydrogen producing rig in preparation for future 
studies into hyperpolarisation techniques. A standard operating procedure for obtaining 
optimal yields is also included. 
Structure determination of chemical products isolated from natural sources is an 
essential part of the natural drug discovery process. Chapter five briefly documents how 
NMR was used in this step for a natural product with pro-angiogenic biological 
properties extracted from soybean extracellular fluids that proved difficult to identify 
via other methods. 
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1 Introduction to Paramagnetic NMR and  
Outline of Thesis 
Paramagnetic NMR is of particular interest to the author and has constituted a 
large portion of this body of work both theoretically and practically. The following 
introduction reviews paramagnetism in NMR, contextualising the major component of 
this work, documented in chapter two. 
1.1 Paramagnetism in Structural NMR 
The magnetic moment of an electron is 658 times larger than that of a proton.* 
Consequently, interactions between the nucleus and an unpaired electron can cause 
much larger effects in the NMR experiment than bi-nuclear interactions. Paramagnetic 
species can generate four long-range effects that provide structural information about 
the system: paramagnetic relaxation enhancement (PRE), residual dipolar couplings 
(RDCs), paramagnetic shifts (Fermi contact shifts (FCSs) and pseudocontact shifts 
(PCSs)), and cross-correlation between the Curie-spin and dipole-dipole relaxation 
(CCR).3-6 These four effects can be conveniently measured in a 15N-HSQC experiment 
by comparison of a diamagnetic state to the paramagnetic state.3 They depend on the 
magnetic susceptibility tensor (χ tensor), which is related to the electron g-factor by7 
 
(1.1) 
where µ0 is the permeability of free space, NA is Avogadro’s number, µB is the magnetic 
moment of the free electron, S is the electron spin quantum number, k is the Boltzmann 
constant and T is the temperature. This equation assumes that the zero-field splitting is 
negligible compared to the electron spin Zeeman energy.4-7 
 
* The proton magnetic moment (µp) is equal to 1.410606743 x 10-26 JT -1, where the electron magnetic moment (µB) is 
equal to -928.476430 x 10-26 JT -1.1,2 
χ = g2 · µ0NAµ
2
BS(S + 1)
3kT
 2 
The relationship between the χ tensor and the g-factor means that, in general, 
systems with an anisotropic g-factor will have an anisotropic χ tensor. The anisotropy of 
the χ tensor can be described by the Δχ tensor with axial and rhombic components:3,4 
 
(1.2) 
 (1.3) 
For systems with isotropic χ tensors, only the PRE effect is significant, whereas 
all four effects occur in systems with anisotropic χ tensors.3,4 The four effects are 
described in the following sections. 
1.1.1 Paramagnetic Relaxation Enhancement 
Paramagnetic centres generally cause line broadening due to paramagnetic 
relaxation enhancement (PRE). Two mechanisms contribute to this relaxation – 
Solomon-Bloembergen-type dipole-dipole relaxation and Curie-spin magnetic moment 
relaxation – as reviewed below. 
PRE due to Dipole-Dipole Interactions (Solomon-Bloembergen Type 
Relaxation) 
The first description of PRE relaxation is based on dipole-dipole interactions 
between the nucleus and the unpaired electron. Modified Solomon-Bloembergen 
equations can describe longitudinal (Γ1) and transverse (Γ2) PRE rates, and are 
described in terms of the probability of nuclear spin-flipping involving ωI or ωS (single-
quantum transition frequencies of the nucleus or electron), or the sum or difference of 
ωI and ωS (double- and zero-quantum transitions):4,6-11 
  
∆χax = χz − χx + χy
2
∆χrh = χx − χy
 3 
 
(1.4) 
 
(1.5) 
where γI is the gyromagnetic ratio of the nucleus, ωI and ωS are the Larmor frequencies 
of the nucleus and electron respectively and A/ħ is the contact coupling constant, which 
is non-zero only for nuclei coordinated with the metal ion. τc and τf in the above 
equations are composed of the correlation times of the mechanisms of relaxation, 
namely the electron relaxation time (τs), the rotational correlation time (τr) and the 
exchange time (τM):4 
 
(1.6) 
The electron relaxation time is much faster than the rotational correlation time 
for most metal ions, and the exchange time is generally negligible for metallo-enzymes. 
τM may be small for non-covalent PRE inducing tags, however, it is usually much 
longer than the electron relaxation time. 
From these equations, it can be seen that both Γ1 and Γ2 have an r -6 distance 
dependence. For most metal ions, there is little dependence on the rotational correlation 
time (τr) due to the short electron relaxation time (τs), but significant dependence on the 
gyromagnetic ratio of the nucleus particularly for transverse relaxation, where nuclei 
with lower gyromagnetic ratio such as 15N and 13C will suffer less from PRE than 1H or 
19F. It follows that longer distances can be measured on 1H than on heteronuclei. These 
equations rely on the assumption that electron relaxation arises from molecular motions 
Γ1 =
2
15
￿µ0
4π
￿2 γ2I g2eµ2BS(S + 1)
r6
×
￿
τc
1 + (ωI − ωS)2τ2c
+
3τc
1 + ω2I τ
2
c
+
6τc
1 + (ωI + ωS)2τ2c
￿
+
2
3
S(S + 1)
￿
A
￿
￿2 ￿ τf
1 + ω2Sτ
2
f
￿
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1
15
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r6
×
￿
4τc +
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+
3τc
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2
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6τc
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2
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￿
+
1
3
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￿
A
￿
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τf
1 + ω2Sτ
2
f
￿
τ−1f = τ
−1
s + τ
−1
M
τ−1c = τ
−1
s + τ
−1
r + τ
−1
M
where τ−1s ￿ τ−1r
and τ−1M ￿ 0
∴ τ−1f ￿ τ−1c ￿ τ−1s
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other than rotational tumbling.7,11 Notably, however, molecular reorientation 
significantly contributes to electron relaxation.12,13 
PRE due to Magnetic Susceptibility (Curie-Spin Relaxation) 
The second mechanism for the PRE effect is described by magnetic 
susceptibility, or Curie-spin relaxation, where longitudinal PRE (Γ1) and transverse PRE 
(Γ2) relaxation rates are described by4,6-11 
 
(1.7) 
 
(1.8) 
τc in the above equations is determined by the sum of the inverse correlation 
times of different mechanisms of relaxation. In contrast to dipole-dipole relaxation, τs 
does not appear in the equations because the notion of a Curie-spin assumes extremely 
fast electron relaxation:4 
 
(1.9) 
This leaves the exchange time (τM), which is generally negligible for metallo-
enzymes, so that τc is often equivalent to τr. τM is not zero for non-covalent PRE 
inducing tags and is not necessarily insignificant compared to the contribution from the 
rotational correlation time. It is interesting to note that paramagnetic labelling is also 
useful in solid-state NMR, particularly as it has been shown that the Curie-spin 
contribution to PRE is absent in solids due to the absence of molecular tumbling.14 
From the above equations, the same r -6 distance dependence is evident as for 
dipole-dipole relaxation. In contrast, however, there is a B02 dependence. There is also 
an inverse dependence on temperature T. This is compounded by the fact that τr 
increases with decreasing temperature. As in the case of dipole-dipole relaxation, there 
is a quadratic dependence on the gyromagnetic ratio of the nucleus. 
  
Γ1 =
2
5
￿µ0
4π
￿2￿B0γIg2eµ2BS(S + 1)
3kTr3
￿2
×
￿
3τr
1 + ω2I τ
2
r
￿
Γ2 =
1
5
￿µ0
4π
￿2￿B0γIg2eµ2BS(S + 1)
3kTr3
￿2
×
￿
4τr +
3τr
1 + ω2I τ
2
r
￿
τ−1c = τ
−1
r + τ
−1
M
where τ−1M ￿ 0
∴ τ−1c ￿ τ−1r
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PRE for Structural Measurements 
As the Curie-spin relaxation mechanism of PRE depends largely on τr and not τs, 
the Curie-spin relaxation mechanism becomes particularly important for samples with 
large τr, such as proteins. Conversely, the Solomon-Bloembergen-type dipole-dipole 
relaxation relies heavily on τs. Therefore, where τr is much greater than τs, as is the case 
for all lanthanide(III) ions other than Gd(III), the Curie-spin predominates the 
transverse relaxation mechanism.6,13 For electrons where the electron spin-state is 
longer-lived than the rotational correlation time, the Solomon-Bloembergen-type 
dipole-dipole relaxation mechanism predominates the PRE relaxation. Bertini et al. 
described the cross-correlation between the Curie-spin relaxation mechanism to dipole-
dipole interactions that causes errors in PRE calculations (section 1.1.3).2 In the extreme 
case, this error can even cause the paramagnetic state to have a slower relaxation than 
the diamagnetic state. For this reason, PRE measurements are usually applied using 
unpaired electrons with long spin-state life times to make the dipole-dipole relaxation 
PRE mechanism predominant (such as for Mn(II), Gd(III) or the nitroxide radical).3  
Regardless of the mechanism of relaxation enhancement, the r -6 distance 
dependence is the basis of structural information gained from PRE measurements, 
somewhat akin to distance restraints from NOE measurements. Unfortunately, 
additional effects complicate practical experimental work with biomolecules ligated 
with paramagnetic metal-binding tags. The importance of taking tag flexibility into 
account when calculating structures via PRE measurements has been pointed out in the 
literature.4-7 Bertini et al. discuss the point dipole approximation,4 where it is assumed 
that the unpaired electron is localised exactly on the metal ion. They advise that the 
assumption is suitable only for distances greater than 3 – 4 Å from a 4f electron, and 
7 Å in the case of a 3d electron. However, this guideline was only valid in the case of a 
metal immobilized in a rigid metal-binding site on a metallo-protein. In the situation of 
a metal-binding tag attached to a protein via some flexible linker or a non-covalent tag 
in fast exchange between a binding site on the biomolecule and the unbound state, tag 
flexibility and uncertainty in electron position must be taken into account in structure 
calculations. Ma et al.11 approximated the distance from the unpaired electron (Δr) as 
the sum of the distance from the metal centre (rM) and the distance from the pz orbitals 
of the carbon or nitrogen in the metal ligands (rL), along with a correlation factor 
between the metal-centred and the delocalised unpaired electron spin:11 
 6 
 (1.10) 
where ρπ is the normalized unpaired electron spin density in the pz orbital, and a and b 
approximate to 0.16 and -0.4 for heteronuclei, and approximately 0.116 and 
0.59cos(2φ)* for protons. They conclude that the value for Δr is dominated by the 
ligand-centred term for PREs measured for heteronuclei in a copper(II) protein and note 
that PREs measured for protons depend less on the ligand terms, claiming that 1H-metal 
distances less than 10 Å can be accurately estimated. It is important to note that the lone 
electrons of lanthanide ions reside in the 4f orbitals, which largely isolates them from 
the ligand field, and they do not delocalise as readily as unpaired 3d electrons do.12,13 
This factor improves the accuracy of PRE measurements using paramagnetic centres 
such as Gd3+. 
It is difficult to measure any other paramagnetic effects for nuclear spins close to 
the paramagnetic metal centre due to the significant line broadening caused by PRE. 
This can be overcome by measuring heteronuclear spins, which are less susceptible to 
PRE broadening. To regain some of the proton sensitivity, methods have been 
established to measure paramagnetic effects close to a binding site by using a tag with 
fast metal exchange between a paramagnetic and diamagnetic species15 or by using 
exchange spectroscopy with mixing times before and after the nitrogen evolution time.16  
While it is straightforward to measure PREs by quantifying the increased T2 
relaxation rates and comparing with an appropriate diamagnetic reference, issues can 
arise if the paramagnetic tagging is incomplete and the chemical shift of the nuclear 
spin is the same in the diamagnetic and paramagnetic state, as any residual diamagnetic 
signal will affect the accuracy of peak line fitting of the paramagnetic species. 
Another difficulty with PRE distance calculations in proteins is with locating 
dynamic loops or residues. Due to the r -6 distance dependence of the PRE, the distance 
r calculated from the average PREs will always be closer to the unpaired electron than 
the actual average position of the nucleus. 
With the above considerations, distance restraints based solely on PREs need to 
be carefully assessed prior to assuming a simple r -6 relationship for any relaxation 
enhancement measured.  
 
* φ is the angle between the metal-proton vector and the carbon/nitrogen-proton bond 
∆r = r
−6
M + ar
−6
L (ρ
π)2 + br−3M r
−3
L ρ
π
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1.1.2 Residual Dipolar Couplings 
Molecules containing a paramagnetic centre with an anisotropic g-tensor will 
display weak molecular alignment in the presence of a high magnetic field. A result of 
this partial alignment is that residual dipolar couplings (RDCs), which give distance-
independent information on the orientation of scalar-coupled spin pairs with respect to 
the principal axes of the molecular alignment tensor, become observable. The direct 
relationship between the alignment tensor A and the χ tensor is given by 
 
(1.11) 
This can be used to describe the RDCs as a function of the Δχ tensor:3,4 
 
(1.12) 
where γA and γK are the gyromagnetic ratios of nuclei A and K, rAK is the distance 
between nuclei A and K, χax and χrh are the axial and rhombic components of the 
alignment tensor, θ is the angle between the A-B internuclear vector and the z-axis of 
the χ tensor, and φ is the angle between the projection of the A-B internuclear vector on 
the xy-plane and the x-axis of the χ tensor. 
Interpretation of the equation highlights magnetic field and temperature 
dependence. The magnetic field dependence is a strong argument for measuring other 
paramagnetic parameters at lower magnetic fields as the decreased spectral resolution 
due to RDCs at high field increases the measurement error.6,13 This effect is not a 
special case for paramagnetic samples, but a property of partial molecular alignment 
with respect to the magnetic field. 
As the use of RDCs was not specifically explored in this thesis, the reader is 
directed to the large body of literature available on the topic.17-20 
  
Aax,rh = ∆χax,rh
B20
15µ0kT
DAK =
hB20γAγK
240π3r3AKkT
￿
∆χax(3 cos
2 θ − 1) + 3
2
∆χrh sin
2 θ cos 2φ
￿
 8 
1.1.3 Cross-Correlated Relaxation 
Curie-spin relaxation (CSR) is mathematically similar to chemical shift 
anisotropy (CSA) and the similarity extends to cross-correlated relaxation (CCR). 
Analogous to the TROSY21 effect, cross-correlation between CSR and dipole-dipole 
(DD) relaxation is manifested in differential line broadening of doublets. The difference 
in line width at half height in Hz for a spin A coupled to spin K depends on the 
orientation and position of the inter-spin vector with respect to the χ tensor:3,22 
 
(1.13) 
where θAK is defined as the angle between the AK vector and the vector connecting the 
paramagnetic centre and spin A. The measurement of the CCR effect due to 
paramagnetism is restricted to nuclear spins far enough from the metal ion that the line 
width is not dominated by the PRE effect, and close enough to the metal for the 
paramagnetic CSR/DD CCR to remain significant with respect to diamagnetic CSA/DD 
CCR. Importantly, paramagnetic CCR relies on the Curie-spin relaxation mechanism, 
which is only significant for paramagnetic centres with anisotropic χ tensors as 
described above (section 1.1.1). As with RDC measurements, CCR was not measured 
directly in this project and the reader is referred to the appropriate literature.2-4,22-24 
1.1.4 Paramagnetic Shifts 
Metals with anisotropic χ tensors also cause changes to chemical shifts termed 
hyperfine shifts. The measured chemical shift is a linear combination of the diamagnetic 
shift, the Fermi contact shift and the pseudocontact shift. 
Fermi Contact Shifts 
Fermi contact shifts (FCSs) are due to the delocalisation of the unpaired electron 
through covalent bonds.24-26 FCSs are similar to scalar couplings in as much as they 
depend on bond and dihedral orientation, and they decay rapidly as the number of bonds 
between the paramagnetic metal and the nucleus observed increases.3 FCSs due to 
metals with highly anisotropic χ tensors are also orientation dependent and are more 
difficult to calculate. In general, for paramagnetic lanthanide centres and 1H detection, 
few FCSs are observable, as the signals would be broadened beyond detection by the 
PRE effect. 
∆ν =
￿µ0
4π
￿ B0γ2AγKh
10π3r3AKr
3
χiso × τr(3 cos2 θAK − 1)
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Pseudocontact Shifts due to Magnetic Susceptibility 
The more interesting form of paramagnetic shift is the pseudocontact shift 
(PCS). This effect arises from the magnetic dipole field generated at the site of the 
nucleus by rapidly relaxing unpaired electrons (Curie-spin). It is a through-space effect 
that can be observed at distances as great as 60 Å from the metal centre.27 
Due to the fast electron relaxation time, it can be assumed that the electron 
magnetic moment is always aligned with the magnetic field. This causes an increased 
magnetic field along the B0 z-axis and a reduced field in the xy-plane. If the χ tensor is 
isotropic, the magnetic dipole moment associated with the unpaired electron is constant 
and any change in magnetic field experienced by surrounding nuclei averages to zero 
upon molecular rotation. However, if the χ tensor is anisotropic, the magnitude of the 
magnetic dipole field depends on the orientation of the Δχ tensor, so that molecular 
tumbling leaves behind a net dipole field.4,28 This is depicted in cartoon form in Figure 
1-1. 
Based on the molecular tumbling argument above, the PCS effect is independent 
of the isotropic χ tensor. Therefore, it is typically defined with respect to the Δχ tensor 
components in an equation that bears strong resemblance to equation (1.12):3,4 
 
(1.14) 
where r is the distance between the unpaired electron and the nuclear spin, Δχax is the 
axial component and Δχrh is the rhombic component of the Δχ tensor and θ and φ are, 
similar to equation (1.12), the spherical polar angles of the nuclear spin with respect to 
the principal axis. Measured in ppm, there is no magnetic field dependence or 
dependence on gyromagnetic ratio. PCSs give rise to approximately diagonal shifts in 
the 15N-HSQC experiments typically performed in biological NMR, as the nitrogen of a 
NH group is close in space to the observed proton so that, at large distances from the 
paramagnetic centre, both nuclei experience very similar PCSs (Figure 1-2). 
∆δPCS =
1
12πr3
￿
∆χax(3 cos
2 θ − 1) + 3
2
∆χrh sin
2 θ cos 2φ
￿
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Figure 1-1 The electron magnetic moment (purple arrow) is always aligned with the B0 field, and generates a 
magnetic dipole field. Top) The effect of the magnetic dipole field at the site of the proton spin (red arrow) averages 
to zero upon molecular tumbling if the χ tensor is isotropic. Bottom) If the χ tensor is anisotropic the magnetic dipole 
field changes in magnitude as the χ tensor axes reorientate with respect to B0, generating a net change in overall 
magnetic field strength at the site of the nuclear spin. 
Slight deviations from diagonal shifts can arise from residual anisotropic 
chemical shifts (RACS),29,30 which are dependent on the chemical shielding anisotropy 
tensor (CSA tensor). This correction is small for backbone proton shifts, but can be 
significant for the nitrogen shift of backbone amides. Software applications such as 
Numbat30 attempt to correct for RACS using pre-defined CSA-tensors,31 but typically 
PCSs are simply measured on proton shifts to remove the need for this correction. 
Isotropic Ȥ
Anisotropic Ȥ
= B0
+ induced field - induced field
+++ induced field - induced field
= B0ǻLQGXFHGILHOG
B0
B0
 11 
 
Figure 1-2 PCS can be easily measured as the change in chemical shift using 15N-HSQC spectra of a paramagnetic 
sample (Tb3+: green, Tm3+: pink, Yb3+: purple) and a diamagnetic reference (Y3+: cyan). IMP-1 ligated with a 4-
vinyl-DPA lanthanide binding tag32 to the cysteine mutant A69C. A selection of PCSs is highlighted with black bars. 
The samples were measured in 20 mM MES buffer, pH 6.5, 100 mM NaCl at 310 K on a Bruker 800 MHz NMR 
spectrometer with a TCI cryoprobe. 
PCSs also display a pronounced temperature dependence arising from the 
definition of the Δχ tensor,33 due to the temperature dependence of the spin state of the 
unpaired electron (equations (1.7) and (1.8)). The temperature dependence becomes 
apparent if the PCS is written as follows: 
 
(1.15) 
where the Δχ components have been substituted with Δg components, and the terms 
from equation (1.1) are substituted. 
PCSs can be predicted accurately once the Δχ tensor is known. For a given 
molecular structure, this requires computational fitting of a minimum of eight 
parameters including the axial and rhombic components of the Δχ tensor, three Euler 
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angles to define the orientation of the Δχ tensor with respect to the molecular frame, and 
the three coordinates x, y and z to define the location of the metal centre. Fitting 
algorithms are available in software such as Numbat30 or PyParaTools34. 
Paramagnetic Shifts for Structural Measurements 
There are few cases where significant structural data have been obtained from 
FCSs, as they decay rapidly over few chemical bonds.4,28,35,36 Aside from the difficulty 
of measuring NMR signals of nuclei very close to the paramagnetic metal due to PRE 
line broadening, FCSs and PCSs occur together. It has been shown that the separation of 
FCSs and PCSs is possible, however, if a series of very chemically similar 
paramagnetic metals can be incorporated into a metal complex that is axially 
symmetric.35 More recently, the separation has also been achieved for lower symmetry 
systems.36 The separation is possible for lanthanide ions because of their similar 
coordination chemistry and ionic radii (La3+ - 1.04 Å to Lu3+ - 1.00 Å). 
Measurements of PCSs have the potential to provide long-range structural 
information that can be obtained up to 40 Å33 or, more recently, 60 Å27 from the 
paramagnetic centre. The main difficulty with structure determination from PCSs is that 
often the Δχ tensor needs to be determined, which requires prior knowledge of the 
structure. The problem is currently approached in the PCS-ROSETTA37 or 
GPS-ROSETTA38 schemes by first predicting a structure using ROSETTA structure 
prediction methodology,39 using the predicted structure to calculate the Δχ tensor and 
then utilising PCSs to rank the results to determine the best fitting structure. There has 
also been a series of attempts to use PCSs to assist NMR residue and backbone 
assignment,15,40-43 however, these methods require prior knowledge of a high-resolution 
structure and sometimes involve complex labelling schemes. 
PCS measurements are quite sensitive to flexibility of tags or nuclear spins and 
will yield average PCSs if the mobility is fast on the NMR time scale. If the metal 
moves with respect to the protein, inaccuracies in the Δχ tensor fit occur, as a single 
tensor cannot describe PCS effects arising from different metal positions. Shishmarev 
and Otting investigated the implications of tag mobility in a modelling study and found 
that tag mobility can still be approximated by a single tensor if the largest PCS 
measurements are ignored or if fitting is performed on small local areas of interest such 
as a protein active site, rather than performing a global fit.44 
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PCSs can be used to assist protein structure determinations determined by 
different methods. For example, PCS measurements have been used to correct crystal 
packing artefacts,45 assess differences between NMR and X-ray diffraction structures38 
and verify homology models of ‘open’ and ‘closed’ forms of a protein that proved 
difficult to crystallise.46 PCS measurements have also be used to determine structures of 
protein-ligand complexes,47 small-molecule binding sites on protein surfaces,48 protein-
protein complexes49 and as a method for fragment-based ligand screening.50 
1.2 Outline of Thesis 
An application note resulting from this thesis is reproduced in chapter three, 
while the rest of the text describes unpublished work. Chapters two and three relate to 
the main body of work contained by this thesis on the IMP-1 metallo-β-lactamase. 
Chapter four documents the optimisation of a para-hydrogen-producing apparatus 
developed at the Research School of Chemistry at the ANU. It also includes a general 
protocol developed specifically for this apparatus. Chapter five documents the NMR 
work performed for a publication currently in the late stages of drafting describing a 
natural product identified with pro-angiogenesis properties. This work derives from a 
collaboration of the Research School of Biology, the Research School of Chemistry and 
the John Curtin School of Medical Research, all at the ANU. 
Chapter 1. Introduction to Paramagnetic NMR and Outline of Thesis 
Chapter 2. Biomolecular and Biophysical Analysis of IMP-1 Metallo-β-
Lactamase 
Chapter 3. Cell-Free Protein Synthesis with 2H/15N/13C-Labelled Amino Acids in 
H2O for the Production of Perdeuterated Proteins with 1H in the 
Exchangeable Positions 
Chapter 4. The Set-Up, Optimisation and Operation of an In-House Built Para-
Hydrogen Producing Rig 
Chapter 5. Promotion of Mammalian Angiogenesis by Neolignans Derived from 
Soybean Extracellular Fluids – NMR Elucidation of Natural 
Products 
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2 Biomolecular and Biophysical Analysis of IMP-1 
Metallo-β-Lactamase 
2.1 Introduction 
2.1.1 β-Lactam Antibiotics 
The largest group of antibacterials used in the clinic contain the β-lactam ring.51 
This class of antibiotics has bactericidal properties based on the inhibition of enzymes 
responsible for the formation of peptidoglycan cross-linking required for cell wall 
biosynthesis in both Gram-negative and Gram-positive bacteria. The cell wall is 
essential for the survival of most bacteria to maintain osmotic stability and cell shape. 
The inhibition of these penicillin-binding proteins (PBPs) causes the equilibrium of cell 
wall biosynthesis and autolysis to become unbalanced, resulting in cell lysis.52,53 
There are six main structural subtypes of β-lactam antibiotics that are clinically 
relevant – penams (or penicillins), penems, cephalosporins, cephamycins, monobactams 
and carbapenems (Figure 2-1). Of these, the penams, penems, cephalosporins and 
cephamycins have a wide range of activity against Gram-positive and Gram-negative 
bacteria, whereas the monobactams are only active against aerobic Gram-negative 
bacteria. Finally, the carbapenems have potent and broad activity against Gram-positive 
and Gram-negative bacteria and are important for the treatment of multi-drug resistant 
bacteria. Carbapenems are currently the ‘last line of defence’ against many multi-drug 
resistant pathogens.52 
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Figure 2-1 The chemical structures of clinical β-lactam drugs. A) The penams consist of the β-lactam ring fused with 
a 5-membered thiazolidine ring. The ring further destabilises the strained C-N amide bond of the β-lactam. 
Benzylpenicillin (i) was the first β-lactam discovered but is poor at passing through bacterial membranes. Extended 
spectrum penams include amoxicillin (ii), ampicillin (iii) and piperacillin (iv) and all have improved membrane 
penetration properties. B) The penems differ from the penams only by unsaturation of the fused ring. No naturally 
occurring penems exist and faropenem (v) is yet to attain FDA (USA) or TGA (Aus) approval. C) Cephalosporins 
have a fused 6-membered desaturated ring. They are typically classed into generations. Cephalexin (vi) is an example 
of the first-generation cephalosporins and is active against Gram-positive and Gram-negative bacteria. Cefprozil (vii) 
and other second-generation cephalosporins have extended activity against Gram-negative bacteria. Third-generation 
cephalosporins, including ceftriaxone (viii), have increased activity against Gram-negative bacteria, can penetrate the 
central nervous system and are useful in treating many hospital-acquired infections. Cefepime (ix) and other fourth-
generation cephalosporins are zwitterions and have better penetration of outer membranes of bacteria. They can also 
cross the blood-brain barrier and so are useful in meningitis treatment. D) Cephamycins such as cefoxitin (x) are 
often classed as cephalosporins but differ by the presence of the methoxy group on the β-lactam ring. E) The 
monobactams are unique as they do not have a fused ring to the β-lactam core. Aztreonam (xi) is the only clinically 
available monobactam to date. F) Carbapenems are similar to the penems but with a carbon instead of a sulfur in the 
fused ring. Their structures make them resistant to most β-lactamase activity, and are often the antibiotics of last 
resort for many infections. Imipenem (xii) and meropenem (xiii) are both examples of ultra-broad spectrum injectable 
antibiotics. Chemical structures sourced from commercial supplier websites.54 
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2.1.2 β-Lactam Antibiotic Resistance 
Resistance to β-lactam antibiotics typically appears within 2 – 3 years after the 
introduction of a new antibiotic into clinical use.51 This resistance can be conferred 
through at least four distinct mechanisms. 
Evolution of Penicillin Binding Proteins 
Changing active site residues of PBPs can lower the affinity of β-lactam 
antibiotics without losing essential cell-wall biosynthesis activity. This subsequently 
increases resistance to β-lactam compounds, as is the case with the PBP2x, PBP2b and 
PBP2a genes in organisms such as Streptococcus spp., Neisseia spp. and 
Staphlococcus spp.52,53 
Downregulation of Outer Membrane Proteins 
By reducing the number of outer membrane proteins, there are fewer porin 
channels by which the β-lactam antibiotic can enter the periplasm to inhibit the PBPs. 
This means that they must now diffuse directly through the outer membrane, which 
limits the concentration of drug at the target site. This is the case with some Klebsiella 
pneumoniae, Escherichia coli and Enterobacter spp. where the loss of the OprD gene is 
associated with imipenem resistance. Usually, however, this mechanism alone is not 
enough to confer clinically relevant antibiotic resistance and is usually found in 
combination with β-lactamase expression.52,55,56 
Evolution of Efflux Pumps 
The evolution of efflux pumps to recognise and actively excrete β-lactams out of 
the periplasm also limits the concentration of the drug at the target site. These pumps 
are not only important in β-lactam resistance but other antibacterials also. This is a 
major component of the resistance in organisms such as Pseudomonas aeruginosa 
where the upregulation of the MexA-MExB-OprD system, along with the organism’s 
low outer membrane permeability, attains penicillin, cephalosporins, quinolone, 
tetracycline and chloramphenicol resistance.52,53,55 
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β-Lactamase Production 
By far the most common mechanism of β-lactam resistance is the synthesis of a 
β-lactamase, an enzyme capable of hydrolysing the β-lactam antibiotic into an inactive 
compound.52,57 
2.1.3 β-Lactamases 
The first β-lactamase was discovered in 1940 in Escherichia coli before the 
clinical use of benzylpenicillin.58 It was originally thought that the enzyme was not 
clinically relevant as benzylpenicillin was targeted to treat staphylococcal and 
streptococcal infections. Now there are over 1350 identified β-lactamases,52,59 with 
many of these being clinically relevant. 
The two types of β-lactamase enzymes hydrolyse the β-lactam substrate either 
by forming an acyl-enzyme intermediate through an active-site serine, or by utilising 
one or two catalytic metal ions, usually Zn2+, to stabilise a reactive hydroxide molecule. 
Both groups of enzymes are ancient, with the serine group estimated from sequence 
diversity studies to have evolved with bacteria over the past 2 billion years.51 Some of 
the serine β-lactamases are estimated to have been encoded on mobile genetic elements 
for at least millions of years.51 
Classification 
Classification of these β-lactamases has traditionally been based on either the 
functional characteristics, or the amino-acid sequence of the enzymes. The most 
prevalent classification system based on amino-acid sequence is that described by 
Ambler et al. and defines four molecular classes based on conserved and distinguished 
amino-acid motifs.60-62 Of these classes, A, C and D consist of serine β-lactamases, 
whereas the metallo-β-lactamases make up class B (Table 2-1). 
Table 2-1 Sequence classification scheme for bacterial β-lactamasesi 
Main Type Class Distinct Conserved Amino Acids 
Metal B 116H/N-x-H-x-D, 196H, 221C/S, 263H 
Serine 
 Locus Iii Locus IIiii Locus IIIiv 
A 70S-x-x-K 130S-D-N 234K-T/S-G 
C 64S-x-x-K 150Y-A/S-N 315K-T/S-G 
D 70S-x-x-K 144Y-G-N/H 216K-T/S-G 
i data from references63,64, numbering as per references65-68. An x signifies any amino acid. 
ii locus I includes the catalytic serine and a lysine three residues away 
iii locus II corresponds to 130Ser in class A, 150Tyr in class C and 114Tyr in class D 
iv locus III corresponds to 234Lys in class A, 315Lys in class C and 216Lys in class D 
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Despite large sequence diversity in class B, the catalytic scaffold is relatively 
conserved and enables simple classification into three subclasses. B1 and B3 subclasses 
coordinate the Zn1 site using three histidines, whereas subclass B2 utilises two 
histidines and an asparagine residue. Also, B1 and B2 coordinate the Zn2 site with an 
aspartate, cysteine and histidine residue, whereas B3 has an aspartate and two histidines 
(Table 2-2). There has been some argument that B3 should form a completely distinct 
class due to its significant sequence difference to the B1 and B2 subclasses.69-71 
Table 2-2 Subclasses of class B β-lactamases and metal coordinating residuesi 
 B1 B2 B3 
Zn1 116H, 118H, 196H 116N, 118H, 196H 116H, 118H, 196H 
Zn2 120D, 221C, 263H 120D, 221C, 263H 120D, 121H, 263H 
i numbering as per reference67 
While the sequence based system of classification is straightforward for 
biochemists to apply, an alternative classification system was suggested in 198972-74 
then updated in 199575 and 201076 by Bush et al. This system relates the varied enzymes 
by their function and defining analytical characteristics, which is perhaps more relevant 
given the clinical importance of the enzymes. Both the Bush and Ambler systems are 
used in current literature. 
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Table 2-3 Functional classification scheme for bacterial β-lactamasesi 
Group Class Distinctive substrate 
Inhibited by 
Defining characteristics Representative enzymes CA or 
TZBii EDTA
ii 
1 C cephalosporins No No 
Greater hydrolysis of 
cephalosporins than 
benzylpenicillin; hydrolyses 
cephamycins 
AmpC, P99, 
ACT-1, FOX-1 
1e C cephalosporins No No 
Increased hydrolysis of 
ceftazidime and often other 
oxyimino-β- lactams 
GC1, CMY-37 
2a A penicillins Yes No 
Greater hydrolysis of 
benzylpenicillin than 
cephalosporins 
PC1 
2b A penicillins, early cephalosporins Yes No 
Similar hydrolysis of 
benzylpenicillin and 
cephalosporins 
TEM-1, TEM-2, 
SHV-1 
2be A 
extended-
spectrum 
cephalosporins, 
monobactams 
Yes No 
Increased hydrolysis of 
oxyimino-β-lactams 
(cefotaxime, ceftazidime, 
ceftriaxone, cefepime, 
aztreonam) 
TEM-3, SHV-2,  
2br A penicillins No No Resistance to clavulanic acid, sulbactam, and tazobactam TEM-30 
2ber A 
extended-
spectrum 
cephalosporins, 
monobactams 
No No 
Increased hydrolysis of 
oxyimino-β-lactams combined 
with resistance to clavulanic 
acid, sulbactam, and tazobactam 
TEM-50 
2c A carbenicillin  Yes No Increased hydrolysis of carbenicillin PSE-1, CARB-3 
2ce A carbenicillin, cefepime Yes No 
Increased hydrolysis of 
carbenicillin, cefepime, and 
cefpirome 
RTG-4 
2d D cloxacillin Variable No Increased hydrolysis of cloxacillin or oxacillin OXA-1, OXA-10 
2de D 
extended-
spectrum 
cephalosporins 
Variable No 
Hydrolyses cloxacillin or 
oxacillin and oxyimino-β-
lactams 
OXA-11, 
OXA-15 
2df D carbapenems Variable No Hydrolyses cloxacillin or oxacillin and carbapenems 
OXA-23, 
OXA-48 
2e A 
extended-
spectrum 
cephalosporins 
Yes No 
Hydrolyses cephalosporins. 
Inhibited by clavulanic acid but 
not aztreonam 
CcpA 
2f A carbapenems Variable No 
Increased hydrolysis of 
carbapenems, oxyimino-β-
lactams, cephamycins 
KPC-2, IMI-1 
3a 
B (B1) 
carbapenems No Yes 
Broad-spectrum hydrolysis 
including carbapenems but not 
monobactams 
IMP-1, VIM-1, 
CcrA 
(B3) L1, GOB-1 
3b B (B2) carbapenems No Yes Preferential hydrolysis of carbapenems CphA, Sfh-1 
i adapted from Table 1 in Bush et al.76 
ii CA: clavulanic acid; TZB: tazobactam; EDTA: ethylenediaminetetraacetic acid 
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Group 1 – AmpC β-lactamases 
Group 1 enzymes (class C) have been termed AmpC β-lactamases and are 
distinct in that they hydrolyse cephalosporins more efficiently than benzylpenicillin. 
They are not usually inhibited by clavulanic acid and are encoded on the chromosomes 
of many Enterobacteriaceae and a few other organisms.68 In many organisms the 
expression of group 1 enzymes is low but inducible in the presence of certain β-lactams. 
Subgroup 1e enzymes are variants of group 1 with greater activity against ceftazidime 
and have been termed extended-spectrum AmpC (ESAC) β-lactamases. Group 1 
enzymes are particularly significant in the clinic when the producing organism also has 
reduced outer-membrane permeability due to porin mutations.56 
Group 2 – Serine β-Lactamases 
Group 2 enzymes include the enzymes from molecular classes A and D and 
make up the largest group of β-lactamases. Like group 1 enzymes, group 2 enzymes 
have an active site serine residue responsible for activity. The group has been 
subdivided into 12 subgroups. Subgroup 2a (class A) can hydrolyse penicillins but are 
usually inhibited by clavulanic acid. This subgroup is largely insignificant clinically as 
they do not hydrolyse current generation β-lactams. Subgroup 2b (class A) can also 
hydrolyse early cephalosporins but are also easily inhibited by clavulanic acid. 
Subgroup 2be comprises the extended-spectrum β-lactamases (ESBLs) and retain their 
activity against penicillins and cephalosporins but, in addition, can hydrolyse one or 
more oxyimino-β-lactams. They are still susceptible to clavulanic acid inhibition. 
Subgroups 2br and 2ber are similar to subgroups 2b and 2be, respectively, but have also 
acquired at least partial resistance to clavulanic acid. Subgroup 2c (class A) enzymes 
can hydrolyse carbenicillin or ticarcillin and subgroup 2ce also has expanded activity 
against cefepime and cefpirome. Both can be inhibited with clavulanic acid. Subgroup 
2d (class D) enzymes can hydrolyse cloxacillin or oxacillin and have been referred to as 
OXA enzymes. Many of these enzymes have varied susceptibility to clavulanic acid 
inhibition, but are inhibited by the presence of NaCl.64 Subgroup 2de and 2df also have 
extended activity against oxyimino-β-lactams or carbapenems, respectively. Subgroup 
2e (class A) enzymes have the ability to hydrolyse extended-spectrum cephalosporins 
and can be inhibited by clavulanic acid. They are often confused for either group 1 or 
subgroup 2be, however, they are distinguished by their poor affinity for aztreonam. 
Subgroup 2f (class A) can hydrolyse carbapenems and can be inhibited better by 
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tazobactam than by clavulanic acid. Some plasmid-encoded subgroup 2f β-lactamases 
have been responsible for significant outbreaks of multi-drug resistant Gram-negative 
infections in USA77 and Israeli78 hospitals. 
Group 3 – Metallo-β-Lactamases 
Group 3 comprises the metallo-β-lactamases (class B) and all require at least one 
metal cation cofactor, usually zinc, for activity. They differ structurally and functionally 
from the other groups and are usually produced in combination with one or two other 
β-lactamases in clinical isolates. Prior to the discovery of groups 2df and 2f, they were 
functionally distinguished by their ability to hydrolyse carbapenems. They are now 
identifiable by their poor hydrolysis of monobactams and that they are not inhibited by 
clavulanic acid but are inhibited by ion chelators such as EDTA, dipicolinic acid or 
1,10-phenanthroline.79,80 Subgroup 3a (subclasses B1 and B3) include the clinically 
relevant metallo-β-lactamase families such as IMP,* VIM† and NDM‡ that have spread 
globally. They require two zinc ions for maximal enzymatic activity and have a broad 
range of substrates. Subgroup 3b (subclass B2) enzymes are distinct in that they 
preferentially hydrolyse carbapenems in contrast to penicillins or cephalosporins. This 
subgroup differs from subgroup 3a as, mechanistically, the enzyme is most effective in 
hydrolysing carbapenems if only one zinc-binding active site is populated. In fact, the 
presence of the second zinc ion is actually inhibitory to the enzyme.81,82 
Clinically Available β-Lactamase Inhibitors 
A naturally-occurring β-lactamase inhibitor, clavulanic acid (Figure 2-2A), was 
discovered in the late 1970’s.83-85 This β-lactam is naturally synthesised by 
Streptomyces clavuligerus and shows little antimicrobial activity alone, but when 
combined with amoxicillin significantly lowers the MIC§ against numerous bacteria.83,86 
Shortly after the discovery of clavulanic acid, sulbactam (CP-45,899),87,88 and later 
tazobactam (YTR 830)52,89 were described (Figure 2-2B/C). Both of these compounds 
are penicillic acid sulfones developed by the pharmaceutical industry as synthetic 
compounds. These inhibitors are useful in the clinic in combinatorial drug therapy with 
 
* IMP: metallo-β-lactamase active on imipenem 
† VIM: Verona integron-encoded metallo-β-lactamase 
‡ NDM: New Dehli metallo-β-lactamase 
§ MIC: minimum inhibitory concentration 
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penam antibiotics. They are commonly administered as amoxicillin-clavulanate as 
Augmentin® (GlaxoSmithKline) and Clavamox® (Pfizer), ampicillin-sulbactam as 
Unasyn® (Pfizer) and Ampictam® (ELSaad), piperacillin-tazobactam as Tazocin® 
(Pfizer) and Piptaz® (Willow). 
While these inhibitors are usually quite effective for the treatment of most of the 
serine β-lactamases (most of group 2 - class Α and some class D), they are completely 
ineffective for group 3 (class B) β-lactamases. 
 
Figure 2-2 The chemical structures of A) clavulanic acid, B) tazobactam and C) sulbactam. The three β-lactamase 
inhibitors all contain the β-lactam ring, but are poor inhibitors of PBPs. Chemical structures sourced from 
commercial supplier websites.54 
2.1.4 Metallo-β-lactamases 
Metallo-β-lactamases (MβLs) were discovered over 40 years ago, but were not 
initially considered a serious issue for antibiotic therapy because they were only found 
chromosomally encoded in nonpathogenic organisms.53,90-92 That view was abruptly 
altered by the appearance of the first acquired MβLs,92 encoded by mobile genetic 
elements that enable rapid and vast horizontal gene transfer between species and even 
genera of bacteria. These mobile MβLs were then able to transfer from clinically 
irrelevant bacteria to important human pathogens.93 The most frequent MβLs present in 
clinically relevant Gram-negative bacterial pathogens are of the IMP and VIM type.92,94 
Interestingly, significantly different IMP and VIM subtypes have appeared in distinct 
geographical areas, suggesting that the corresponding genes have been captured 
independently from natural reservoirs, rather than always being due to patient transfer.94 
It was also originally thought that MβL resistance was simply correlated to 
carbapenem use. However, studies analysing patient histories found that most had not 
received carbapenem therapy prior to isolation of MβL-positive strains.95-98 In a 2003 
study in a Japanese hospital, only 15% of patients were identified as having been treated 
with cabapenems prior to blaIMP-positive infections.96 In fact, 22% were identified as 
not having been treated with any antibiotics at all.96 As MβLs often co-exist on mobile 
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integrons with one or two other β-lactamases or antibiotic resistance genes, it is possible 
that they can be co-selected by unrelated classes of antibiotics.97 This emphasises the 
complex relationship between antibiotic use and antibiotic resistance, and clearly 
demonstrates that limiting carbapenem consumption cannot be the only strategy for 
controlling MβLs in clinical practice. 
At least two new acquired MβL families have been discovered in the last 5 
years. The first of the NDM family was reported in 2009,99 and since then 10 variants 
have been assigned.100-104 This family of enzymes is particularly worrying as virtually 
all currently described isolates harbouring blaNDM are also resistant to all commonly 
used non-β-lactam drugs.105 NDM-1, NDM-3 and NDM-4 have been sporadically 
identified in Australia and New Zealand since 2009.106,107 At this stage, all isolates were 
from patients recently returning from the Indian subcontinent. Most recently, in 2013, a 
new enzyme named FIM-1 was reported as being identified in a Pseudomonas 
aeruginosa clinical infection in a hospital in Florence, Italy.108 
Activity 
Unlike the serine β-lactamases, MβLs have a wide, plastic active-site groove, 
which makes the group of enzymes able to accommodate most β-lactam 
substrates.109,110 Also unlike the serine β-lactamases, MβLs are thought to not form a 
covalent substrate-enzyme intermediate, but rather to stabilise a catalytic water 
molecule or hydroxide ion to perform the hydrolysis.53 
Recent crystallographic works have structurally characterised bound 
intermediates of ampicillin, methicillin, benzylpenicillin, oxacillin and meropenem to 
NDM-1.111,112 These works have supported the hypothesised mechanism of β-lactam 
hydrolysis, indicated schematically in Figure 2-3, with the anionic intermediate 
stabilised in both group 3a and 3b enzymes by coordination with the zinc ions.100 
Computation docking studies have also been performed and identified two 
distinct substrate docking modes (Figure 2-4).113 ‘S’ conformers position the carbonyl 
oxygen of the β-lactam ring in coordination with Zn1 and the negatively charged oxygen 
from the carboxylate in coordination with Zn2. This positions the C-N amide bond of 
the β-lactam ring appropriately for hydrolysis by the bridging water/hydroxide ion. For 
‘I’ conformers, the carboxylate oxygen either displaces the bridging hydroxide 
ion/water or simultaneously coordinates both Zn1 and Zn2 ions. These simulations seem 
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to match experimental evidence, with all ‘good’ substrates binding predominantly in the 
‘S’ conformer, and ‘poor’ substrates (such as aztreonam and clavulanic acid) binding in 
the ‘I’ conformer.113 
 
Figure 2-3 Schematic illustration of imipenem binding to a metallo-β-lactamase. A) In group 3a (class B1 and B3), 
the two zinc ions of the enzyme stabilise a bridging water/hydroxide ion and position the substrate so that 
nucleophilic attack on the C-N bond of the β-lactam ring can be performed. B) In group 3b (class B2) enzymes, a 
histidine and an aspartate residue position the water/hydroxide ion and the zinc ion positions the substrate. The 
enzyme i) positions the substrate then ii) stabilises the nitrogen anion intermediate. Figure constructed from data in 
reference53 
 
 
Figure 2-4 Different conformers of β-lactam binding predicted through computational docking simulations to 
NDM-1.113 A) In the ‘S’ conformer, the bridging water/hydroxide ion is positioned to perform nucleophilic attack on 
the C-N bond of the β-lactam ring. B) However, in the ‘I’ conformers the bridging water/hydroxide ion is displaced 
and the β-lactam is no longer positioned at the catalytic site. Figure constructed from data in reference113 
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While all MβLs are inhibited in vitro by metal chelators such as EDTA, EGTA, 
dipicolinic acid or 1,10-phenanthroline, these agents have no clinical significance.57 
However, at least for the IMP family, EDTA and EGTA are poor inhibitors, whereas 
1,10-phenanthroline and dipicolinic acid are strongly inhibitory.79,114 This has 
ramifications for current phenotypic detection assays used in the clinic to identify 
MβLs, which typically rely on in vitro return of imipenem bactericidal activity in the 
presence of EDTA.114 The mechanism of inhibition by these polydentate chelators is 
argued to be not due to scavenging of the free metal but to the formation of a transient 
enzyme-metal-chelator ternary complex,79 presumably in analogous way to the ‘I’ 
conformer (Figure 2-4B). 
With the hope of finding novel inhibitors for metallo-β-lactamases, carbapenem 
derivatives,115 simple thiol containing molecules,116-118 thioester derivatives,119 succinic 
acid derivatives,120 N-arylsulfonyl hydrazones,121 a series of tricyclic natural products122 
and captopril123-125 have all been assayed as potential inhibitors with only partial 
success. No clinically available inhibitor yet exists for bacterial infections with 
resistance due to MβLs.82,126 
Expression and Cellular Location 
As β-lactam inhibition of PBPs occurs at the site of cell-wall biosynthesis, the 
MβLs must be shuttled through the inner membrane to the periplasm of Gram-negative 
bacteria. They achieve this by means of an N-terminal signal peptide, which is cleaved 
upon transport through the inner membrane. Two potential shuttling pathways are 
available, either prior to or following enzyme folding. In 2009 it was determined that 
they are shuttled in a metal-free, unfolded form to the periplasmic space via interaction 
with the DnaK and Sec systems.127 It has been reported that MβLs are also secreted, 
after active transport to the periplasm, into the local environment.128 
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Metallo-β-Lactamase Superfamily 
While MβLs share less than 25% amino-acid sequence identity,67 structural 
studies of multiple MβLs indicate that they all share a unique αβ/βα sandwich fold,110 
with the active site located at the interface between the two domains. This MβL αβ/βα 
sandwich fold type gave rise to the naming of the metallo-β-lactamase superfamily of 
6000 metallo-enzymes defined in 1997 (Table 2-4).129 Most of the members of the 
superfamily display a dinuclear metal active site, have diverse biological function57 and 
are known to bind a wide range of metals including Zn(II), Fe(II), Fe(III), and 
Mn(II).130 The superfamily consists of 16 families, of which only 10 have representative 
structures experimentally determined.57,131 The MβL fold is the most abundant metal-
binding domain found in archaea and bacteria, and widely spread in eukaryotes.130 The 
prevalence of the metal-β-lactamase superfamily has hampered drug development as 
any potential drug that inhibits the broad family of β-lactamases needs to avoid 
inhibiting the wide range of human proteins based on this fold.57,126,131 
The broad substrate specificity, poor inhibition by clinically available 
β-lactamase inhibitors and fast horizontal genetic spread make MβLs a more 
particularly potent threat to the existing arsenal of β-lactam antibiotics than other 
classes of β-lactamases.82 
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Table 2-4 Enzymes of the metallo-β-lactamase superfamilyi 
Group Enzyme family 
(representative enzyme) 
Metal cofactorsiii Function 
1ii metallo-β-lactamases (IMP-1) 1 or 2 zinc ions β-lactam hydrolysis 
2ii glyoxalases II 2 ions – mix of zinc, iron or manganese S-D-lactoglutathione hydrolysis 
3ii 
flavoproteins 
(rubredoxin:oxygen 
oxydoreductase) 
2 iron ions Reduction of dioxygen 
4ii arylsulfatase (tRNaseZ) 2 zinc ions Phosphodiesterase,  pre-tRNA processing 
5 type II polyketide synthetases ND Production of actinorhodin, granaticin, griseusin, monensin, mithramycin, etc. 
6ii β-CASP – RNA (CPSF-73) 2 zinc ions Processing mRNA 3’-ends 
7ii β-CASP – DNA (SNM1) 2 zinc ions Repair of DNA interstrand crosslinks 
8 comE ND DNA uptake 
9ii choline binding protein E (Pce) 2 iron ions Hydrolyses choline-phosphoester bonds 
10 PhnP protein ND Alkylphosphonate uptake 
11 CMP-N-acetylneuraminate monooxygenase 2 iron ions Synthesis of N-glycolylneuraminic acid 
12ii N-acyl homoserine lactone hydrolase (AiiA) 2 zinc ions Quorum-quenching lactonase 
13ii alkylsulfatase (SdsA1) 2 zinc ions Degradation and metabolism of the biocide SDS 
14 carbofuran hydrolase ND Hydrolysis of the insecticide carbofuran 
15ii methyl parathion hydrolase (MPH) 2 zinc ions 
Hydrolysis of the insecticide methyl 
parathion 
16 class II 3’, 5’-cyclic nucleotide phosphodiesterases ND Control of cAMP in yeast 
i data from references57,131 
ii groups that have at least one representative structurally characterised  
iii ND: Not yet determined. 
2.1.5 IMP Metallo-β-Lactamases 
IMP-1 (so named as it is active on imipenem132) was first discovered in a 
Pseudomonas aeruginosa strain collected in 1988 in Japan133 and was the first mobile 
MβL identified as a source of acquired resistance to carbapenems in clinically relevant 
Gram-negative pathogenic bacteria. Since then, 48 members of the IMP family have 
been assigned in the Lahey Clinic,59 however, citations and sequences are currently 
withheld for seven of these (Table 2-5). 
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Classification and Family 
The IMP family belongs to group 3a (class B1) and its members coordinate two 
catalytic zinc ions. Zhao et al. reviewed the IMP family in mid 2011 and analysed the 
relation between the variants.134 Six subgroups were defined with at least 88% sequence 
identity between members of the subgroups. Since then, sequences for IMP-27, IMP-28 
and IMP-29 have been released and 14 new IMP variants have been reported.135-137 
Figure 2-5 contains an updated phylogenetic tree including the released sequences and 
members of the family newly reported since 2011. Using the same method of 
subdivision, the previously defined six subgroups can logically be extended to eight, 
where IMP-27 makes up subgroup 7 and IMP-31 and IMP-35 constitute subgroup 8 
(see Figure 2-5). 
Table 2-5 IMP family of metallo-β-lactamases 
ID GenBank Ref. Identityi Ref.  ID GenBank Ref. Identityi Ref. 
IMP-1 S71932 100 138  IMP-25 EU541448 99.1 139 
IMP-2 AJ243491 89.0 140  IMP-26 GU045307 95.2 141 
IMP-3 AB010417 99.1 142  IMP-27 JF894248 81.6 135 
IMP-4 AF244145 95.6 143  IMP-28 JQ407409 93.4 136 
IMP-5 AF290912 94.3 144  IMP-29 HQ438058 89.4 137 
IMP-6 AB040994 99.6 145  IMP-30 DQ522237 99.6 146 
IMP-7 AF318077 92.5 147  IMP-31 KF148593 81.5 148 
IMP-8 AF322577 89.8 149  IMP-32 JQ002629 83.3 150 
IMP-9 AY033653 86.3 151  IMP-33 JN848782 86.0 152 
IMP-10 AB074433 99.6 153  IMP-34 AB715422 99.6 154 
IMP-11 AB074436 87.2 155  IMP-35 JF816544 83.8 156 
IMP-12 AJ420864 85.0 157  IMP-36 ii   
IMP-13 AJ550807 85.8 158  IMP-37 JX131372 85.0 159 
IMP-14 AY553332 83.3 160  IMP-38 HQ875573 95.2 161 
IMP-15 AY553333 91.6 162  IMP-39 ii   
IMP-16 AJ584652 86.4 163  IMP-40 AB753457 99.1 164 
IMP-17 ii    IMP-41 AB753458 86.7 
164 
IMP-18 AY780674 82.9 165  IMP-42 AB753456 99.6 164 
IMP-19 EF118171 89.4 166  IMP-43 AB777500 92.1 167 
IMP-20 AB196988 88.9 168  IMP-44 AB777501 86.3 167 
IMP-21 AB204557 86.7 169  IMP-45 KJ510410 85.9 170 
IMP-22 DQ361087 87.3 171  IMP-46 ii   
IMP-23 ii    IMP-47 
ii   
IMP-24 EF192154 89.4 172  IMP-48 ii   
i Percentage identity to IMP-1 after sequence alignment. Signal peptides were predicted using the SignalP 4.1 
Server173 and removed prior to alignment using Clustal Omega174,175 on the EBI web server.176 
ii Members of the family that have been assigned an ID without sequence information or a citation yet available.59 
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Figure 2-5 Updated unrooted phylogenetic tree of the IMP family based on amino-acid sequences. IMP-1 is 
highlighted in red, and IMP family members with sequences made available since the review by Zhao et al. in mid 
2011134 are highlighted in blue. Grey boxes indicate the subgroups – subgroups 7 and 8 are newly defined in this 
work. Horizontal branch lengths are drawn to scale and are proportional to the number of different amino-acid 
residues. The distance along the vertical axis is of no significance. The amino-acid sequences were downloaded from 
GenBank under the accession numbers listed in Table 2-5. Signal peptides were predicted using the SignalP 4.1 
Server173 and removed prior to alignment using Clustal Omega174,175 on the EBI web server.176 The phylogenetic tree 
was calculated using ClustalW2-Phylogeny,177,178 also on the EBI web server.179 Figure generated using FigTree 
v1.4.0.180 
Genetic Context 
The IMP family of MβLs are typically encoded on class 1 mobile integrons and 
occasionally on class 3 mobile integrons. These are extremely mobile genetic elements 
and provide a mechanism for efficient horizontal transfer of the blaIMP gene between 
bacteria. The blaIMP gene cassette generally includes aminoglycoside resistance genes 
(such as aacA4), class D β-lactamase genes (blaOXA) and chloramphenicol resistance 
genes (catBs).134 This means that patient treatment with β-lactam, aminoglycoside and 
chloramphenicol medications results in selective pressure, favouring bacteria 
harbouring these multi-resistant gene cassettes and further compromising these 
antibiotic regimes. 
Structure 
To date, only IMP-1 has been crystallised while the other members of the family 
are yet to be structurally characterised. IMP-1 is a 228 amino-acid protein not including 
the additional N-terminal 18 amino-acid signal peptide that is cleaved during transport 
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to the periplasm (Figure 2-6). It has a molecular weight of 25.2 kDa and a pI of about 
9.79,181 
 
Figure 2-6 Amino-acid sequence for IMP-1 metallo-β-lactamase. The signal peptide is included at the N-terminus 
and highlighted in green. Residues involved with metal ligation are in bold. Secondary structure elements are also 
indicated (as per crystal structure 1JJE120). Residues in red are disordered and not observed in crystal structures 
1DDK182 or 1JJE120. 
Six structures for the wild type118,120,182,183 and four structures of single amino-
acid mutants109,184 are listed in the PDB. The wild type structure solved to 3.1 Å 
resolution without any inhibitors present (1DDK) is shown in Figure 2-7. The structure 
shows the typical MβL αβ/βα fold with the two metal ions residing between the two β-
sheets. The two zinc ions have a distance separation of 3.3 Å* while for the structures of 
wild type IMP-1 with reversible inhibitors, the distance between the two zinc ions is 3.6 
– 3.7 Å. The authors argue the difference is due to the poor resolution of the 1DDK 
structure (3.1 Å).182 However, it is noted that the B-factor of Zn2 and its coordinating 
ligands are much higher than that of Zn1 (Table 2-6). This suggests that the occupancy 
of the zinc ions could be lower than 100% for the Zn2 site, which could account for the 
discrepancy in measured inter-metal distance. 
Table 2-6 B-factors of the active-site zinc ions and their coordinating ligands in 1DDK182 
Residuei Atom B-factor  Residuei Atom B-factor 
Zn1 Zn 3.13  Zn2 Zn 11.16 
77His Nδ1 5.17  81Asp Oδ2 18.23 
79His Nε2 5.20  158Cys Sγ 2.10 
139His Nε2 4.44  197His Nε2 9.49 
i numbering as per Figure 2-6. 
 
* The authors report a distance of 3.5 Å between the two zinc ions in 1DDK, however, this measurement could not be 
replicated.182 Measurement of this distance using the coordinate file of 1DDK currently listed in the PDB gives a 
distance of 3.28 Å. 
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The bridging water/hydroxide ion was not observed in this structure and this was 
also originally attributed to the low resolution,182 however, an acetate ion was 
cocrystallised into the active site with one of the oxygens bound to both zinc ions. This 
binding of acetate to the active site is echoed in another structure at 3.0 Å resolution 
(1WUP).184 It is more likely that the acetate ligand has replaced the bridging 
water/hydroxide ion in both of these cases, rather than the water/hydroxide ion not 
being observable. 
 
Figure 2-7 Structure of IMP-1 metallo-β-lactamase (1DDK).182 Grey spheres indicate zinc ions. Side chains are 
depicted for residues involved in metal ligation. α-helices and loops are depicted in dark green, and β-sheets are 
highlighted in light green. The αβ/βα fold is particularly evident in the orientation of the structure on the right. 
The highest resolution structures of the wild-type enzyme were solved to 1.8 Å 
with biaryl succinic acid inhibitors (1JJE and 1JJT).120 These structures, along with all 
the other structures of inhibitor bound IMP-1, have a sulfur or oxygen atom from the 
inhibitor replacing the coordination site of the bridging water/hydroxide ion, ligating to 
both zinc ions similar to the ‘I’ conformer mentioned earlier (Figure 2-4). This adds 
weight to the previously proposed mechanism of inhibition of group 3a MβLs.113 
Following this logic, it could be conceived that the acetate ion, found in 1DDK and 
1WUP, acts as an inhibitor, albeit a poor one.79 
Relevance of IMP-Type MβLs in Australia 
In Australia, the predominant type of carbapenem resistance detected is due to 
IMP-4,185 identified at the Alfred Hospital (Melbourne, Australia) in 2002186 and then 
linked to a large clinical outbreak at the same hospital in 2004 and 2005.98,187 In this 
outbreak, 62 patients were identified as carrying MβL-producing organisms, of which 
40 were either inpatients or recently discharged (within 48 hours) from the Intensive 
Care Unit (ICU), and the other 12 had a prior ICU stay within 2 months. 72 isolates of 
90°
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MβL-producing organisms belonging to 8 different genera of pathogenic bacteria were 
collected during the outbreak. Genotypic characterisation determined all the isolates to 
contain an IMP-type MβL gene and all sequenced isolates identified the presence of 
blaIMP-4. It is proposed that the presence of MβL-producing organisms contributed to 15 
(65%) of the 23 deaths in this group. A further 6 new cases were identified in the 8 
months following the study.98 
In September 2006, a patient known to be blaIMP-4 positive was transferred from 
another Sydney hospital to the Burns Unit (BU) at the Concord Repatriation General 
Hospital (CRGH) (Sydney, Australia).185 A clinical outbreak of blaIMP-4 followed, 
lasting at least until August 2012. 92 MβL-producing isolates were detected in 63 
patients at the CRGH during the study, of which 55% were related to the BU. All 
isolates were blaIMP-4 positive except for a single non-BU case of blaVIM-1. During the 6-
year study, 1.5% of BU patient admissions were deemed to acquire an MβL-producing 
infection during their stay. Fortunately, most cases consisted of asymptomatic 
colonisations rather than clinical infections, and no deaths were attributed to IMP-4 
producing bacteria during the study. 71 environmental isolates, predominantly from 
shared patient shower facilities, were confirmed to be MβL positive. The persistence of 
multi-drug resistant Gram-negative bacteria in mostly wet areas, despite heightened 
hospital disinfection protocols, highlights the need to pursue more effective cleaning 
and sterilisation techniques, especially for areas such as plumbing and drains that are 
susceptible to biofilm formation.185 
Subject of Study 
Protein NMR analysis can provide valuable structural and dynamic information 
that is unavailable through other analyses such as X-ray crystallography. However, 
NMR analysis of β-lactamases has been limited to date, with BMRB assignment entries 
for only TEM-1 (class A – group 2b, BMRB: 6042, 6357, 7236-7239), and CcrA (class 
B1 – group 3a, BMRB: 4102). IMP-1 is the subject of the present study as a 
representative of the IMP family and group 3a metallo-β-lactamases. To the best of my 
knowledge, no protein NMR studies have been performed on IMP-1 or any IMP–type 
metallo-β-lactamase to date. 
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2.1.6 Anomalous X-Ray Scattering 
Anomalous X-ray scattering experiments were used in this project and are 
briefly introduced here. 
Normal X-ray scattering applies only for X-radiation that is far removed from 
any resonant frequency of the atom. However, if the X-ray source is close to the 
resonant frequency of the atom, scattering is damped due to absorption of the 
X-radiation energy. This leads to resonant-scattering terms:188 
 (2.1) 
where f is the total scattering, fo is the normal scattering and the real and imaginary 
terms f’ and f” are the change in amplitude and phase of the scattering between two 
X-ray energies, respectively. The f’ and f” terms are often small in respect to fo and so 
were initially only investigated in early X-ray scattering experiments for the purpose of 
applying a wavelength dependent correction for the ‘anomalous scattering’. The 
wavelength dependence is element specific and can be derived by theoretical 
approximation189 using accessible tools such as the online interface implemented at the 
Biomolecular Structure Center.188 The values of f’ and f” change most drastically at the 
ion absorption edge, as depicted in Figure 2-8. 
After the adaptation of tuneable X-ray sources at synchrotrons, anomalous 
scattering, which is now sometimes referred to as resonant scattering, can be useful for 
the identification of element type. By tuning the X-radiation source to the ion edge, 
large anomalous scattering coefficients can be observed and identification of metal ion 
type can be assigned.190 This is particularly useful in determining metal ion type in 
multinuclear binding sites. 
f = fo + f
￿ + if ￿￿
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Figure 2-8 Plot of the theoretical anomalous absorption and dispersion coefficients, f’ (light line) and f” (heavy line), 
for sulfur (orange), iron (purple) and zinc (green).188,191 The sulfur, iron and zinc κ absorption edges are at 2472.0, 
7112.0 and 9658.6 eV respectively.188 
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2.2 Results: Initial System Optimisations 
Expression, purification and NMR protocols were optimised prior to dedicated 
analysis of the IMP-1 enzyme. 
2.2.1 In vivo Expression of IMP-1 
The recombinant expression of IMP-1 from E. coli was optimised based on the 
protocol by Sivashanmugam et al.192 Two rounds of colony selection were performed to 
find highly expressing colonies. Further selection for triple-labelled protein was also 
performed using 70% D2O rich media plates as recommended.192 Expression yields 
were found to be optimal for cultures expressing at 25 °C for 20 to 22 hours. This is 
consistent with literature reports for IMP-1 and other metallo-β-lactamases.128 
Starter culture conditions were found to have a significant impact on expression 
yield. Much higher yields were obtained by using a two-step starter culture that was 
then concentrated for expression. Optimal and reproducible yields were obtained by 
using a 50 mL starter culture, grown for 8 hours, to inoculate a 1 L culture grown for 
16 hours. The cells from this culture were then spun down and resuspended into 200 mL 
of defined media (section 2.9.2). 
It was also discovered that, after resuspension of the cells in minimal media, the 
pH of the culture had dropped to a level close to the limit of the buffering capability of 
the phosphate buffer, and would drop to below pH 4.1 in less than 5 hours after 
induction (Figure 2-9), and as low as pH 3.5 after 22 hours. Adjusting the pH of the 
culture directly after resuspension to between 8.0 and 8.4 with dilute NaOH or KOH 
regained control of the pH for the duration of the expression. It was noted that 
increasing the phosphate buffer concentration also improved pH stability, however, this 
alternative was abandoned as large amounts of precipitant, presumably insoluble metal 
phosphate salts, formed in the media prior to resuspending the bacterial cells. 
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Figure 2-9 pH of the high cell density defined media after induction with 1 mM IPTG. The pH of the media dropped 
to less than 4.1 in under 5 hours after induction (blue). Even adjusting to pH 7.5 one hour prior to induction (purple) 
still allowed the media to drop outside the buffering capability of the phosphate buffer by 3 hours, whereas 
‘overshooting’ to pH 8.0 to 8.4 one hour prior to induction (red) maintained a suitable pH range for the entire 
expression time course of 22 hours (data not shown). Adjusting the pH to 7.2 hourly (green) also maintained pH 
stability, but gave no increase of protein yield. 
Finally, it was noted that, due to the high cell density protocol, a large amount of 
genomic DNA was present in the lysate prepared for purification and the lysate was still 
viscous even after long centrifuge runs at 32,000 g. While protein was obtainable from 
the thick lysate after filtration, a significant increase in the yield of purified protein was 
obtained if the lysate was treated with DNase I prior to the centrifugation step. This also 
reduced the viscosity of the lysate and facilitated filtering prior to chromatography. 
Using the method described in section 2.9.2, the typical yield of isotope-
labelled, purified protein was approximately 220 mg/L of labelled media, or 45 mg/L of 
initial rich media growth culture. 
2.2.2 Purification of IMP-1 
The initial purification protocol from P. aeruginosa expressions described by 
Watanabe et al. used an ammonium-sulfate precipitation followed by ion exchange 
chromatography and, finally, two size exclusion columns.133 Laraki et al. and Goto et 
al. later improved the purification method of the enzyme from E. coli overexpression to 
a cation exchange separation followed by either anion exchange or size exclusion 
chromatography.79,193 This was simplified to a single cation exchange column in the 
present work (section 2.9.6). After binding the crude protein sample onto the SP 
Sepharose column using 50 mM HEPES at pH 7.5, a wash step with 100 mM NaCl was 
applied for 1 column volume, followed by a linear gradient from 100 to 500 mM NaCl 
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over 5 column volumes. Fractions were collected and pooled for a single peak evident 
in the UV280 trace. This shortened the protocol down to a single column, dramatically 
reducing both the purification time and buffer use. Employing this method, purity of 
greater than 95% (estimated from SDS-PAGE) was easily obtained (Figure 2-10). This 
purification method, followed by rapid desalting via gravity-flow gel filtration and 
concentration via ultrafiltration, enabled completion of the entire process, from 
harvesting the cells from the expression media to a prepared NMR sample, in less than 
4 hours.* 
 
Figure 2-10 15% SDS-PAGE showing the typical high purity obtained for IMP-1 (highlighted by black arrow) after 
only SP Sepharose cation exchange chromatography with a shallow NaCl gradient. 
It was noted early in the project that cell-free samples gave very little signal in 
the NMR experiment, however, a coarse purification through a short SP cation 
exchange column resulted in the expected signals (Figure 2-11).† This prompted the 
development of a rapid parallel method of rough purification using Amicon Pro Affinity 
Concentrators (Millipore) (section 2.9.6). 
 
* It is noted that a somewhat similar single-column purification protocol was developed concurrently elsewhere,194 
however, the method described here avoids lengthy dialysis steps and is more specific to the high yields obtained 
from the high-cell-density protein production method used in this work. 
†  The initial observation and suggestion to purify cell-free products was by A/Prof. X.-C. Su prior to the 
commencement of this PhD project. This observation was confirmed by the author, as demonstrated in Figure 2-11. 
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Figure 2-11 15N-HSQC spectrum of IMP-1 labelled with 15N-Trp, Cys, Met and Gln either A) after 2.5 × 108-fold 
dilution of unbound small molecules using an ultrafiltration device or B) following rapid purification through a short 
SP cation exchange column. Purification of cell-free products is essential to observe NMR signals. Samples measured 
in 20 mM MES pH 6.5 at 298 K. 
2.2.3 NMR Conditions 
NMR experiments formed the foundation of the project, and the early 
optimisation of NMR conditions was essential. Initial NMR spectra recorded were 
noted to have large variations in signal intensity, specifically with the more dispersed 
signals where many cross-peaks in a 3D HNCA experiment were missing. Therefore, 
the NMR conditions for the enzyme were optimised using the 1-1 echo experiment195 
(Figure 2-12) in the manner described by Anglister et al.196 
 
Figure 2-12 1-1 echo NMR experiment. Black bars indicate π/2 hard pulses. Delay T = (1/4δ) (85 µsec at 600 MHz), 
where δ is the frequency difference between the water resonance and the amide protons. The relaxation delay Δ is 
varied to obtain an estimate of the transverse relaxation time T2. 
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Figure 2-13 1-1 echo NMR experiment result, where Δred = 8 ms and Δblue = 2.4 ms. Intensity ratio of amide signals 
estimated by scaling the 1D spectrum in overlay display in TopSpin software (in this case: Ired/Iblue ≈ 0.5). 
Using different Δ delays, a rough estimate for τc can be made by comparing the 
intensities of 1D spectra (Figure 2-13) applying the relationships in (2.2),196 
 
(2.2) 
where Δ is the variable delay and I is the average peak height of the amide region. 
Initial results in 50 mM HEPES, pH 7.0 at 298 K, gave τc estimates of 
approximately 19 ns, consistent with a protein size of about 48 kDa. This suggested that 
dimerisation may be occurring under these conditions so a series of temperatures, 
buffers and salt additives was tested to find conditions consistent with the monomeric 
form. Final conditions of 20 mM MES buffer (pH 6.5) with 100 mM NaCl at 310 K 
yielded a τc estimate of 11 ns, which correlates with the monomeric mass of 25 kDa. 
The protein was found to be very stable under these conditions and NMR spectra could 
be recorded for several weeks with minimal product degradation observed. 
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2.3 Results: Identification of an Iron-Binding IMP-1 Species 
2.3.1 Identification of Purple Pigment in IMP-1 Protein Preparations 
It was noted that several high expression trials of the enzyme had a purple 
colouration after purification, which was unexpected for a zinc-binding enzyme (Figure 
2-14). To the best of my knowledge, this purple colouration of IMP-1 had not been 
described previously apart from a brief comment by Moali et al.,197 noting a dark violet 
pigment for a highly expressing single mutant of another metallo-β-lactamase, BcII, 
which included a loop from IMP-1 (EVNGWGV). The reported removal of the pigment 
by dialysis against 100 mM citrate, followed by dialysis against 50 mM HEPES 
(pH 7.5) with 1 mM ZnSO4 implies the possibility of the colouration being due to a 
contaminating metal ion, as the citrate potentially acted as a chelating agent. Initial 
NMR spectra of the violet IMP-1 samples in this study showed many examples of peak 
doubling, which would also be consistent with the notion that a contaminating metal 
was coordinating the enzyme (Figure 2-15). 
 
Figure 2-14 Purple coloured sample of IMP-1 in a 5 mm NMR tube. 
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Figure 2-15 15N-HSQC spectrum of purple coloured IMP-1 metallo-β-lactamase. Several examples of peak doubling 
are highlighted in red boxes, with peaks belonging to the same residue linked by a red bar. This peak doubling is 
consistent with a mixed sample containing different metal cofactors. 
To assess whether one of the metals present in Studier’s 1,000 × Me Mix198 was 
contaminating the protein preparation, a series of expressions lacking one of the trace 
elements was prepared and purified. All the preparations expressed reasonably, 
although there was an approximately 50% reduction of yield from the sample lacking 
zinc, and 25% reduction for the sample lacking iron. All the purified preparations were 
still slightly purple-tinged except for the sample lacking iron. A literature search 
revealed examples of other purple coloured iron proteins such as the purple acid 
phosphatases128,199, and ferritin200,201, which were reported to gain their colour due to 
an Fe(III)-tyrosinate complex. 
The possibility of iron being associated with the IMP-1 sample was supported 
by mass spectrometry performed at the mass spectrometry facility at the University of 
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Wollongong *  under denaturing conditions (50% MeOH and 0.1% TFA). A 
fragmentation peak was observed with an isotope pattern matching an iron-containing 
complex (Figure 2-17). 
A colourimetric test for iron was also run using 1,10-phenanthroline (section 
2.9.8). The colour change suggested the presence of iron (Figure 2-18). Each of the 
metals included in Studier’s 1000 × Me Mix198 were then tested to ensure that the 1,10-
phenanthroline test was specific for iron (Figure 2-19). No other metal in the trace metal 
mix reacted to give the red colour obtained for the IMP-1 sample, so it was concluded 
that iron was present in the enzyme preparation. 
 
Figure 2-16 Expression yield estimate for samples expressed by omitting one of the metals at a time from the 
1000 × Me Mix in Studier’s defined media.198 No attempt was made to remove all trace metal impurities from other 
buffers. 50% loss of yield was observed for the sample not supplemented with zinc, and yield of the sample without 
iron supplement was reduced by 25%. None of the samples performed as well as the control, indicating that a full 
complement of trace elements improves the protein yields. 
 
* Mass spectra were recorded by Prof. T. Huber and Dr K. Loscha 
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Figure 2-17 ESI+ mass spectrum of IMP-1 under denaturing conditions (50% MeOH, 0.1% TFA) in black. The peak 
at 701.4 displays the typical isotope distribution of iron, simulated in orange (for a FeC39H65O7 molecule) using 
mMass.200 
 
 
Figure 2-18 The Fe(II) complex with 1,10-phenanthroline (A) produces a strong blood red colour, whereas the Zn(II) 
complex (D) forms a white precipitate. After reduction with TCEP, treatment of the IMP-1 sample (B) produced the 
expected red colouration. A negative control (C) without 1,10-phenanthroline shows the background colour of the 
reduced sample. 
m/z
a.i.
699 700 701 702 703 704 705
0
30
60
90
120
701.40754
699.40598
702.4114
700.40924
703.41456
704.40929
 45 
 
Figure 2-19 1,10-phenanthroline was found to be specific for the presence of iron among the metals of Studier’s 
1000 x Me Mix.198 Metal solutions were reduced with approximately 100 mM TCEP prior to treatment with 1,10-
phenanthroline. 
Finally, quantitative metal analysis using inductively coupled plasma optical 
emission spectroscopy (ICP-OES) (section 2.9.9) at the microanalysis unit at the 
Research School of Chemistry, ANU confirmed that up to 0.7 equivalents of iron per 
protein molecule were present in the purple preparation of IMP-1 (Figure 2-20). 
 
Figure 2-20 ICP-OES metal analysis of violet IMP-1. Results show cobalt, manganese, molybdenum, nickel, and 
selenium at trace levels. 0.03 equivalents of copper and 0.12 equivalents of calcium were also found, however, were 
not observed at as high a level after optimisation of the ICP-OES experiment conditions. 0.71 equivalents of iron and 
1.16 equivalents of zinc were determined to be the main products present in the protein sample. These results are 
accurate relative to each other but are only approximate relative to protein concentration due to inaccurate 
concentration determination of the unknown mixture of [FeZn]IMP-1 and [ZnZn]IMP-1 (section 2.4.1). 
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The degree of iron substitution varied significantly between preparations of 
protein expressed in LB rich media,202 so all future expressions were performed using 
the high-cell density method described in section 2.9.2 using defined media, where 
results were much more reproducible. The variation in metal content was attributed to 
subtle differences in metal ion composition between batches of the commercial tryptone 
and yeast extracts used in LB media.198 
2.3.2 Attempted De-Metallation of IMP-1 
To simplify analysis, it was desirable to obtain the pure zinc-substituted IMP-1 
enzyme reliably in high yield. Several attempts have been made to remove the active 
site metals of IMP-1 to form the apo-enzyme and then generate non-zinc substituted 
proteins, however, both metal ions remained tightly bound by IMP-1, as evidenced by 
their retention after exposure to chelators, prolonged dialysis, or purification in the 
absence of metal ions.79,203,204 Two recent publications had advertised independent 
methods for generating the apo-enzyme: Griffin et al.194 utilised a dilute solution of the 
enzyme that was dialysed over several steps against either 1,10-phenanthroline or 
EDTA; and Yamaguchi et al.205 used a concentrated protein sample that was directly 
treated with EDTA at elevated temperature in the presence of 30% glycerol and 1 M 
NaCl (see section 2.9.10). Both of these methods were tested in this study, however, as 
shown in Figure 2-21, the Griffin method caused significant proteolysis of the enzyme, 
and the Yamaguchi method produced large amounts of precipitate that could not be 
refolded. 
The soluble fractions from both of these methods were analysed for iron and 
zinc metal ion content by ICP-OES (Figure 2-22). 
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Figure 2-21 15% SDS-PAGE of de-metallation trials. Lane 1 contains the pre-treated sample control showing full-
length IMP-1 protein. The Griffin method194 produced large amounts of proteolytically degraded enzyme (lane 2), 
with some insoluble protein (lane 3), whereas the Yamaguchi method205 did not cause cleavage of the enzyme (lane 
4), but generated lots of insoluble denatured protein (lane 5), which could not be refolded. 
 
 
Figure 2-22 ICP-OES metal analysis of de-metallation attempts. Iron is indicated by purple bars, and zinc is 
indicated by green bars. The relative soluble protein yield is indicated by silver squares. While the Griffin method194 
appears to reduce the metal content significantly, the majority of the protein sample has been cleaved into smaller 
fragments (Figure 2-21). The Yamaguchi method184 is also imperfect, producing a yield of about 6% soluble apo-
enzyme. Protein concentration estimates assumed a mixed sample of 80% [FeZn]IMP-1 and 20% [ZnZn]IMP-1 for 
determination of the ε280 value. 
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While the Griffin method194 appears to have largely succeeded in removing the 
bound metals from the protein, the majority of the product had been proteolysed as 
shown in Figure 2-21, requiring repurification. In contrast, the Yamaguchi method205 
was successful in removing about 60% of the metals, however, only 9% of the total 
protein remained soluble, equating to a yield of approximately 6% apo-enzyme. It was 
concluded that neither of these methods was suitable for generating high-yielding 
protein samples for NMR or X-ray crystallography studies. 
2.3.3 Control of Metal Ion Content of IMP-1 via Expression Conditions 
As it proved difficult to reconstitute the IMP-1 protein with zinc, the expression 
conditions were adjusted to favour the [ZnZn] form. A series of small-scale expressions 
was prepared with increasing amounts of extra ZnSO4 added to the minimal media. A 
titration of FeCl3 was also trialled in parallel. ICP-OES data showed that control of the 
metal substitution in the active site could be achieved by supplementing the expression 
media with either 500 µM ZnSO4 or FeCl3 (Figure 2-23). 
 
Figure 2-23 ICP-OES metal analysis of zinc (green) and iron (purple) titration. Up to 2.0 equivalents of zinc per 
protein molecule could be obtained by supplementing the expression media with 500 µM ZnSO4. Even in the 
presence of excess iron, never more than one equivalent of iron was detected. Protein concentration (silver square) 
was determined using a calculated ε280 value assuming a mixed population of [FeZn]IMP-1 and [ZnZn]IMP-1 species 
defined by the ratio of metals (section 2.4.1). 
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It was determined that IMP-1 would bind close to one equivalent of iron even in 
relatively low iron concentrations. This raised the possibility of iron being a 
biologically relevant active-site metal for IMP-1. It was also interesting to note that the 
protein would only ever incorporate a maximum of one equivalent of iron, even in a 
large excess of iron, which also suggested that the iron was binding to a specific metal 
site, or that the presence of one iron ion prevented the binding of a second. 
Now that pure [ZnZn]IMP-1 sample could be made, most of the peak doubling 
was resolved in the NMR spectra (Figure 2-24). 
 
Figure 2-24 15N-HSQC spectrum of [ZnZn]IMP-1. Control over metal substitution simplified NMR spectra into 
mostly a single metal coordinated species. The same cross-peaks are highlighted as in Figure 2-15. Very small 
amounts of [FeZn]IMP-1 are still evident in the spectrum, but are significantly attenuated. 
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2.3.4 Validation of [FeZn]IMP-1 Existence in Periplasm 
In the natural system, IMP-1 is transported to the periplasm via membrane-
bound transport proteins that recognise and cleave an 18 amino-acid, N-terminal signal 
peptide. To ensure that the observed metal character was not an experimental artefact of 
the protein being expressed into the cytosol, the signal peptide was cloned onto the 
N-terminus of the protein in pET47b(+), and the construct transformed into BL21(DE3) 
cells. To verify that the native membrane transport proteins recognised the signal 
peptide, a simple agar antibiotic plate assay was then run. 
 
Figure 2-25 In vivo β-lactamase activity assay showing transport of IMP-1 to the periplasm is essential for 
antibacterial resistance. The radius of inhibition is an indication of the inhibitory concentration of ampicillin. Filter 
paper disks were supplemented with 20 µL of 1, 10, 100 or 200 mg/mL ampicillin as marked. Even without induction 
(A), the ‘leaky’ expression of IMP-1 with the N-terminal signal peptide to transport the enzyme to the periplasmic 
space is enough to confer β-lactam resistance to the E. coli cells. With 0.25 mM IPTG induction (B), the cells can 
withstand over 100 mg/mL concentrations of ampicillin. With 0.5 mM IPTG induction (C), the cell growth is 
inhibited, presumably because the high level of overexpression of the IMP-1 enzyme overloads the native membrane 
transport proteins. If the N-signal peptide is absent (D), thus keeping the expressed enzyme in the cytosol (1 mM 
IPTG), little antibacterial resistance is observed with a MIC of < 1 mg/mL. 
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From the results in Figure 2-25 it was determined that the overexpression of 
IMP-1 with the N-terminal signal peptide limited the growth of the cells, and the 
enzyme was active in vivo in the E. coli strain BL21(DE3). While this assay is not 
quantitative, the results are compelling and consistent with the signal peptide being 
recognised and processed by the native BL21(DE3) membrane transport proteins. 
The protein was then overexpressed (section 2.9.4), and the media, total cell, 
periplasm, and cytosolic fractions were analysed on SDS-PAGE (Figure 2-26). 
 
Figure 2-26 15% SDS-PAGE gel of periplasmic expression of IMP-1 with the N-signal peptide. The molecular mass 
of IMP-1 (25.5 kDa) is highlighted by the arrow. IMP-1 expressed without the N-terminal signal peptide (lanes 1 to 
4) is only present in the cytosol (lanes 4 & 8, 2 µL loaded) and total cell (lanes 2 & 6, 2 µL loaded) fractions, whereas 
with the N-terminal signal peptide (lanes 5 to 8), the protein is present in the periplasm (lanes 3 & 7, 30 µL loaded) 
and also in the medium (lanes 1 & 5, 30 µL loaded) fraction. Note that much more protein (IMP-1 and other proteins) 
was released into the medium for the N-signal peptide sample. This may be attributed to cell-lysis due to stress on the 
membrane transport proteins or to up-regulation of membrane transport proteins. 
It was found that the majority of the expressed protein was released into the 
medium during expression, which is consistent with results reported for other metallo-β-
lactamases.128 The medium fraction was concentrated then diluted with salt-free buffer 
until the salt concentration was low enough for ion exchange chromatography. 
It was noted that the total protein level in the media was higher for the 
periplasmic expression than for the cytosolic expression. This could be due to the cells 
up-regulating their membrane transport proteins in response to the overexpression of the 
periplasmic form of IMP-1, or might be explained by cell lysis. To ensure the media 
fraction contained protein transported to the periplasm, rather than protein released from 
lysed cells, mass spectrometry was performed on the sample. This was diagnostic as 
protein transported to the periplasm would have had the N-terminal signal peptide 
cleaved by the membrane transport proteins (expected mass = 25,041.6, observed mass 
= 25,046.2), whereas any protein from lysed cells would still have the signal peptide 
 52 
attached (expected mass = 27,120.1). It was concluded that the protein purified from the 
media had been transported to the periplasm and that the N-terminal signal peptide had 
been cleaved (Figure 2-27). 
 
Figure 2-27 MaxEnt reconstructed ESI-MS spectrum under denaturing conditions (1% formic acid) showing 
[FeZn]IMP-1 protein collected from the media has been cleaved and transported to the periplasm. Expected mass: 
25,041.6 observed: 25,046.2. None of the uncleaved product from the cytosol is observed (27,120). MaxEnt 
reconstruction run in Waters MassLynx 4.1, figure generated in mMass200. 
The protein product was then expressed in vivo under different media 
conditions, specifically high zinc (supplemented with 500 µM ZnSO4), 0.5 × Studier’s 
Me Mix ratio198, and high iron (supplemented with 500 µM FeCl3). The protein was 
harvested and purified from the media (section 2.9.3), then analysed for iron and zinc 
content by ICP-OES analysis. Clearly, the [FeZn] species was not limited to cytosolic 
expressions, and was even more prevalent in samples expressed in the periplasm. Up to 
24% of the IMP-1 protein population was in the [FeZn] form even in the sample 
expressed under the same excess zinc conditions used to produce [ZnZn]IMP-1 in the 
cytosol (Figure 2-28). 
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Figure 2-28 ICP-OES metal analysis of periplasmic expression study. Iron is indicated in purple and zinc is indicated 
in green. Periplasmic expressions with 0.5 × Studier’s Me Mix198 ratio of metals indicated up to 36% of expressed 
protein was in the [FeZn] form, and even in the presence of excess zinc, up to 24% of the protein was the [FeZn] 
form. In excess iron conditions, up to 100% of the protein produced was in the [FeZn] form. Due to difficulties with 
protein concentration measurements of these particular samples, a [FeFe]IMP-1 species cannot be ruled out, however, 
no other experiment performed in this study supports the possibility of iron binding to both sites of IMP-1. 
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2.4 Results: Biochemical Comparison of [FeZn]IMP-1 and 
[ZnZn]IMP-1 
2.4.1 Protein Concentration Measurements 
Estimates of native-fold extinction coefficients for determining protein 
concentration are usually quite reliable, however, using this method for concentration 
determination of [FeZn]IMP-1 requires a specific correction between the native and 
denatured protein estimates as the iron forms a chromophore in the native state. Thus 
the ε280 value was established using a method described by Kelly et al.206 
A Cary UV-VIS spectrometer was used for calibration of the ε280 values. A 
suitable amount of protein in buffer (20 mM MES, pH 6.5, 100 mM NaCl) was 
determined to give an absorbance at 280 nm of approximately 0.8 over a 10 mm path 
length. 250 µL of this sample was then diluted with either 750 µL of buffer, or 750 µL 
of 8 M guanidine hydrochloride, and absorbance at 280 nm over a 10 mm path length 
was measured. This was performed in triplicate for both [FeZn]IMP-1 and 
[ZnZn]IMP-1, and an average correction factor of the absorbance of the denatured state 
was established (1.220 and 0.989 respectively). An estimate of the extinction coefficient 
for the denatured protein was then made using the following formula,207 
 (2.3) 
where W is the number of tryptophan residues (6), Y is the number of tyrosine residues 
(8), and CC is the number of disulfide bonds (0).207 For IMP-1, this gives a value of 
44,380 M-1cm-1. This estimate does not suffer the problem of the iron chromophore, so 
it is more reliable than the estimate for the folded protein. 
The value was then multiplied by the determined correction factor to arrive at 
the corrected ε280 values. [FeZn]IMP-1 was determined to have an 
ε280 = 54,130 M-1cm-1 and [ZnZn]IMP-1 to have an ε280 = 43,870 Μ-1cm-1. As a 
comparison, the predicted value for the protein by the folded estimate method described 
by Pace et al.208 was ε280 = 44,920 M-1cm-1, which is close to the determined 
[ZnZn]IMP-1 value as expected. The ε280 estimate reported in the literature116,193 is 
quite varied with ε280 = 44,380 M-1cm-1 to 49,000 M-1cm-1. These values fall between 
the [ZnZn]IMP-1 and [FeZn]IMP-1 estimates described here, as would be expected for 
a mixed sample of [ZnZn] and [FeZn] forms. 
￿280 = 5690 W + 1280 Y + 120 CC
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It is worth noting that with the corrected ε280 values calculated here, all ICP-
OES measurement results became significantly more accurate. For example, where the 
previous concentration estimate determined 1.62 equivalents of metal (iron plus zinc) 
for one sample of [FeZn]IMP-1, the new estimate determined 2.02 equivalents of metal. 
2.4.2 UV/Vis Absorption 
The absorption spectrum in the UV and visible range was measured, and shows 
a weak, broad absorption band at 520 nm, which gives rise to the visible purple 
colouration of [FeZn]IMP-1 samples. A strong, broad absorbance band is also present at 
around 300 nm, responsible for the protein concentration determination issues 
highlighted in section 2.4.1. 
 
Figure 2-29 UV/Vis absorption spectrum of [FeZn]IMP-1 (purple) and [ZnZn]IMP-1 (green). The [FeZn] form has a 
weak, broad absorbance band at 520 nm and a strong, broad absorbance band at ~300 nm. Spectra were recorded on a 
NanoDrop NV1000 with a 1 mm and 0.1 mm pathlength. Absorbance is scaled to show the UV/Vis absorbance 
spectrum of 0.23 mM protein (A280 of 1 for the [ZnZn]IMP-1 with a 1 mm pathlength). 
In an attempt to probe the oxidation state of the iron, the visible absorbance 
spectra were acquired of the [FeZn]IMP-1 enzyme after either reduction with TCEP or 
oxidation with H2O2. This resulted in a red-shift in the absorbance band at 520 nm to 
570 nm after treatment with TCEP, and little change after oxidation, which would 
suggest the iron was in the 3+ oxidation state (Figure 2-30). This result was later 
confirmed by NMR data collected on cell-free samples (Figure 2-58). 
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Figure 2-30 Visible absorbance spectrum of 1.8 mM [FeZn]IMP-1 before treatment (purple), after reduction with 
40 mM TCEP (blue) and after oxidation with 1.2 mM H2O2 (red). 2 µL samples of ~ 1.8 mM protein in 30 mM 
HEPES (pH 7.5), 180 mM NaCl were measured on a NanoDrop ND-1000 with a pathlength of 1 mm. 
2.4.3 Circular Dichroism 
Circular Dichroism Spectroscopy 
Differences in the secondary structure content between the [FeZn]IMP-1 and 
[ZnZn]IMP-1 species were probed using circular dichroism (CD). The CD spectra 
observed in the far UV were essentially identical between the two samples, indicating 
similar secondary structure (Figure 2-31A). There is only a subtle intensity difference at 
193 nm and even less at 230 nm, which is perhaps indicative of a subtle change in the α-
helical component, but this difference may not be significant. The near UV region is 
more indicative of tertiary structure changes and differences between the two 
preparations become more apparent, specifically in the region from 300 to 380 nm, 
where the [FeZn]IMP-1 has a consistently higher intensity (Figure 2-31B). However, 
the curves are still very similar, suggesting that any differences in tertiary fold of the 
two species are minimal. Visible CD is possible with coloured proteins, and a signal is 
apparent for the [FeZn]IMP-1 species (Figure 2-31C) that is significantly different to 
the [ZnZn]IMP-1 signal. This is indicative of the binding environment of the iron, but 
no conclusions can be drawn in comparison to the [ZnZn]IMP-1 sample.  
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Figure 2-31 Comparison of CD spectra of [FeZn]IMP-1 (purple) and [ZnZn]IMP-1 (green). A) Mean residue 
ellipticity in the far UV of approximately 5 µM protein, 1 mm pathlength B) Molar ellipticity in the near UV of 
approximately 50 µM protein, 10 mm pathlength C) Molar ellipticity in the visible range of approximately 50 µM 
protein, 10 mm pathlength. All samples were measured in 50% D2O, chloride-free 23 mM phosphate buffer, pH 7.0, 
19 mM Na2SO4 at 293 K. 
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Circular Dichroism Thermal Denaturation 
The CD spectra in the far UV range during a thermal melt of [ZnZn]IMP-1 and 
[FeZn]IMP-1 are shown in Figure 2-32. ‘Smeared’ isosbestic points are present near 
202 nm and 230 nm in the [ZnZn]IMP-1 spectra, indicating a multiple-step unfolding 
pathway. The isosbestic point at 202 nm is not smeared in the [FeZn]IMP-1 melt, 
suggesting that the [FeZn] has at least different denaturation kinetics, if not also an 
alternate denaturation pathway. Significant secondary structural elements are still 
present in both species even at 90 °C. Interestingly, the spectra acquired at 90 °C from 
each species differ significantly (Figure 2-32C). These differences are irreversible and 
are still evident after cooling to 25 °C. Unfortunately, a small degree of precipitant 
formed over the course of the thermal melts, complicating spectral analysis. Although 
attenuation of the CD signal appears minor, indicating little or no light scattering due to 
large protein aggregates, comparison of the structures at 90 °C between the two species 
is not possible. 
Several wavelengths were selected and thermal melting curves were fitted with a 
simple sigmoidal function (Figure 2-33). All fits had an R2 value greater than 0.987. 
Statistical analysis was performed on the two spectral regions (208-220 and 186-
198 nm) as two independent groups to determine if the two regions reflected the same 
average melting temperature (Tm) or relative slope (dx). Table 2-7 shows the mean and 
standard deviation of the Tm and dx results, along with a Student’s t-test calculated in 
Microsoft Excel. 
The two peaks give insignificantly different melting temperatures for the [ZnZn] 
species (likelihood of different mean = 68.5%), but there is a significant difference in 
dx. While the two peaks could have the same mean Tm, the observation of different 
slopes (dx) suggests non-uniform melting of the protein. The [FeZn] species has 
significantly different Tm between the two peaks (likelihood of different mean = 
99.87%), and also a significant difference between the dx. This could be explained if the 
presence of iron promotes one of the steps required for unfolding, or stabilises a 
structurally different denaturation product. The Tm values for [ZnZn]IMP-1 and 
[FeZn]IMP-1 were then compared using a pooled global average of all the points fitted 
in Figure 2-33. Table 2-8 shows the means and standard deviations of the Tm and dx 
results.  
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Figure 2-32 Far UV mean residue ellipticity during thermal melt of A) [ZnZn]IMP-1 and B) [FeZn]IMP-1. The 
thermal melt was applied stepwise in two degree increments from 10 °C (black) to 90 °C (red). The thermal melt in 
both cases was irreversible. Even at 90 °C there is evidence of residual secondary structure in both samples. C) 
Comparison of the CD spectrum of [ZnZn]IMP-1 (green) and [FeZn]IMP-1 (purple) at 90 °C (dark) and subsequent 
cooling to 25 °C (light). The change in the CD spectrum of IMP-1 under these conditions is irreversible. The protein 
does not exhibit a typical random coil CD spectrum, even at 90 °C in either case, potentially indicating residual β-
sheet structures or protein aggregates. 
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Figure 2-33 Sigmoid function fit of CD mean residue ellipticity thermal melt for A) [ZnZn]IMP-1 and B) 
[FeZn]IMP-1. The sigmoid function was fit independently to each wavelength using KaleidaGraph software. Each fit 
had an R2 > 0.987. 
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Table 2-7 Statistical analysis of CD temperature melt – comparison of the signal at 198-186 nm to the signal at 220-
208 nm for the [ZnZn]IMP-1 and [FeZn]IMP-1 species individually.i 
[ZnZn]IMP-1 
220-208 peak 198-186 peak 
Tm (°C) dx Tm (°C) dx 
mean 69.03 3.22 68.2 5.12 
standard deviation 0.91 0.11 1.5 0.65 
significance (t-test)ii 31.5% 0.24%   
 
[FeZn]IMP-1 
220-208 peak 198-186 peak 
Tm (°C) dx Tm (°C) dx 
mean 68.26 4.229 66.10 6.65 
standard deviation 0.38 0.039 0.76 0.57 
significance (t-test)ii 0.13% 0.065%   
i Mean and standard deviation are calculated from the different wavelength fits on a single thermal melt run for each 
[ZnZn]IMP-1 and [FeZn]IMP-1. 
ii A two-tailed Student’s t-test with 5% confidence. Results highlighted in blue indicate high likelihood that the two 
samples are independent and have different mean values. Results highlighted in red indicate statistical insignificance. 
Table 2-8 Analysis of CD temperature melt - comparison of [ZnZn]IMP-1 and [FeZn]IMP-1 using all data points 
measured (global).i 
Global Average 
[ZnZn]IMP-1 [FeZn]IMP-1 
Tm dx Tm dx 
mean 68.6 4.2 67.2 5.4 
standard deviation 1.3 1.1 1.3 1.3 
i Mean and standard deviation are calculated from the different wavelength fits on a single thermal melt run for each 
[ZnZn]IMP-1 and [FeZn]IMP-1. 
2.4.4 Exogenous Metal Exchange 
Cadmium Exchange 
Siemann et al.203 described the facile exchange of cadmium into the binding site 
of IMP-1, and tentatively designated the cadmium-binding site to the Zn2 site. This 
experiment was repeated with both the [ZnZn]IMP-1 and [FeZn]IMP-1 samples and 
assayed using mass spectrometry (Figure 2-34). While it was evident that cadmium did 
exchange into the protein in place of an active-site metal, the mass accuracy was not 
high enough to determine conclusively whether it was iron or zinc that was replaced. To 
ascertain which metal was exchanged by cadmium, samples were prepared and analysed 
by ICP-OES (Figure 2-35). 
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Figure 2-34 Deconvoluted +ESI-MS spectrum in 100 mM ammonium acetate for A) [ZnZn]IMP-1 and B) 
[FeZn]IMP-1 before (dark) and after (light) treatment with CdCl2. Both species rapidly exchange one cadmium ion 
for an active-site metal. Expected difference for Zn replaced by Cd: 47, Expected difference for Fe replaced by Cd: 
57. Observed for [ZnZn]IMP-1: 47. Observed for [FeZn]IMP-1: 49. 
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Figure 2-35 ICP-OES result for cadmium (orange), iron (purple) and zinc (green) in the cadmium ion exchange 
experiment. Only two equivalents of metal were observed for the treated samples. Protein ε280 values used for 
concentration estimates are scaled using the ratio of iron to zinc and assume ε280 of the [CdZn] protein is the same as 
the [ZnZn] protein, and that ε280 of the [FeCd] form is the same as the [FeZn] protein. 
Only 2.0 ± 0.1 metal equivalents were observed for all samples before and after 
treatment, confirming cadmium exchanges with one of the active site metals. 0.18 
equivalents of iron and 0.14 equivalents of zinc were lost from the [FeZn]IMP-1 sample 
after cadmium treatment and substituted with 0.50 equivalents of cadmium within the 
5 minute treatment time. The total metal content of the [FeZn]IMP-1 sample increased 
from 1.9 to 2.1 equivalents after treatment. The [ZnZn]IMP-1 sample lost 50% of zinc 
after cadmium treatment, and has 1.1 equivalents of cadmium per protein molecule 
within the 5 minute treatment period. 
Zinc and Iron Exchange 
Using the same conditions as the cadmium exchange experiment, an attempt was 
made to exchange zinc or iron into the active site of either [FeZn]IMP-1 or 
[ZnZn]IMP-1. Exchange of metals was evident, and the treatment of [FeZn]IMP-1 with 
zinc did reduce the iron content as expected. Unexpectedly, a significant excess of metal 
was present in the case of the addition of iron(III), where 19.56 and 19.48 equivalents of 
iron were observed in the [FeZn] and [ZnZn] forms respectively. This was very close to 
the excess of iron that was used to treat the samples. The results were reproducible even 
after using two desalting steps in series on new NAP-5 and PD-10 columns and in the 
presence of 100 mM NaCl. 
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Figure 2-36 ICP-OES result for iron (purple) and zinc (green) in the zinc and iron ion exchange experiment. The 
treatment of [FeZn]IMP-1 with zinc does reduce the iron content. Protein concentrations for the iron treated samples 
were estimated from measurements of the [FeZn] and [ZnZn] forms treated with cadmium, as the strong yellow 
colour from the dissolved iron interfered with A280 measurements. 
2.4.5 Comparison of Activity of [FeZn]IMP-1 and [ZnZn]IMP-1 
The activity of both forms of IMP-1 was assayed against benzylpenicillin at pH 
7.5 at 37 °C (Table 2-9). 
Table 2-9 Relative kinetic parameters of the purified [FeZn]IMP-1 enzyme compared to the [ZnZn]IMP-1 enzymei 
 [ZnZn]IMP-1 [FeZn]IMP-1 
kcat (s-1)ii 461 135 
Km (µM) 275 1340 
kcat/Km (µM-1 · s-1) 1.676 0.101 
i The values for [ZnZn]IMP-1 were independently measured. Data are means of three measurements. Standard 
deviations never exceeded 10%.  
ii The Δε value for benzylpenicillin in the plate assay was not directly determined. Results for kcat were therefore 
approximated by scaling the result for kcat to match the report by Iyobe et al.142 (see section 2.9.14 for further details). 
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2.5 Results: X-Ray Diffraction Structure Determination of 
[FeZn]IMP-1 and Anomalous Scattering 
2.5.1 Crystallisation Screening 
A number of automated protein crystallisation screens, using commercial high-
throughput screening plates, were attempted at different protein concentrations and 
temperatures. Constructs with and without the N-terminal MASMTG expression tag 
were trialled, and the addition of an inhibitor (captopril123-125) also attempted. 
The addition of excess iron was attempted for the [FeZn]IMP-1 sample. It was 
observed that 2 to 3 equivalents of FeCl3 increased the solubility of the enzyme and 
reduced precipitant in almost every condition screened in the high-throughput format, 
even at high concentrations of protein. 
It was noticed from NMR spectra that a number of peaks would be lost or would 
shift after about 2 weeks of measurement at 37 °C (Figure 2-37), and from mass spectra 
that N-terminal residues were cleaved over time (data not shown). Consequently, a heat 
incubation step, followed by removal of any precipitant via filtration, was trialled in 
crystallisation screening. Successful crystallisation of [FeZn]IMP-1 (without the 
MASMTG N-terminal tag and with no other additives) required that the protein be heat 
treated for a minimum of 5 days at 37 °C. Single crystals large enough for X-ray 
analysis were successfully grown at 24 °C over 2 weeks using the hanging drop vapour 
diffusion method and microseeding by mixing 1 µL of 25 to 30 mg/mL protein in 
10 mM HEPES pH 7.0 with 1 µL of the microseeding solution over a 1 mL reservoir 
containing 0.2 M sodium acetate, 0.2 M sodium citrate and 26% PEGMME 2K (Figure 
2-38). 
Two crystals were selected and flash cooled with liquid nitrogen in a 
cryoprotecting buffer of 0.2 M sodium acetate, 0.2 M sodium citrate and 35% 
PEGMME 2K prior to shipping to the Australian Synchrotron. 
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Figure 2-37 15N-HSQC spectrum of [FeZn]IMP-1 before (blue) and after (red) 2 weeks of measurement at 310 K. 
The older sample was exchanged into fresh NMR buffer prior to measurement to remove the possibility of pH shift. 
A few strong peaks get weaker or are lost (blue arrows) and some new peaks appear (red arrows) indicating the 
enzyme is aged over the course of time at 310 K. 
 
 
Figure 2-38 Micrograph of one of the crystals used for X-ray diffraction studies. Conditions were 0.2 M sodium 
acetate, 0.2 M sodium citrate and 26% PEGMME 2K at 28 °C. 
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2.5.2 X-Ray Diffraction Structure 
Two crystals of [FeZn]IMP-1 were submitted for X-ray diffraction experiments* 
at the Australian Synchrotron. The protein crystals were found to have unit cell 
dimensions of a = 49.99 Å, b = 75.91 Å, c = 82.36 Å, α = 83.45°, β = 75.30°, γ = 74.01° 
and consisted of four monomer chains per asymmetric unit in the P1 space group. The 
crystals were quite resilient to X-radiation damage and numerous complete data sets 
were measured successfully with little sample degradation. Both crystals diffracted to a 
resolution of 1.8 Å. The structure was solved via molecular replacement, with the 
published crystal structure of IMP-1 having the most similar crystallography conditions 
(PDB code: 2DOO183). Electron density was observed in the active site and found to be 
citrate from the crystallisation conditions. A structure for the citrate (FLC) substrate was 
obtained from the PDB (PDB code: 1C5R209) and was modelled into the active site. 
After several rounds of refinement, a structure of the [FeZn]IMP-1 was 
determined. Monomers A and C included residues 4 to 221, and monomers B and D 
included residues 4 to 220. The unit cell contained 465 resolved water molecules. The 
crystallographic R factor was 0.18, the Rfree was 0.21, and the RMSDs from ideal bond 
lengths and angles were 0.022 Å and 1.386°, respectively. The four monomers had 
backbone RMSD to each other of between 0.20 Å (A-D) and 0.32 Å (A-C). The atoms 
with the largest difference were at the C-terminus (residues 216-221), and the flap 
(residues 23-32). When these residues were excluded, the backbone RMSD of each 
monomer to each other monomer ranged from 0.12 Å (A-D) to 0.21 Å (B-C). The metal 
ions were separated by 3.75 Å (D) to 3.81 Å (C), and the active residues had a backbone 
and sidechain RMSD between the four monomers of 0.08 Å (A-B) to 0.11 Å (B-C). The 
average B factor for each of the monomers was 28.53 Å2 (A), 28.74 Å2 (B), 27.74 Å2 
(C) and 28.76 Å2 (D). 
The A chain had a calculated backbone nitrogen RMSD of 0.344 Å to the model 
used for molecular replacement (PDB code: 2DOO) and 0.616 Å to another IMP-1 
structure with a similar active-site ligand at 1.8 Å resolution (PDB code: 1JJE120) 
(Figure 2-39). The diffraction-component precision index (DPI)210 for the [FeZn]IMP-1 
structure was calculated to be 0.11 Å with an estimated maximal error of 0.09 Å. 
 
* All X-Ray diffraction experiments were performed by Dr P. Carr (RSC, ANU) with assistance from staff at the 
Australian Synchrotron 
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Figure 2-39 Cartoon structural alignment between [FeZn]IMP-1 (purple) and A) 2DOO (orange) or B) 1JJE (green). 
The global structure is almost identical, and the calculated backbone nitrogen RMSD was 0.34 Å to 2DOO and 
0.63 Å to 1JJE. Metal ions in the active site are shown as spheres. The ligand in the active site (citrate for 
[FeZn]IMP-1, succinic acid derivative for 1JJE and a fluorescent probe for 2DOO) is shown as sticks. 
A
B
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2.5.3 Determination of Iron-Binding Site 
The X-ray fluorescence* scan observed after excitation at the Se-K edge is seen 
in Figure 2-40. Strong fluorescence bands assigned to Zn Kα1, Kα2 and Kβ1 are present 
at 8,638, 8,615 and 9,572 eV. Weaker fluorescence bands are present for Fe Kα1 
(6,404 eV), Kα2 (6,391 eV) and the Kβ1 band at 7,058 eV is close to the noise level. 
Anomalous scattering experiments were run on the [FeZn]IMP-1 crystal above the iron 
and zinc absorption edges (7,162.0 and 9,660.0 eV). The anomalous scattering data 
maps obtained after refinement are shown in Figure 2-41. 
 
Figure 2-40 X-ray fluorescence scan at the Se-K edge. Assignments of iron and zinc Kα1, Kα2 and Kβ1 fluorescence 
bands are indicated. An unassigned fluorescence is present around 8,000 eV, which could correlate with the Cu-Kα 
band, but no appreciable amount of copper was determined in the protein via ICP-OES. The fluorescence for iron is 
weak and is highlighted with a cyan curve that has been multiplied by 10. 
The scattering maps were inconsistent with what was expected from the 
experiment, as the metal ion in the Zn1 site displayed the maximal anomalous scattering 
at both the zinc and iron ion edges rather than only one edge. This unexpected anomaly 
was corrected after close examination of the crystal temperature B factors of the metal 
ions and the citrate substrate. Initial rounds of refinement produced structures with 
metal ion B factors that differed greatly between the active-site metals and the active-
site ligands. By refining the occupancy of the metal ions and of the citrate substrate 
using Coot211, the B factors of the metals aligned more reasonably with those of the 
atoms from the protein that were directly ligating the metal ions (Table 2-10). 
 
* All X-ray diffraction experiments were performed by Dr P. Carr (RSC, ANU) with assistance from staff at the 
Australian Synchrotron 
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Figure 2-41 Anomalous scattering map showing anomalous diffraction around both active-site metals. A) Scattering 
at the iron ion edge (purple) is only around the metal in the Zn1 site, whereas B) anomalous scattering at the zinc ion 
edge (green) is in both the Zn1 site and the Zn2 site. Spheres represent the metal ions, and the active site residues are 
represented as sticks. Scattering maps are scaled to just see the signal on the sulfur of the cysteine ligand at the Zn2 
site. 
 
Table 2-10 Comparison of B factors prior and post active-site metal occupancy refinement 
Atom B factor Metal ion 
B factor before 
occupancy 
refinement 
B factor after 
occupancy refinement 
(occupancy) 
H77-Nε2 i 15.45 
Zn1 21.19 16.52 (0.81) H79-Nδ1 i 12.92 
H139-Nε2 i 14.61 
D81-Oδ2 ii 19.76 
Zn2 40.94 16.96 (0.31) C158-Sγ ii 19.91 
H197-Nε2 ii 24.96 
i atoms coordinating the Zn1 metal site 
ii atoms coordinating the Zn2 metal site. The higher B factors indicate higher flexibility, consistent with a low 
occupancy of the Zn2 metal ion-binding site 
 
Table 2-11 Anomalous scattering values before and after metal occupancy refinement. 
 
Rawi Correctedii Ratioiii Expectediv 
Fe edge Zn edge Fe edge Zn edge Fe edge Zn edge Fe edge Zn edge 
Zn1 Site 0.1267 0.1447 0.1567 0.1786 1.00 0.57 1.00 0.60 
Zn2 Site NDv 0.0972 NDv 0.3135 NDv 1.00 0.20 1.00 
i raw anomalous scattering data measured using COOT211 anomalous scattering map 
ii scaled to account for an occupancy of 0.81 for the Zn1 site and 0.31 for the Zn2 site 
iii experimental ratio between anomalous scattering in the Zn1 and Zn2 site 
iv expected ratio between anomalous scattering assuming iron in the Zn1 site and zinc in the Zn2 site188 
v anomalous scattering for the Zn2 site at the iron ion edge was below the background noise of the experiment 
With these refined metal occupancies, the anomalous scattering data were 
reanalysed and also became more consistent, suggesting that the Zn1 site was occupied 
A
Zn1
Zn2
Zn1
Zn2
B
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by iron (81% occupancy) and the Zn2 site was occupied by zinc (31% occupancy (Table 
2-11). 
2.5.4 Structural Comparison of [FeZn]IMP-1 to [ZnZn]IMP-1 
The crystal structure of [FeZn]IMP-1 was compared to two [ZnZn]IMP-1 
structures with similar resolutions and similar active-site ligands (PDB code: 1JJE120 
and 1DD6182) (Figure 2-42). Analysis was performed using chain A of the [FeZn]IMP-1 
structure, as this monomer was the most similar to the other three chains in the unit cell. 
Two chains are present in both 1JJE and 1DD6 but comparison was performed against 
only chain A in both cases. A global alignment between the structures yielded a 
backbone RMSD of 0.49 Å (1JJE) and 0.35 Å (1DD6). The active-site residues 
(backbone and side chain) aligned with an RMSD of 0.30 Å (1JJE) and 0.40 Å (1DD6).  
 
Figure 2-42 Structure of the active site of A) [FeZn]IMP-1, B) 1JJE and C) 1DD6. The bound ligand in all cases is 
shown in cyan sticks, and the side chains of the protein responsible for metal binding are also shown in sticks. The 
metal ions are shown in spheres, with zinc in grey and iron in orange. A very high degree of structural similarity is 
evident between 1JJE and [FeZn]IMP-1 in terms of the bound ligand, with an oxygen from a carboxylic acid group 
bridging between the two metal ions. In the absence of a ligand, the metal ions are likely bridged by a 
water/hydroxide ion. In 1DD6, a sulfur atom forms the bridge. 
 
Table 2-12 Metal-ligand distances from [FeZn]IMP-1, 1JJE and 1DD6 
Zn1 site  Zn2 site 
 [FeZn] (Å)i 1JJE (Å) 1DD6 (Å)   [FeZn] (Å)i 1JJE (Å) 1DD6 (Å) 
H77-Nε2 2.09 2.08 2.19  D81-Oδ2 2.04 2.03 2.10 
H79-Nδ1 2.02 2.06 2.15  C158-Sγ 2.38 2.15 2.33 
H139-Nε2 2.12 1.99 2.16  H197-Nε2 2.18 2.28 2.26 
L-1 2.00 2.00 2.24  L-1ii 2.44 2.14 2.40 
     L-2ii 2.24 2.30  
     L-3ii 2.26   
i [FeZn] is the structure solved in this work 
ii L-1 is the atom in the bridging water/hydroxide ion position from the ligand. L-2 is the second carboxylic oxygen 
for both the succinic acid derivative in 1JJE and the citrate ion in [FeZn]IMP-1. L-3 is the alcohol oxygen in the 
citrate ion in [FeZn]IMP-1 
The inter-metal distance was 3.56 Å in 1JJE, 3.60 Å in 1DD6 and 3.80 Å in the 
[FeZn]IMP-1 structure. Other key distances are listed in Table 2-12. It is worth noting 
BA C
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that the ligands in 1JJE and [FeZn]IMP-1 provide extra oxygen ligands to the Zn2 site. 
The metal molecular geometries for the three structures are also included in Table 2-13. 
Table 2-13 Active site metal-ligand geometryi 
[FeZn]ii Zn1 – 4 ligands   Zn2 – 6 ligands 
 H79-Nδ1 H139-Nε2 L-1iii   C158-Sγ H197-Nε2 L-1iii L-2iii L-3iii 
H77-Nε2 101.2 109.7 123.5  D81-Oδ2 99.2 104.8 86.7 161.9 87.4 
H79-Nδ1  106.3 108.5  C158-Sγ  109.1 100.1 93.4 163.6 
H139-Nε2   106.5  H197-Nε2   146.1 83.1 83.3 
     L-1iii    78.2 65.1 
     L-2iii     77.2 
           
1JJE Zn1 – 4 ligands   Zn2 – 5 ligands 
 H79-Nδ1 H139-Nε2 L-1iii   C158-Sγ H197-Nε2 L-1iii L-2iii  
H77-Nε2 97.7 105.0 122.6  D81-Oδ2 106.9 89.9 91.3 150.6  
H79-Nδ1  107.8 113.3  C158-Sγ  107.9 110.2 102.5  
H139-Nε2   109.1  H197-Nε2   139.7 79.6  
     L-1iii    79.9  
           
1DD6 Zn1 – 4 ligands   Zn2 – 4 ligands 
 H79-Nδ1 H139-Nε2 L-1iii   C158-Sγ H197-Nε2 L-1iii   
H77-Nε2 108.0 108.4 124.6  D81-Oδ2 112.8 100.0 105.3   
H79-Nδ1  107.5 107.2  C158-Sγ  106.9 118.8   
H139-Nε2   99.9  H197-Nε2   111.6   
i all angles in degrees 
ii [FeZn] is the structure solved in this work 
iii L-11 is the atom in the bridging water/hydroxide ion position from the ligand. L-2 is the second carboxylic oxygen 
for both the succinic acid derivative in 1JJE and the citrate ion in [FeZn]IMP-1. L-3 is the alcohol oxygen in the 
citrate ion in [FeZn]IMP-1 
It was noted, however, that the local RMSD significantly reduced for 1JJE if 
structural alignments were performed only for the N-terminal or C-terminal regions 
(Figure 2-43). When residues 1 to 120 were aligned, a backbone RMSD of 0.45 Å was 
measured. The global RMSD with this alignment was 0.69 Å and the RMSD of the C-
terminal half was 0.88 Å. Similarly, if residues 120 to 221 were aligned, a backbone 
RMSD of 0.45 Å was measured, with a global RMSD of 0.65 Å and an N-terminal half 
RMSD of 0.80 Å. The improvement of alignment with 1DD6 was not as drastic, with 
the N-terminal alignment yielding RMSDs of 0.36 Å to the N-terminal region, 0.43 Å to 
the C-terminal region and 0.40 Å globally. The C-terminal alignment yielded RMSDs 
for the N-terminal region of 0.45 Å, the C-terminal region of 0.28 Å, and globally of 
0.38 Å.* 
 
* All RMSD calculations excluded the most mobile regions including residues 1 to 4 of the N-terminus, residues 23-
32 of the flap, and 216-221 of the C-terminus. 
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Figure 2-43 Structural alignment of the N- and C-terminal halves of the solved crystal structure of [FeZn]IMP-1 to 
1JJE (green) and 1DD6 (light green). The N-terminal half of [FeZn]IMP-1 is coloured pink, where the C-terminal 
half is coloured purple. A) When residues 1 to 120 of the N-terminal half are aligned to 1JJE (RMSD: 0.45 Å) an 
offset of the C-terminal half is evident to 1JJE (RMSD: 0.88). B) Conversely, when only the C-terminal domain is 
aligned (RMSD: 0.45 Å) the N-terminal domain is also offset by a similar amount (RMSD: 0.80 Å). Alignment of the 
C) N-terminal domain or the D) C-terminal domain to 1DD6 does not have as drastic an effect. The Cα atom of 
Gly120 is indicated as a small sphere at the bottom of each structure. The flap region (excluded from RMSD 
calculations) is evident at the top of each structure. Only the metal ions from the [FeZn]IMP-1 structure are shown as 
spheres, with iron in orange and zinc in grey. The ligands co-crystallised in each structure are indicated as sticks. 
The difference from 1JJE would seem to suggest that the sandwich αβ/βα-fold of 
the enzyme is somewhat flexible, enabling a slightly larger opening in the active site 
groove. This can be quantified by measuring the angle defined by the three Cα atoms of 
Ala53, Gly120 and Leu205. The [ZnZn] form in 1JJE has an angle of 66.5° and for the 
[FeZn] form an angle of 68.8° is present. This difference is probably not due to the 
metal substitution as the same angle measured in 1DD6 is 68.9° (Figure 2-44). 
A
1JJE
N-Term
B
1JJE
C-Term
C
1DD6
N-Term
D
1DD6
C-Term
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Figure 2-44 αβ/βα-fold opening angle. A) The [FeZn]IMP-1 structure solved in this work has a wider opening than 
B) the 1JJE structure, but C) a very similar opening to 1DD6. Small spheres highlight the Cα atoms of A53, G120 
and L205 that were used to measure the reported angles. The two active-site metals are shown in spheres, with zinc in 
grey and iron in dark orange. Active-site ligands are shown as sticks. 
Finally, packing-density analysis of chain A from the [FeZn]IMP-1 structure 
and chain A from the 1JJE and 1DD6 structures was performed using Voronoia 
software.212 The results are listed in Table 2-14 below. Of the [ZnZn]IMP-1 structures, 
1DD6 had the least efficient packing density (0.716) with 15 internal cavities. 1JJE had 
a buried packing density of 0.709 with 19 internal cavities. The [FeZn]IMP-1 structure 
had a packing density of 0.710, and 15 internal cavities. The cavities are visualised in 
Figure 2-45. Of the cavities found, 8 are shared between all structures. The 
[FeZn]IMP-1 structure has 4 unique cavities, and of particular interest is the location of 
one directly under the active site. This is highlighted in Figure 2-45D. 
Table 2-14 Results from packing-density calculations 
Proteini Av. VdW 
volume (Å3)ii 
Av. solvent 
excluded (Å3)iii 
Av. total 
volume (Å3)iv 
Av. packing 
densityv 
Number of 
cavitiesvi 
[FeZn]IMP-1 10.90 5.35 16.25 0.710 15 
1JJE 10.83 5.38 16.21 0.709 19 
1DD6 10.92 5.22 16.15 0.716 15 
i Surface atoms are defined by rolling a virtual water molecule (a 1.4 Å radius sphere) over the protein. Any atom that 
is touched by the probe is assigned to the surface and excluded from the density analysis. All other atoms are defined 
as buried. 
ii Average Van-der-Waals radii calculated volume per atom analysed 
iii Average volume of solvent excluded per atom analysed excess to the Van-der-Waals volume 
iv The average sum of Van-der-Waals volume and solvent excluded volume per atom analysed 
v Average packing density, defined as column 3 divided by the sum of column 4 and 5 
vi Number of cavities identified as a void that a virtual 1.4 Å radius probe could fit where there is no escape path out 
of the protein without collision with a protein atom. 
A B C
68.8° 68.9°66.5°
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Figure 2-45 Visualisation of calculated cavities large enough to fit a 1.4 Å radius sphere (water molecule) for A) 
[FeZn]IMP-1, B) 1JJE and C) 1DD6. The cavities are indicated by red surfaces. 19 cavities were found in the 1JJE 
structure whereas only 15 cavities were found in the [FeZn] form and 1DD6. Cavities around the active site are 
highlighted in D-F) where cavities common to all three structures are coloured white, cavities common to 1JJE are 
coloured green, cavities common to 1DD6 are coloured light green, cavities common to [FeZn]IMP-1 are coloured 
purple, and unique cavities are coloured red. Of particular note is the unique cavity found under the metal ions in the 
[FeZn]IMP-1 structure. 
  
A B C
D E F
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2.6 Results: NMR Analysis of IMP-1 
2.6.1 Protein Samples Prepared by Cell-Free Synthesis with 
Combinatorial and Individual 15N-Labelling 
NMR assignments and analyses were aided by the cell-free production of IMP-1 
with combinatorial-labelling,213-215* however, total control over the metal substitution of 
the enzyme was not attained even after the addition of excess zinc. This resulted in 
spectral overlap of some of the peaks in the [FeZn] form with peaks from the [ZnZn] 
form (Figure 2-46), and was especially problematic since the method relies on accurate 
superposition of the spectra from different samples for amino-acid type identification. 
The resulting occasional misassignment of amino-acid type was resolved by the 
individual labelling of 19 samples in cell-free protein synthesis, †  which was 
supplemented with exogenous zinc. While complete control over the metal incorporated 
into the enzyme was still not attained, the amino-acid typing of the [ZnZn]IMP-1 was 
rendered reliable (Figure 2-47). 
 
Figure 2-46 A) Combinatorial labelling failed to correctly identify a Trp residue due to overlap of [FeZn]IMP-1 
peaks with [ZnZn]IMP-1 peaks. Overlapping peaks from set 1 (red), set 2 (orange), set 3 (green), set 4 (blue) and set 
5 (purple) imply the highlighted peak on the left is a Gln residue, but B) single labelling with 15N-Gln (grey) and Trp 
(purple) resolves the overlap issue and significantly simplifies analysis. 
 
* Samples with combinatorial 15N-labelling were synthesised with assistance from Mr J. Chew 
† Samples with individual 15N-labelling were synthesised by Ms E. Cliff under supervision by Dr C.T. Loh and the 
author 
7.727.767.807.84 7.727.767.807.84
121.4
121.8
122.2
122.6
Set 2,4,5 = Gln GlnTrp
A B
Set 2,4,5 = Gln?
į2(1H)/ppm
į1(15N)
  ppm
 77 
 
Figure 2-47 Overlay of 19 15N-HSQC spectra used for amino-acid typing. Comparison to a [1H-15N]-TROSY 
spectrum of an in vitro uniformly 2H/13C/15N-labelled [ZnZn]IMP-1 sample (black) is highlighted for an overlapped 
region. Amino acids are coloured as follows: alanine (red), arginine (dark grey), asparagine and aspartate (maroon), 
cysteine (light pink), glutamine (grey), glutamate (mid pink), glycine (orange), histidine (green), isoleucine (mid 
green), leucine (cyan), lysine (teal), methionine (sky blue), phenylalanine (navy), serine (blue), threonine (mid blue), 
trptophan (mauve), tyrosine (magenta), valine (pink). 
The amino-acid pairs serine-threonine and serine-serine only occur once in the 
IMP-1 sequence, enabling individual assignments of two residues close to the active 
site, Ser92 and Thr99, by 15N-Thr and 13C15N-Ser labelling using cell-free protein 
synthesis.* When a 15N-HSQC spectrum was measured with 13C decoupling only for the 
Cα region, two doublets were observed corresponding to a 1JNC’ coupling of 
approximately 14 Hz (Figure 2-48) corresponding to either an ST or SS dipeptide 
sequence. Comparison with the spectra of combinatorial or single amino-acid labelled 
samples allowed distinction between the two cases. 
 
* Samples with 13C15N-labelled serine and 15N-labelled threonine were synthesised with assistance from Mr J. 
Neeman 
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Figure 2-48 15N-HSQC NMR spectrum of 15N-Thr and 13C15N-Ser labelled IMP-1 recorded with 13C decoupling of 
C’ but not Cα. Assignments were made by identifying two peaks with doublet splitting in the nitrogen dimension due 
to 1JNC’ couplings of approximately 14 Hz (highlighted by red boxes). The two peaks can be assigned to serine or 
threonine by comparison with other spectra where serine or threonine residues were selectively labelled with 15N. 
2.6.2 Assignment of Backbone Resonances via 3D NMR Experiments 
HNCA, HN(CO)CA, HNCACB and CBCA(CO)NH experiments were recorded 
of the [ZnZn]IMP-1 in vivo sample for assignment purposes. Approximately 50% of the 
non-proline backbone amide resonances were assigned this way, however significant 
overlap made further assignment impossible. 
To address the problem of overlapping cross-peaks, a 2H/13C/15N-labelled 
sample was expressed in vivo and [1H-15N]-TROSY, TROSY-HNCA, TROSY-
HNCACB, TROSY-HNCO and TROSY-HN(CA)CO experiments were recorded. As 
the enzyme could not be refolded, back-exchange of the amide protons could only be 
achieved by exposure to H2O as it occurs, for example, during protein purification. The 
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spectral resolution obtained from the triple-labelled sample was vastly improved and 
enabled the deconvolution of many overlapping peaks, but amides of buried residues 
were not easily observed due to limited back-protonation. 
The issue of proton back-exchange prompted the project described in chapter 3. 
In brief, a protein sample uniformly labelled with 2D/13C/15N amino acids was made by 
cell-free synthesis in H2O.* This made the need for back-exchange of amide protons 
dispensable. With this sample, [1H-15N]-TROSY, TROSY-HNCA, TROSY-HNCACB, 
TROSY-HNCO and TROSY-HN(CA)CO experiments were recorded. 
Using the information from the combinatorially 15N-labelled samples, the 
individually 15N-labelled cell-free samples, the in vivo 15N-labelled [ZnZn] samples and 
the triple-labelled sample prepared by cell-free synthesis, 89.5% of the non-proline 
backbone amide resonances of the [ZnZn]IMP-1 protein were assigned. †  These 
assignments were mapped onto the NMR spectra of the [FeZn]IMP-1 sample assuming 
similarity of backbone amide shifts, and confirmed where possible by checking for 
similarity of Cα chemical shifts.‡ All completed assignments of [ZnZn]IMP-1 and 
[FeZn]IMP-1 are listed in Table 2-15 and Table 2-16, respectively. 
Regions of the [ZnZn] protein with unassigned backbone resonances were 
limited to β-turns and to flexible loops near the active site (Figure 2-49). 
 
 
* The sample with uniform 2H13C15N-labelled amino acids in H2O cell-free protein synthesis reaction was performed 
by Dr C.T. Loh in consultation with the author 
† Degree of assignment (including proline residues) of [ZnZn]IMP-1 including the N-terminal MASMTG tag: 
H 196/219, N 196/233, Cα 212/233, Cβ 175/212, C’ 168/233. 
‡ Degree of assignment (including proline residues) of [FeZn]IMP-1 including the N-terminal MASMTG tag: 
H 156/219, N 156/233, Cα 162/233. 
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Table 2-15 Table of backbone assignments of [ZnZn]IMP-1i 
Residue H N Cα Cβ C’ 
-4 Met      
-3 Ala      
-2 Ser      
-1 Met 8.57 122.5 
  
176.9 
0 Thr 8.07 113.7 
  
175.6 
1 Gly 8.24 111.0 45.4 - 174.5 
2 Glu 8.08 120.3 56.4 30.1 176.8 
3 Ser 8.16 116.4 58.2 63.7 174.3 
4 Leu 8.03 125.1 52.9 41.5 175.1 
5 Pro - 
 
62.3 30.5 175.5 
6 Asp 7.66 119.4 53.7 42.2 175.7 
7 Leu 7.95 120.2 55.9 42.6 176.8 
8 Lys 9.01 127.9 54.7 35.3 175.7 
9 Ile 8.13 123.5 61.1 40.1 175.6 
10 Glu 8.73 124.7 54.4 34.1 175.0 
11 Lys 9.00 126.6 58.1 32.5 175.5 
12 Leu 8.89 129.8 55.3 44.5 175.2 
13 Asp 8.24 116.3 51.4 43.6 175.4 
14 Glu 9.16 122.1 58.1 28.3 177.7 
15 Gly 8.63 113.7 46.5 - 173.6 
16 Val 7.99 117.9 61.9 34.7 174.0 
17 Tyr 9.46 126.9 56.5 41.1 175.4 
18 Val 9.54 121.1 60.0 33.8 176.8 
19 His 8.32 126.0 52.6 34.9 174.5 
20 Thr 9.32 120.1 61.6 70.5 172.4 
21 Ser 8.44 120.0 56.0 67.5 173.0 
22 Phe 8.67 116.2 57.6 43.6 174.6 
23 Glu 7.91 120.0 54.5 31.3 
 24 Glu 8.69 124.7 55.9 29.8 175.9 
25 Val 8.57 127.9 61.3 33.2 176.7 
26 Asn 
     27 Gly 
  
45.5 - 174.4 
28 Trp 8.21 120.3 57.7 31.4 176.3 
29 Gly 8.24 108.4 44.7 - 173.2 
30 Val 8.33 122.1 63.0 31.4 176.6 
31 Val 9.07 130.0 58.8 34.3 
 32 Pro - 
 
61.2 32.6 176.9 
33 Lys 8.74 119.8 53.3 35.1 175.7 
34 His 9.83 128.8 53.7 29.4 176.2 
35 Gly 8.79 112.7 43.1 - 172.9 
36 Leu 8.78 115.1 53.0 46.2 178.3 
37 Val 9.15 121.2 63.0 34.0 174.9 
38 Val 8.94 126.5 60.4 34.2 174.7 
39 Leu 8.96 126.4 53.3 41.2 177.6 
40 Val 9.28 125.3 61.5 32.6 176.3 
41 Asn 
  
55.9 37.1 174.5 
42 Ala 8.33 123.4 52.8 17.8 176.2 
43 Glu 8.18 119.2 55.2 31.5 174.5 
44 Ala 8.78 122.1 50.1 21.4 176.2 
45 Tyr 8.90 119.0 56.6 40.5 175.5 
46 Leu 8.72 122.9 55.3 41.3 175.2 
47 Ile 9.25 125.8 60.5 33.9 175.2 
48 Asp 8.91 117.9 57.2 38.8 175.1 
49 Thr 6.87 104.5 58.3 67.9 173.5 
50 Pro 
  
62.5 33.2 173.6 
51 Phe 6.86 111.9 61.2 41.0 177.6 
52 Thr 7.13 99.5 58.6 73.8 
 53 Ala 
  
55.6 17.9 179.9 
54 Lys 8.15 117.9 59.2 31.2 179.6 
55 Asp 7.69 118.1 56.8 40.6 178.8 
56 Thr 7.65 119.9 68.6 66.9 174.6 
57 Glu 7.70 122.1 58.8 27.8 179.5 
58 Lys 7.60 121.2 60.1 32.3 178.8 
59 Leu 7.87 120.9 58.1 42.2 177.6 
60 Val 8.23 116.5 67.4 31.4 178.5 
Residue H N Cα Cβ C’ 
61 Thr 8.50 115.2 67.1 68.9 175.1 
62 Trp 7.82 122.1 62.3 29.5 179.6 
63 Phe 7.36 112.8 63.6 39.0 179.0 
64 Val 8.98 124.1 66.2 31.4 182.1 
65 Glu 8.69 120.3 58.7 28.6 178.1 
66 Arg 6.79 117.1 56.0 29.4 175.5 
67 Gly 7.64 105.7 45.3 - 174.5 
68 Tyr 7.69 119.5 57.5 39.0 175.1 
69 Lys 8.15 119.9 54.6 33.5 176.3 
70 Ile 8.60 124.0 59.2 33.8 176.1 
71 Lys 8.71 127.8 54.2 32.9 176.9 
72 Gly 6.75 102.1 45.6 - 171.5 
73 Ser 8.38 113.3 56.2 66.6 173.6 
74 Ile 9.21 124.3 57.9 40.3 173.8 
75 Ser 7.86 121.8 58.8 65.2 174.3 
76 Ser 10.78 120.6 60.3 63.7 173.8 
77 His 7.68 110.3 55.4 27.2 175.9 
78 Phe 9.15 115.7 59.9 39.2 175.0 
79 His 
     80 Ser 
     81 Asp 
  
55.0 38.1 173.8 
82 Ser 7.46 108.4 60.7 66.9 178.0 
83 Thr 7.48 109.6 61.3 71.7 176.7 
84 Gly 8.37 113.0 47.7 - 176.1 
85 Gly 8.61 106.3 45.5 - 174.6 
86 Ile 7.87 121.4 67.2 36.8 177.1 
87 Glu 8.80 120.3 60.6 28.6 178.9 
88 Trp 8.74 122.0 62.9 28.4 180.6 
89 Leu 8.46 120.8 58.8 40.2 179.9 
90 Asn 9.17 119.3 55.4 36.4 180.8 
91 Ser 8.07 118.8 61.1 62.6 174.9 
92 Arg 7.09 122.3 54.2 28.8 175.5 
93 Ser 7.76 111.0 59.1 61.0 174.3 
94 Ile 7.72 123.3 58.4 38.1 174.9 
95 Pro - 
 
64.3 33.0 174.9 
96 Thr 7.05 111.9 58.4 72.0 174.9 
97 Tyr 9.11 120.0 56.8 41.7 176.5 
98 Ala 8.29 121.5 51.3 21.0 174.3 
99 Ser 9.44 117.1 57.2 64.1 174.8 
100 Glu 7.93 120.3 59.9 29.1 179.4 
101 Leu 7.96 119.7 57.5 40.5 178.8 
102 Thr 8.15 119.1 66.6 67.2 176.6 
103 Asn 8.21 119.0 54.9 37.0 179.0 
104 Glu 7.98 122.6 59.4 28.8 179.4 
105 Leu 7.93 121.5 57.8 38.9 180.4 
106 Leu 8.36 120.7 58.3 40.9 179.1 
107 Lys 7.84 119.8 59.4 31.7 181.5 
108 Lys 8.07 121.0 59.2 31.6 177.8 
109 Asp 7.29 117.7 54.2 42.1 176.8 
110 Gly 7.94 108.4 46.2 - 175.2 
111 Lys 8.02 119.3 53.3 33.8 176.0 
112 Val 7.84 120.1 63.5 31.6 175.9 
113 Gln 7.75 121.8 55.7 31.0 177.9 
114 Ala 8.36 122.7 51.7 18.5 179.1 
115 Thr 8.74 114.5 63.8 69.5 174.8 
116 Asn 8.38 119.3 52.7 41.6 173.4 
117 Ser 8.38 115.0 55.9 65.9 174.2 
118 Phe 6.81 116.0 55.2 40.4 174.0 
119 Ser 8.43 115.8 57.1 65.2 174.3 
120 Gly 8.17 108.8 44.4 - 174.3 
121 Val 8.20 117.2 64.4 32.1 175.1 
122 Asn 7.68 114.9 52.1 42.0 174.0 
123 Tyr 8.58 122.9 57.1 41.7 174.1 
124 Trp 8.21 127.5 55.4 28.0 174.4 
125 Leu 7.23 127.1 56.8 42.0 177.1 
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Residue H N Cα Cβ C’ 
126 Val 6.96 112.8 61.3 34.5 176.9 
127 Lys 
  
59.2 30.9 175.9 
128 Asn 5.89 116.2 56.1 37.6 173.9 
129 Lys 7.73 115.5 56.9 35.8 176.4 
130 Ile 8.49 116.7 62.1 40.9 173.5 
131 Glu 9.22 131.7 54.6 32.1 174.0 
132 Val 9.16 126.9 60.9 32.0 175.1 
133 Phe 8.76 126.9 55.5 43.1 173.2 
134 Tyr 8.45 129.5 52.5 38.9 171.8 
135 Pro 
     136 Gly 
   
- 
 137 Pro - 
    138 Gly 
   
- 
 139 His 
  
59.1 
  140 Thr 7.50 103.8 59.6 
  141 Pro - 
 
65.2 
  142 Asp 9.54 108.4 53.2 
  143 Asn 6.57 116.7 54.8 39.4 175.6 
144 Val 9.03 115.3 59.2 34.3 176.1 
145 Val 9.01 111.6 58.7 32.3 175.0 
146 Val 8.27 118.1 60.7 34.7 173.0 
147 Trp 9.81 131.1 54.3 33.6 173.9 
148 Leu 7.90 125.9 50.2 39.6 175.3 
149 Pro - 
 
64.2 32.1 179.1 
150 Glu 8.61 114.4 59.1 29.2 178.4 
151 Arg 6.55 111.3 52.9 30.4 175.1 
152 Lys 7.53 114.1 57.1 28.9 175.6 
153 Ile 6.37 116.2 60.0 41.1 173.0 
154 Leu 8.82 127.2 52.4 45.7 175.9 
155 Phe 10.29 128.4 57.1 38.2 174.4 
156 Gly 7.93 113.4 43.9 - 
 157 Gly 5.72 104.9 47.4 - 176.5 
158 Cys 9.32 128.7 60.1 27.0 174.0 
159 Phe 6.97 116.5 60.4 40.5 174.7 
160 Ile 6.18 111.6 57.9 35.3 179.3 
161 Lys 6.80 121.9 59.4 
  162 Pro - 
 
63.3 
  163 Tyr 7.77 114.1 55.9 
  164 Gly 
   
- 
 165 Leu 
     166 Gly 
   
- 
 167 Asn 
     168 Leu 
  
55.0 
  169 Gly 8.54 109.1 48.1 - 
 170 Asp 7.96 117.1 54.0 
  171 Ala 7.24 122.1 52.2 21.0 
 172 Asn 8.25 118.4 51.6 38.1 
 173 Ile 8.35 121.8 62.8 
  174 Glu 7.95 117.7 59.1 29.7 178.6 
175 Ala 7.47 118.6 53.0 20.3 179.1 
176 Trp 7.81 119.8 61.3 26.9 
 177 Pro - 
 
66.8 30.5 180.0 
Residue H N Cα Cβ C’ 
178 Lys 7.26 118.9 59.9 31.5 180.3 
179 Ser 8.74 118.9 60.4 
  180 Ala 9.43 123.2 55.0 18.2 
 181 Lys 8.26 122.3 60.1 
  182 Leu 7.74 121.9 58.1 
  183 Leu 8.18 118.6 58.3 41.4 178.2 
184 Lys 7.94 117.4 59.2 31.9 177.9 
185 Ser 7.74 113.1 60.8 62.9 176.2 
186 Lys 7.54 120.7 57.9 32.6 178.2 
187 Tyr 7.55 114.1 56.7 37.4 175.5 
188 Gly 7.14 105.9 47.1 - 174.6 
189 Lys 7.48 115.4 55.2 30.7 176.2 
190 Ala 7.66 122.1 53.8 18.8 176.6 
191 Lys 9.27 122.7 57.9 33.3 176.9 
192 Leu 7.21 114.5 53.1 46.8 175.4 
193 Val 9.07 122.0 60.6 32.7 174.2 
194 Val 9.13 126.0 59.1 33.1 174.7 
195 Pro - 
    196 Ser 
     197 His 
  
54.8 
  198 Ser 7.08 111.5 57.6 63.2 
 199 Glu 8.30 117.3 57.0 29.9 176.6 
200 Val 7.96 118.3 64.0 31.4 176.5 
201 Gly 8.12 114.2 45.1 - 172.1 
202 Asp 7.99 120.6 52.3 41.5 
 203 Ala 8.20 116.2 55.1 17.5 
 204 Ser 9.18 119.5 62.3 
  205 Leu 8.11 119.7 58.3 40.9 
 206 Leu 
     207 Lys 
     208 Leu 
  
58.1 
  209 Thr 7.32 113.9 67.6 69.4 
 210 Leu 7.02 121.3 58.7 
  211 Glu 8.03 116.8 59.5 29.4 
 212 Gln 8.18 118.0 58.0 31.4 
 213 Ala 8.25 124.1 55.0 
  214 Val 8.27 119.7 67.0 
  215 Lys 7.79 120.4 59.7 32.3 
 216 Gly 8.17 105.9 46.4 - 
 217 Leu 7.90 123.3 57.7 
  218 Asn 8.23 118.7 55.9 38.3 
 219 Glu 8.26 118.7 58.0 29.7 
 220 Ser 7.71 114.7 60.1 63.8 
 221 Lys 7.56 121.0 55.9 32.3 
 222 Lys 7.79 122.6 
   223 Pro - 
 
63.2 32.1 
 224 Ser 8.30 116.5 58.3 64.1 
 225 Lys 8.11 123.7 54.1 32.9 
 226 Pro - 
 
63.4 32.1 
 227 Ser 8.27 116.2 58.3 63.9 173.9 
228 Asn 7.90 125.4 55.0 40.2 179.7 
 
i Chemical shifts reported in ppm. Shifts highlighted in red were not observable in the TROSY-type experiments that 
contained constant time elements, and were measured of non-deuterated protein using conventional HNCA or 
HNCACB NMR experiments. Blank fields indicate unassigned resonances. The six metal-coordinating residues are 
highlighted in bold type. 
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Table 2-16 Table of backbone assignments of [FeZn]IMP-1i 
Residue H N Cα 
-4 Met    
-3 Ala    
-2 Ser    
-1 Met   56.0 
0 Thr 8.09 113.7 62.1 
1 Gly 8.26 111.0 45.5 
2 Glu 8.11 120.5 56.6 
3 Ser 8.19 116.6 58.2 
4 Leu 8.05 125.1 53.1 
5 Pro -  62.6 
6 Asp 7.72 119.6 53.7 
7 Leu 8.00 120.2 56.2 
8 Lys 9.09 128.1 54.9 
9 Ile 8.18 123.7 61.2 
10 Glu 8.76 124.9 54.5 
11 Lys 9.04 126.8 58.4 
12 Leu 8.94 130.0 55.2 
13 Asp 8.27 116.4 51.4 
14 Glu 9.20 122.2 58.2 
15 Gly 8.66 114.0 46.6 
16 Val 8.01 117.9 62.1 
17 Tyr 9.50 127.1 56.7 
18 Val 9.59 121.3 60.2 
19 His 8.38 126.1 52.6 
20 Thr 9.43 120.4 62.0 
21 Ser    
22 Phe    
23 Glu    
24 Glu    
25 Val    
26 Asn    
27 Gly    
28 Trp 8.22 120.3 57.1 
29 Gly 8.24 108.6 44.6 
30 Val    
31 Val    
32 Pro -   
33 Lys    
34 His    
35 Gly    
36 Leu   53.1 
37 Val 9.20 121.4 63.2 
38 Val 8.97 126.8 60.6 
39 Leu 8.99 126.6 53.3 
40 Val 9.30 125.3 61.7 
41 Asn   56.1 
42 Ala 8.35 123.4 52.9 
43 Glu 8.20 119.2 55.3 
44 Ala 8.81 122.3 50.2 
45 Tyr 8.90 119.1 56.7 
46 Leu 8.75 123.1 55.4 
47 Ile    
48 Asp    
49 Thr    
50 Pro -   
51 Phe    
52 Thr    
53 Ala    
54 Lys 8.20 117.9 59.6 
55 Asp 7.76 118.3 57.0 
56 Thr 7.74 120.1 69.0 
57 Glu 7.76 122.3 59.1 
58 Lys 7.68 121.5 60.1 
59 Leu 7.92 121.1 58.2 
60 Val 8.27 116.7 67.7 
Residue H N Cα 
61 Thr 8.55 115.3 67.3 
62 Trp 7.88 122.2 62.6 
63 Phe 7.39 112.9 63.9 
64 Val 9.00 124.2 66.6 
65 Glu 8.74 120.4 59.0 
66 Arg 6.82 117.2 56.1 
67 Gly 7.68 105.8 45.4 
68 Tyr 7.71 119.5 57.7 
69 Lys 8.16 120.0 54.7 
70 Ile 8.65 124.1 59.4 
71 Lys 8.74 128.1 54.2 
72 Gly 6.80 102.2 45.7 
73 Ser 8.38 113.2 56.3 
74 Ile 9.27 124.8  
75 Ser 7.93 121.9 58.9 
76 Ser    
77 His    
78 Phe    
79 His    
80 Ser    
81 Asp    
82 Ser    
83 Thr    
84 Gly    
85 Gly    
86 Ile 7.88 121.3 67.6 
87 Glu 8.83 120.3 60.9 
88 Trp 8.79 122.0 63.2 
89 Leu 8.50 120.9 59.1 
90 Asn 9.16 119.4 55.4 
91 Ser 8.09 119.0 61.3 
92 Arg 7.11 122.4 54.2 
93 Ser 7.79 111.0 59.2 
94 Ile 7.73 123.3 58.6 
95 Pro -  64.5 
96 Thr 7.11 112.2 58.5 
97 Tyr 9.18 120.2 56.9 
98 Ala 8.29 121.7 51.2 
99 Ser 9.34 117.1 57.2 
100 Glu 7.99 120.4 60.2 
101 Leu 7.96 119.8 57.8 
102 Thr 8.14 119.2 66.8 
103 Asn 8.22 119.2 54.9 
104 Glu 7.97 122.8 59.5 
105 Leu 7.92 121.6 58.2 
106 Leu 8.37 120.9 58.5 
107 Lys 7.84 119.8 59.7 
108 Lys 8.08 121.2 59.6 
109 Asp 7.32 117.9 54.1 
110 Gly 7.95 108.3 46.2 
111 Lys 8.01 119.4 53.5 
112 Val 7.86 120.1 63.7 
113 Gln 7.76 121.8 55.8 
114 Ala 8.38 122.9 51.8 
115 Thr 8.76 114.4 64.0 
116 Asn 8.40 119.4 52.7 
117 Ser 8.40 115.1 56.0 
118 Phe 6.79 115.9 55.3 
119 Ser 8.40 115.7 57.1 
120 Gly 8.15 108.6 44.4 
121 Val 8.21 117.6 64.8 
122 Asn 7.66 114.9 52.1 
123 Tyr 8.58 123.0 57.1 
124 Trp 8.18 127.6 55.3 
125 Leu 7.24 127.0 56.9 
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Residue H N Cα 
126 Val 6.96 112.9 61.6 
127 Lys   59.4 
128 Asn 5.86 116.3 56.3 
129 Lys 7.72 115.6 57.1 
130 Ile 8.50 116.8 62.2 
131 Glu 9.23 131.9 54.7 
132 Val 9.17 126.9 61.2 
133 Phe 8.73 127.0 55.4 
134 Tyr 8.36 129.7 52.5 
135 Pro -   
136 Gly    
137 Pro -   
138 Gly    
139 His    
140 Thr    
141 Pro -   
142 Asp    
143 Asn    
144 Val    
145 Val 8.98 111.8 58.7 
146 Val   60.7 
147 Trp 9.82 131.3 54.2 
148 Leu 7.94 126.2 50.3 
149 Pro -  64.4 
150 Glu 8.62 114.4 59.3 
151 Arg 6.52 111.4 52.9 
152 Lys 7.57 114.1 57.2 
153 Ile 6.32 116.2 60.2 
154 Leu 8.82 127.5 52.3 
155 Phe 10.23 128.0 57.6 
156 Gly   57.9 
157 Gly 6.81 122.0 59.7 
158 Cys    
159 Phe    
160 Ile    
161 Lys    
162 Pro -   
163 Tyr    
164 Gly    
165 Leu    
166 Gly    
167 Asn    
168 Leu    
169 Gly    
170 Asp    
171 Ala    
172 Asn 8.26 118.4  
173 Ile 8.37 122.0  
174 Glu 8.01 117.6 59.3 
175 Ala 7.44 118.6 53.0 
176 Trp 7.81 119.7  
177 Pro -  67.3 
Residue H N Cα 
178 Lys 7.33 118.5 60.2 
179 Ser 8.74 119.2 60.6 
180 Ala 9.54 123.6 55.2 
181 Lys 8.33 122.3 60.4 
182 Leu    
183 Leu 8.16 118.6 58.2 
184 Lys 7.95 117.5 59.2 
185 Ser 7.79 113.3 61.1 
186 Lys 7.68 120.9 58.1 
187 Tyr 7.62 114.3 56.9 
188 Gly 7.08 106.1 47.2 
189 Lys 7.49 115.4 55.1 
190 Ala 7.69 122.3 54.0 
191 Lys 9.24 123.0 58.2 
192 Leu 7.22 114.4 53.1 
193 Val 9.11 122.1 60.7 
194 Val 9.03 126.1 59.3 
195 Pro -   
196 Ser    
197 His    
198 Ser    
199 Glu 8.42 117.7 57.2 
200 Val 7.99 118.4 64.3 
201 Gly 8.07 114.7 45.1 
202 Asp 8.01 120.6 52.3 
203 Ala 8.23 116.3 55.3 
204 Ser 9.18 119.7 62.6 
205 Leu 8.11 119.7 58.3 
206 Leu    
207 Lys    
208 Leu    
209 Thr 7.28 113.8 67.7 
210 Leu 7.01 121.5 59.0 
211 Glu 7.98 116.6  
212 Gln 8.16 118.0  
213 Ala 8.39 124.5 55.2 
214 Val 8.32 119.6 67.2 
215 Lys 7.85 120.5 60.1 
216 Gly 8.23 105.9 46.7 
217 Leu 8.07 123.9 58.2 
218 Asn 8.24 118.8 56.1 
219 Glu 8.31 118.8 58.2 
220 Ser 7.76 114.8 60.2 
221 Lys 7.59 121.0 56.2 
222 Lys 7.81 122.6 54.7 
223 Pro -  63.4 
224 Ser 8.33 116.6 58.5 
225 Lys 8.13 123.7 54.2 
226 Pro -  63.4 
227 Ser 8.30 116.3 58.4 
228 Asn 7.93 125.6 55.1 
 
i Chemical shifts reported in ppm. All measurements were made on non-deuterated protein using a conventional 
HNCA NMR experiment. The backbone amide resonance assignments were readily transferred to the [FeZn] form as 
the chemical shifts varied only subtly from those of the [ZnZn] form. This was possible in crowded spectral regions 
by using HNCA spectra. Blank fields indicate unassigned resonances. HNCACB and HNCO NMR spectra were not 
recorded for [FeZn]IMP-1, so Cβ and C’ resonances were not assigned for the [FeZn] form. The six metal-
coordinating residues are highlighted in bold type. 
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Figure 2-49 Cartoon representation of unassigned backbone amides (red) mapped onto the crystal structure of IMP-1. 
Practically all unassigned residues are in flexible turns, particularly in regions near the active site, which may be 
attributed to line broadening owing to conformational exchange. Segments with proline residues are coloured black, 
and the two zinc ions are depicted as spheres. 
2.6.3 Missing Cross-Peaks 
Notably, certain regions of the protein yielded very weak or unobservable cross-
peaks in the TROSY-HNCA spectrum of the triple labelled cell-free protein sample, 
while they were observable in the HNCA spectrum of the 13C/15N-labelled sample 
expressed in vivo. The loss of the Cα cross-peaks was attributed to the long constant 
time period (approximately 40 ms) used in the TROSY-HNCA experiment, leading to 
loss of magnetization for any signals broadened by conformational exchange. Mapping 
onto the protein structure shows that these resonances are mostly from the C-terminal 
region of the protein structure, specifically the final two helices and the loop linking 
these helices (Figure 2-50). 
 
Figure 2-50 Cartoon representation highlighting regions for which Cα cross-peaks were missing in the TROSY-
HNCA spectrum of the triple-labelled protein prepared by cell-free synthesis. Signals from the dark blue regions 
were completely absent, and light blue colour identifies very weak peaks (with the i-1 Cα cross-peak not observable). 
Proline and unassigned residues are coloured in black, and the two zinc ions are depicted as spheres. 
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2.6.4 Chemical Shift Changes After Ageing 
As mentioned previously (section 2.5.1), significant changes in the NMR spectra 
were evident after incubation of the enzyme at 37 °C for 5 to 10 days. Mapping the 
chemical shift changes observed in 15N-HSQC spectra of [ZnZn]IMP-1 before and after 
incubation onto the structure shows that the largest chemical shift changes were 
associated with the three N-terminal β-strands and an active-site loop near the 
N-terminus (Figure 2-51). A plausible explanation attributes these chemical shift 
changes to the cleavage of N-terminal residues as indicated by mass spectrometry 
results in section 2.5.1. 
 
Figure 2-51 Cartoon highlighting the degree of chemical shift changes after ageing of the protein. Chemical shift 
perturbations are depicted on a colour scale ranging from 0.00 ppm (white) to ≥ 0.08 ppm (blue). The largest 
chemical shift change was 0.11 ppm. Residues that could not be found in the aged sample either due to peak 
broadening or chemical shift changes too large to identify are highlighted cyan. Unassigned and proline residues are 
coloured in black, and the two zinc ions are depicted as spheres. 
2.6.5 Cross-Peak Characteristics 
Peak doubling owing to sample heterogeneity was more pronounced for the 
[ZnZn] form while it was largely absent from the [FeZn] form. The effect was distinct 
from the small population of [FeZn]IMP-1 still present in the [ZnZn] sample (Figure 
2-52). Mapping those residues that displayed peak doubling onto the structure shows 
them spread across the entire protein, although they can be grouped into three main 
clusters (Figure 2-53). Residues near the N-terminus have multiple peaks or appear 
heterogeneous. This could be attributed to the N-terminal expression tag having 
significant flexibility and multiple conformations. The effect was observed in both 
[FeZn] and [ZnZn] forms of the enzyme, although it was less obvious in the [FeZn] 
form, which may be explained by the generally broader line width in the paramagnetic 
sample. The second group includes residues on either side of an unassigned residue 
180°
 86 
located in a β-turn. This doubling can again be attributed to flexibility and occurs in 
both [FeZn] and [ZnZn] forms of the enzyme. The last group includes the majority of 
residues showing peak doubling. These are all concentrated near the active site. Unlike 
the apparent cross-peak heterogeneity of the residues near the N-terminus or β-turns, 
these residues typically displayed two clearly resolved peaks indicative of two distinct 
populations (Figure 2-52A). Most of these residues are not observable in the [FeZn] 
form as PREs broaden the signals below the level of the noise due to their proximity to 
the iron(III) ion. This also excludes the possibility of assigning one of the peaks to 
contamination of the sample with the [FeZn] form. 
 
Figure 2-52 Cross-peak heterogeneity in the [ZnZn]IMP-1 sample (green) compared to the [FeZn]IMP-1 sample 
(purple). Three examples are highlighted in red boxes. In box A, two peaks assigned to Asp142 are clearly evident in 
the [ZnZn]IMP-1 spectrum. There is no corresponding [FeZn]IMP-1 peak due to significant peak broadening by 
PRE. In box B, three peaks assigned Ser99 are observed in the [ZnZn]IMP-1 spectrum, but the resonance most 
upfield in the proton dimension can be attributed to a minor population of the [FeZn]IMP-1 form. The other two 
resonances are assigned to the [ZnZn] form and reflect conformational or chemical heterogeneity of the 
corresponding region of the protein. In box C, the peak doubling observed for residue Ile153 in the [ZnZn] protein is 
due to a strong peak from the contaminating [FeZn]IMP-1 form. 
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If the [ZnZn]IMP-1 sample is incubated at 37 °C for two weeks, a large number 
of the peak doubling instances resolve to a single species (Figure 2-54). As expected, 
residues with peak doubling near the N-terminus are largely resolved into either fewer 
or single peaks as the N-terminal residues are cleaved over time. Conversely, those 
peaks that were doubled due to flexibility of β-turns remain doubled (Figure 2-54B). 
Interestingly, the residues with peak doubling near the active site consolidate into a 
single peak that overlaps with one of the two previous peaks (Figure 2-54A). This 
suggests that the active site of the fresh enzyme exists in two conformations, one of 
which is increasingly populated with time. Cross-peak heterogeneities observed for 
[FeZn]IMP-1 similarly decrease with time. 
Ageing affects the NMR spectra of [FeZn]IMP-1 in a more subtle way, due in 
part to there being fewer residues with peak doubling in the fresh sample. Clear changes 
do occur for the residues near the N-terminal polypeptide segment. Most noticeably, 
ageing reduces the signals from the [ZnZn] form contaminating the sample. However, 
the signal-to-noise ratio was insufficient to determine whether the [ZnZn] form 
selectively dropped in concentration after incubation. 
 
 
Figure 2-53 Cartoon highlighting residues for which peak doubling was observed in the 15N-HSQC spectrum of 
[ZnZn]IMP-1. Residues for which peak doubling was assigned to flexibility in the N-terminal polypeptide segment 
are indicated in light blue. Residues with peak doubling attributed to conformational exchange at β-turns are 
highlighted in cyan. Solid blue highlights residues with significant peak doubling concentrated near the active site. 
Unassigned and proline residues are coloured in black, and the two zinc ions are depicted as spheres. 
180°
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Figure 2-54 Peak doubling in fresh [ZnZn]IMP-1 (green, top) is largely resolved in the aged sample (black). The 
same residues are highlighted as in Figure 2-52. Peaks close to the active site (box A) resolve into a single species. 
Peaks near inherently flexible regions like β-turns (box B) remain doubled. Interestingly, the degree of [FeZn]IMP-1 
contamination in the [ZnZn] sample also decreases (box C). Ageing also seems to simplify the spectrum of 
[FeZn]IMP-1 (purple, bottom), while the limited signal-to-noise ratio prohibits analysis of any minor [ZnZn] form 
present. 
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2.6.6 PRE Analysis of [FeZn]IMP-1 
Fewer cross-peaks were observable for samples of [FeZn]IMP-1 than for 
[ZnZn]IMP-1. This is attributed to the PRE induced by the iron(III) paramagnetic 
centre. Figure 2-55 shows the ratio of peak-heights for each backbone amide signal 
between the [FeZn] and [ZnZn] forms. Mapping the intensity ratios onto the crystal 
structure of [FeZn]IMP-1 shows a clear distance dependence relative to the metals in 
the active site (Figure 2-56). While the paramagnetic centre is clearly in the active site, 
the resolution of the PRE experiment is insufficient to distinguish between the two 
metal ion sites identified by the anomalous X-ray scattering experiment. 
 
Figure 2-55 The ratio of amide 15N-HSQC cross-peak intensities (grey bars) between [FeZn]IMP-1 and 
[ZnZn]IMP-1 correlates with the distance of the amide protons to the Zn1 site (blue line) and Zn2 site (red line). Peaks 
unaffected by PRE are expected to have an intensity ratio of 1 whereas the ratio is 0 for peaks broadened beyond 
detection. Proline and unassigned residues are indentified by with light grey bars plotted with a ratio value of 1. Any 
residues with a ratio greater than 1.05 (i.e. the peak was stronger in the [FeZn]IMP-1 sample) are marked with a 
cross. The cross-peaks of Glu65 (green bar) were used as a reference (ratio set to 1) to scale the two datasets, as its 
peaks were well resolved and the amide proton is more than 26.7 Å from either of the metal sites. 
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Figure 2-56 Cartoon representation of the intensity ratio I[FeZn]/I[ZnZn] from Figure 2-55 mapped onto the crystal 
structure of [FeZn]IMP-1 determined in this work. Residues with amide cross-peaks broadened by PREs beyond 
detection are indicated in red, while unaffected residues are indicated in light blue (as per the scale). A 12 Å sphere 
centred at either the Zn1 or Zn2 site is depicted in orange and grey, respectively. 
  
Zn1
Zn2
135°
135°
10 I[FeZn] / I[ZnZn]
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2.6.7 Oxidation States of Iron 
A series of samples was synthesised cell-free in the presence of iron.* It was 
noted that initial samples did not appear to be coloured purple as were samples 
expressed in vivo at similar concentrations, and that the NMR peaks from the 
[FeZn]IMP-1 samples did not always overlay with the [FeZn]IMP-1 samples expressed 
in vivo. It was discovered that, in the cell-free system, IMP-1 could incorporate either 
Fe(II) or Fe(III) into the active site depending on the oxidation state of iron added to the 
cell-free feed buffer (Figure 2-57). This was unexpected since the cell-free system has a 
reducing agent present and it was assumed that any iron introduced into the system 
would be iron(II). A set of [Fe(II)Zn]IMP-1 and [Fe(III)Zn]IMP-1 samples was then 
synthesised and analysed by NMR. 
 
Figure 2-57 15N-HSQC spectrum of 15N-Ile-labelled IMP-1 synthesised in the presence of zinc (green), iron(II) 
(orange) or iron(III) purple. Three species are evident and assigned as [ZnZn]IMP-1, [Fe(II)Zn]IMP-1 and 
[Fe(III)Zn]IMP-1 as marked. Different PCSs are evident for the Fe(II) and Fe(III) species, indicative of different Δχ 
tensors. 
In agreement with the UV/Vis experiment in Figure 2-30, comparison between 
[Fe(II)Zn] and [Fe(III)Zn] forms synthesised cell-free to [FeZn]IMP-1 synthesised in 
vivo confirmed that the in vivo protein was [Fe(III)Zn]IMP-1 (Figure 2-58). 
 
* Samples with iron(II) and iron(III) were synthesised by Ms E. Cliff under supervision of Dr C.T. Loh and the 
author. 
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Figure 2-58 Comparison of the 15N-HSQC spectra of [Fe(III)Zn]IMP-1 (dark blue), [Fe(II)Zn]IMP-1 (orange) and 
[ZnZn]IMP-1 (light green) from cell-free expression with 15N-isoleucine and 15N-threonine to [FeZn]IMP1 (purple) 
and [ZnZn]IMP1 (green) from in vivo expression with uniform 15N-labelling. Red boxes highlight the comparison, 
showing the cell-free samples above the in vivo samples. 
2.6.8 PCS Analysis 
It was expected that the [FeZn]IMP-1 sample would induce PCSs in the NMR 
spectrum, explaining the variability in the chemical shifts measured in the assignment 
for the enzyme. Closer examination, however, identified a number of peaks that were 
shifted much further in the nitrogen dimension than in the proton dimension, which 
could not be explained by PCSs alone (for example see Figure 2-57A). As analysis of 
the crystal structures of [FeZn]IMP-1 and [ZnZn]IMP-1 suggested very little structural 
difference between the two forms, the differences in the NMR peaks could potentially 
arise either from mobility differences between the two structures or subtle structural 
differences not resolved by X-ray crystallography. 
Gallium(III) had been used previously as a diamagnetic reference for iron(III) 
due to it having both the same charge and similar ionic radius.216-223 Another series of 
samples* was made by cell-free synthesis in the presence of exogenous Ga2(SO4)3, 
which indeed appeared to serve as a better diamagnetic reference, yielding more 
 
* Samples with gallium(III) were synthesised by Ms K. Dugdale under supervision of Dr C.T. Loh and the author. 
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plausible PCSs (Figure 2-59). ICP-OES was performed for the Ga3+ sample and a 
gallium signal was detected, however, due to the poor sensitivity of the gallium ICP-
OES signal, incomplete saturation of the enzyme and the small amount of cell-free 
sample available for analysis, quantitative data was not attainable. 
It was noted that many residues in the gallium samples gave rise to multiple 
peaks. Some of these could be explained as coming from residual [ZnZn]IMP-1 or 
[Fe(III)Zn]IMP-1, but in many cases there were at least two unique resonances present. 
After closer examination, the [Fe(III)Zn]IMP-1 sample expressed in the cell-free system 
also appeared to have multiple peaks that were not present in the in vivo samples. This 
made accurate measurement of PCSs more difficult. An example from Gly72, a residue 
close to the active site, is shown in Figure 2-60. 
 
Figure 2-59 Comparison of the 15N-HSQC spectra of 15N-Gly-labelled [Fe(III)Zn]IMP-1 (purple), [ZnZn]IMP-1 
(green) and [Ga(III)Zn]IMP-1 (orange). Red bars indicate PCSs measured using the [ZnZn] form as the diamagnetic 
reference, where blue bars indicate PCSs measured using the [GaZn] form as the diamagnetic reference. While not 
perfect, the [GaZn] form performs as a better diamagnetic reference for [FeZn]IMP-1 than the [ZnZn] form. 
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Figure 2-60 Example of multiple cross-peaks observed for Gly72 in the cell-free samples of [ZnZn]IMP-1 (green), 
[Fe(III)Zn]IMP-1 (purple) and [Ga(III)Zn]IMP-1 (red). A large circle highlights the major cross-peak for each 
species, while apparent minor cross-peaks are highlighted by a small circle. The measured PCS for this residue is also 
highlighted by a black bar on the [Ga(III)Zn]IMP-1 spectrum. 
Analysis was carried out by selecting the most intense peak for each residue in 
the [Fe(III)Zn] and [Ga(III)Zn] samples that did not overlap with the [ZnZn] form.* 
Initially, 39 resolved PCSs were identified, measured and used for fitting of a Δχ tensor 
to the crystal structure of [FeZn]IMP-1 (Table 2-17). Using the tensor to back-calculate 
the PCSs produced large deviations from the experimental PCSs for a few residues, 
regardless of whether the tensor was centred on the Zn1 or Zn2 metal site. Closer 
inspection of the NMR data for these residues revealed problems that had been 
overlooked in the initial PCS measurements. The cross-peaks of Thr56, which showed 
the largest deviation between experimental and back-calculated PCSs, appeared 
heterogeneous in both [FeZn] and [GaZn] samples. The PCS of Lys178 also fitted 
poorly, especially for the fit to the Zn1 site, and its cross-peaks also displayed 
heterogeneous line shapes. The PCS of Thr102 showed a large deviation in the Zn2 fit 
and proved uncertain due to a very weak cross-peak in the spectrum of [GaZn]IMP-1. 
Thr115 and Phe118 deviated significantly in the Zn2 site fit, but the cross-peaks were 
strong in both the diamagnetic and paramagnetic samples, and were hence retained in 
the fits. Irrespective of whether any of the PCSs discussed above were removed from 
the fits or not, the best Δχ-tensor fits with the smallest root-mean-square deviation 
between experimental and back-calculated PCSs were obtained for tensors centred on 
the Zn1 site (Table 2-18).  
 
* In cases where a ‘major’ peak was difficult to identify, assignments of the in vitro [FeZn] form were chosen by 
reference to the in vivo [FeZn] form, and assignments of the [GaZn] form were chosen to be the peak where the 
change in proton chemical shift (Δδ) was most simmilar to the Δδ of 15N with respect to the in vivo [FeZn] form.15 
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Using the Δχ tensor solved for run 3 in Table 2-18 (omitting the PCSs of Thr56 
and Lys178), it was possible to assign a further 11 PCSs by looking for previously 
ignored peaks matching the back-calculated shifts. Those within 0.05 ppm from the 
prediction for the Zn1 metal site were added to the PCS data set. The 48 PCSs used in 
the final fitting protocol are listed in Table 2-19. These PCSs came from residues 
dispersed over the entire protein, as shown in Figure 2-61. 
Table 2-17 PCS data used for the initial fixed-metal-position fitting of a Δχ tensor to [Fe(III)Zn]IMP-1i 
Residue PCS (ppm)  Residue PCS (ppm) 
I9 +0.040  K108 ±0.000 
K11 +0.058  G110 +0.030 
Y17 -0.028  K111 +0.036 
T20 +0.098  T115 -0.069 
Y45 -0.051  F118 -0.071 
I47 -0.056  Y123 -0.072 
K54 +0.040  K129 -0.045 
T56 -0.021  I130 -0.041 
T61 -0.020  F133 -0.135 
F63 -0.040  K152 -0.010 
G67 ±0.000  I153 -0.089 
Y68 -0.047  K161 -0.029 
K69 +0.002  K178 -0.027 
I70 -0.032  K181 +0.047 
G72 -0.021  G188 -0.035 
I86 +0.069  K189 -0.017 
I94 -0.053  K191 -0.066 
T96 -0.010  G201 -0.047 
Y97 -0.024  K215 +0.040 
T102 -0.082    
i Data measured using [GaZn]IMP-1 as the diamagnetic reference. Only PCSs identified with high confidence were 
included in the fit. PCS values were measured using 1H chemical shifts. 
 
Table 2-18 RMSD scores of the iterative Δχ-tensor fitting protocol for the Zn1 and Zn2 metal sites. 
Run Subset of PCSs 
RMSD (ppm) 
Zn1 Zn2 
1 39 PCSs 0.03308 0.03454 
2 38 PCSs (without 56) 0.03009 0.03270 
3 37 PCSs (without 56, 178) 0.02682 0.03211 
4 37 PCSs (without 56, 102) 0.02986 0.03015 
5 36 PCSs (without 56, 178, 102) 0.02670 0.02930 
6 34 PCSs (without 56, 178, 102, 115, 118) 0.02556 0.02609 
7 32 PCSs (without 56, 178, 102, 94, 63) 0.02514 0.02801 
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Table 2-19 PCS data used for the final fixed-metal-position fitting the Δχ tensor to [FeZn]IMP-1i 
Residue PCS (ppm)  Residue PCS (ppm) 
K8 +0.081  K108 ±0.000 
I9 +0.040  G110 +0.030 
K11 +0.058  K111 +0.036 
G15 -0.008  T115 -0.069 
Y17 -0.028  F118 -0.071 
T20 +0.098  G120 -0.034 
Y45 -0.051  Y123 -0.072 
I47 -0.056  K129 -0.045 
K54 +0.040  I130 -0.041 
K58 +0.042  F133 -0.135 
T61 -0.020  Y134 -0.077 
F63 -0.040  W147 -0.081 
G67 ±0.000  K152 -0.022 
Y68 -0.047  I153 -0.089 
K69 +0.002  F155 -0.119 
I70 -0.032  K161 -0.029 
K71 -0.007  K181 +0.047 
G72 -0.021  K186 -0.007 
I86 +0.069  Y187 -0.038 
I94 -0.053  G188 -0.035 
T96 -0.010  K189 -0.017 
Y97 -0.024  K191 -0.066 
T102 -0.082  G201 -0.047 
K107 +0.015  K215 +0.040 
i Data measured using [GaZn]IMP-1 as the diamagnetic reference. 11 shift assignments were aided by back 
prediction from the Δχ-tensor determined from run 3 in Table 2-18. PCS values were measured using 1H chemical 
shifts. 
 
 
Figure 2-61 PCS measurements were made for residues dispersed all over the protein. The backbone N-atom of each 
amide for which a PCS could be measured is depicted as a blue semi-transparent sphere. The Zn1 and Zn2 sites are 
depicted as orange and grey spheres, respectively. 
A pyParaTools34 fit to the data fixing the metal position at either the Zn1 or the 
Zn2 site yielded Δχ tensors with parameters shown in Table 2-20. The RMSD value for 
the Zn1 site was 1.2 times smaller than for the Zn2 site. The quality of each fit is shown 
graphically in Figure 2-62 by correlations between experimental and back-calculated 
PCSs. 
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Table 2-20 Final Δχ tensor parameters after fitting to either the Zn1 or Zn2 metal site 
 Zn1 Zn2 
xi 33.087 33.940 
yi 13.399 16.627 
zi 59.360 58.603 
Δχaxii -1.106 -0.935 
Δχrhii -0.680 -0.327 
αiii 132.20 151.78 
βiii 37.44 41.46 
γiii 158.72 153.64 
RMSDiv 0.02412 0.02932 
degrees of freedom 43 43 
i metal ion coordinate (Å) in the protein frame set to either the Zn1 or Zn2 site (not fitted) 
ii in units of 10-32 m3 
iii Euler rotations in ZYZ convention (degrees) 
iv in units of ppm 
 
Figure 2-62 Experimental versus back-calculated PCS values (in ppm) for the Zn1 (blue) and Zn2 (red) metal site. A 
perfect fit would have data points lying along the black line (slope = 1). The points align more closely with the 
diagonal for the Zn1-site fit. 
Finally, a grid search of different metal positions was performed to find any 
local minima for the metal site that could indicate a different binding site. The RMSD 
values, when plotted against distance to either the Zn1 or Zn2 positions, converged to a 
minimum close to the active-site metals (Figure 2-63A/B). A second grid was calculated 
at a higher resolution around the active-site metals. This fit more clearly depicted the 
better fit for the Zn1 site (Figure 2-63C/D).* The results from the whole grid and the 
 
* It is worth noting that the same trend of convergence at the active site and closer to the Zn1 metal position was 
evident for the same grid search using the initial set of PCSs listed in Table 2-17, however, the average RMSD value 
was higher. 
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active-site grid were also plotted onto a cartoon of the IMP-1 structure with the RMSD 
values indicated by a colour gradient (Figure 2-64 and Figure 2-65). 
 
Figure 2-63 Quality of PCS fit plotted versus distance from the Zn1 (A, C) and the Zn2 (B, D) site. A cross on the y-
axis depicts the RMSD value for the Zn1 or Zn2 site fits, respectively. A and B: plots of the coarse grid over the 
whole protein show convergence of the RMSD value near the active site. C and D: the fine grid near the metal ions 
produces the smallest RMSD value (0.0234) at a distance of about 1.30 Å from the Zn1 site, and 3.90 Å from the Zn2 
site. 
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Figure 2-64 Graphical representation of the grid search for metal positions with minimal RMSD in the Δχ-tensor fits. 
The grid points are depicted as transparent spheres that are coloured by RMSD value from red (0.023 ppm) to blue 
(0.038 ppm or greater). A cluster of red points comprising the active-site metals (shown as full spheres) locates the 
paramagnetic centre to those metal sites. The sphere radii were scaled with the RMSD value for improved 
visualisation in a 2D display. 
 
Figure 2-65 Graphical representation of the active-site grid search for metal positions with minimal RMSD value. 
The grid points are depicted as crosses that are coloured by RMSD values from red (0.023 ppm) to blue (0.029 ppm 
or greater). The best results cluster around the Zn1 metal site identified by an orange sphere on the left. A grey sphere 
indicates the Zn2 site. 
Figure 2-66 shows PCS isosurfaces plotted onto the protein structure, indicating 
the magnitude of PCSs induced at different sites across the protein. Three levels are 
plotted – 0.02, 0.04 and 0.16 ppm. It can be seen from Table 2-19 that the magnitude of 
PCSs were in this range for the majority of resonances. 
Finally, the orientation of the principal axes of the Δχ tensor in its coordination 
environment is shown in Figure 2-67. Interestingly, the principal axes are oriented so as 
to minimise overlap of any one axis with the coordinating ligands. The oxygen ligand, 
being the most electronegative ligand, is positioned almost perfectly between the three 
180°
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axes. The three nitrogen ligands are then placed to minimise overlap with a priority 
order of His79-Nδ1, His139-Nε2 and finally His77-Nε2. 
 
Figure 2-66 Depiction of PCS isosurfaces. Nuclear spins positioned on the same isosurface experience the same 
PCS. Positive and negative PCS values are plotted as blue and red isosurfaces, respectively. Three levels are shown – 
the largest lobes indicate a 0.02 ppm shift, the medium lobes indicate a 0.04 ppm shift and the smallest lobes indicate 
0.16 ppm shift. The two active-site metals are shown as spheres, Zn1 in orange and Zn2 in grey. 
 
Figure 2-67 Orientation of the principal axes of the fitted Δχ-tensor, highlighting the different axes as red (x), green 
(y) and blue (z) ball-and-sticks attached to the Zn1 site. The principal axes are oriented to place the oxygen (the most 
electronegative ligand) so as to avoid lining up with any of the axes. The three nitrogen ligands (less electronegative 
than the oxygen) are then placed to minimise lining up with any other axis. The Zn1 and Zn2 sites are depicted as 
orange and grey spheres, respectively. The bridging water/hydroxide ion (taken as the coordinating oxygen atom 
from the citrate ligand in the [FeZn]IMP-1 structure) is depicted as a red sphere.  
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2.7 Discussion 
2.7.1 General Observations and Comments on Methodology 
DNA – a Potential Binding Partner for IMP-1 
Desalting or dialysis with buffer is typically all that is required prior to NMR 
measurement after cell-free protein synthesis of isotopically labelled proteins.224 It was 
therefore surprising to find it necessary to purify labelled cell-free protein synthesis 
samples of IMP-1 for observation by NMR. Washing the sample with 20 mM buffer via 
ultrafiltration alone failed to produce NMR cross-peaks. This observation suggests that 
IMP-1 interacts with very large molecules present in the cell-free reaction mixture, such 
as plasmid DNA. 
The hypothesis that IMP-1 binds to DNA is supported by two factors. First, 
IMP-1 has a pI value greater than 8, so is positively charged at the pH chosen for NMR 
(6.5). Second, treating in vivo preparations with DNase I was found to reduce the 
viscosity of the cell-lysate as well as increase the protein yield obtained after filtration. 
Weak binding to negatively charged plasmid DNA in the cell-free reaction mixture thus 
presents a plausible explanation for why only the most flexible residues proved to be 
observable in the NMR spectrum unless the protein was purified further, for example by 
using a cation-exchange column with relatively high concentrations of salt to dissociate 
any bound plasmid DNA. 
In principle, interaction with DNA would be straightforward to assay by adding 
an aliquot of DNA to a purified protein sample to observe the loss of NMR cross-peaks, 
however, as IMP-1 is excreted to the periplasm in the native system, this interaction 
probably has little biological relevance. Considering that the majority of β-lactam 
antibiotics are either zwitterionic or negatively charged at biological pH, the positive pI 
value of IMP-1 may be beneficial for attracting the substrate and improving its activity. 
Protein Crystallisation Conditions Screening of [FeZn]IMP-1 
Previous reports indicated that crystallisation of IMP-1 is difficult to 
reproduce120 and, specifically, that IMP-1 crystals are unstable if they are not incubated 
at 37 °C until crystal growth is complete. In the present work, successful crystallisation 
conditions required ageing of the protein by incubation at 37 °C for approximately a 
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week as a pre-treatment prior to crystallisation at 24 °C. All previously published 
crystallisation conditions* were performed at temperatures of 20 to 37 °C†. 
The ageing process was not entirely benign. Mass spectrometry indicated that 
the N-terminal residues are sensitive to proteolysis over time at room temperature. 
Electron density was missing for the first 3 residues in the crystal structure obtained in 
this work, suggesting that cleavage of these residues may be essential for crystal 
formation. Previous investigators also reported that removing the six most C-terminal 
residues improved crystallisation reliability.120 These six residues were not resolved in 
the current work, nor in most other IMP-1 structures.118,120,182-184 Future crystallisation 
attempts may be more successful with a Δ4-222 construct of IMP-1, or by attaching a 
C-terminal StrepII tag as in the PDB structures 4G6H and 4F6Z109 where the 
C-terminus is resolved. 
X-Ray Diffraction Structure 
In the present work, citrate was observed in the active site of each of the 
monomers of the solved X-ray crystal structure. Citrate is observed in the active site of 
at least one member of each class of metallo-β-lactamase (in each case, citrate has been 
a component of the crystallisation buffer).225 The crystal diffracted to 1.8 Å resolution, 
which is on par with the highest resolution120 structure of the native enzyme to date. 
Citrate has earlier been established as an inhibitor of IMP-1 and is known to 
cause the loss of up to 1.7 equivalents of zinc from a [ZnZn] enzyme at pH 5.79 Loss of 
metal from the enzyme is consistent with the reduced occupancy of the Zn2 metal site 
observed in the crystal structure. 
Treatment of IMP-1 with FeCl3 
The metal exchange experiment with FeCl3 reported close to 20 equivalents of 
iron by ICP-OES. Considering it is unlikely that there are 20 high-affinity iron-binding 
sites on the surface of the native protein (especially as the enzyme has a pI value greater 
 
* Crystals of IMP-1 in the presence of a mercaptocarboxylate inhibitor (1DD6) can reportedly be grown at 4 °C,182 
but the coordinate file in the PDB indicates a crystallization temperature of 293 K. 
† The PDB database reports a crystallisation temperature of 334 K for the structure 1JJE.120 This is inconsistent with 
the original paper (37 °C) and with the conditions listed for another crystal structure from the same article (1JJT120 – 
also 37 °C). In the ‘crystal growth procedure’ field for 1JJE both “310 K” and “temperature 334K” are present. It was 
assumed that this is an error in the database. 
 103 
than 8.0) and that the amount of iron found was stoichiometrically similar to the amount 
used for treatment, the desalting columns appeared to have been inefficient at removing 
non-bound metals ions. Unexpectedly, however, the iron content remained unchanged 
even after two steps of desalting purification with fresh NAP-5 and PD-10 columns. 
This result is not yet understood but may be due in part to pH instability, as the stock 
solution of FeCl3 was solublised in about 5 to 8 mM HCl. Combined with the 20 mM 
MES buffer (pKa 6.15, actual pH 6.5) in the protein sample prior to treatment, the 
addition of the FeCl3 stock required to achieve 20-fold molar excess of iron would have 
come close to overwhelming the buffering capacity. Normally denaturation of IMP-1 is 
accompanied by precipitation (as evidenced by all de-metallation attempts). The 
absence of precipitation despite a very likely sudden drop in pH193 in the metal 
exchange experiment is interesting. The presence of FeCl3 (stock solution in 0.1 M 
HCl) also noticeably reduced precipitation in the high-throughput crystal screens. 
Further experiments would be needed to investigate this phenomonon. Initially, treating 
the protein with iron in the presence of a higher concentration of buffer to maintain the 
pH could shed more light on these observations. 
Cell-Free Protein Synthesis 
Cell-free protein synthesis proved to be a powerful tool in the analysis of 
[FeZn]IMP-1. The ability to generate protein in which single amino-acid types were 
individually 15N-labelled significantly simplified the backbone assignment and enabled 
the measurement of PCSs in crowded regions of the 15N-HSQC spectrum. As sample 
heterogeneities caused significant peak overlap in conventionally prepared samples, the 
samples prepared by cell-free synthesis proved invaluable and enabled the reliable 
fitting of a Δχ-tensor. The cell-free protein synthesis method also enabled the generation 
of a perdeuterated IMP-1 sample, as described in chapter 3 of this work. This sample, 
along with the single amino-acid labelled samples, was instrumental in obtaining the 
backbone assignments that proved much more difficult than for a conventional protein 
of this size. 
Finally, the cell-free method enabled the generation of metal-substituted species 
that were not easily made in vivo. The ability to overwhelm the system with a large 
excess of metal ions, not possible in vivo, enabled the substitution of IMP-1 with non-
biological metals such as gallium. In fact, gallium is toxic to bacteria and is a potentially 
useful antimicrobial,226-230 impeding any in vivo preparation of [GaZn]IMP-1. 
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NMR Cross-Peak Characteristics 
The NMR spectra of [ZnZn]IMP-1 displayed three types of peak heterogeneity 
that were attributed to the flexible N-terminal expression tag, mobile loops and multiple 
distinct active site environments. Resonances for residues in the C-terminal helices were 
also missing in experiments with longer evolution times. Possible reasons are discussed 
below. 
The N-Terminal MASMTG Tag 
Several resonances assigned to residues in close proximity to the N-terminus 
displayed significant cross-peak heterogeneity. This was attributed to conformational or 
chemical heterogeneity of the MASMTG T7 gene 5 expression tag appended to the 
N-terminus of the enzyme concurrently with the transfer of blaIMP-1 into pETMCSI.* 
Ageing of the sample resulted in the loss of cross-peaks from the N-terminal tag, 
consistent with the mass spectral analysis that identified N-terminal degradation over 
time. 
The expression tag is not required for in vivo expressions and may not be needed 
for cell-free expressions either.† It is the author’s recommendation that future NMR 
experiments should be performed on IMP-1 protein lacking the N-terminal expression 
tag if possible. 
Flexible Loops 
Due to inherent mobility of the β-turns and flexible loops of IMP-1, little can be 
done to reduce the peak heterogeneity for these residues. Measurements at a different 
temperature or in the presence of an inhibitor may alter the degree of mobility in the 
enzyme and simplify the NMR spectrum. 
  
 
* The pET47b(+) plasmid in which the gene was originally supplied was not suitable for cell-free protein expression, 
due to the presence of the lacO and lacI genes. 
† The effect of the MASMTG tag on expression yields independent of the expression plasmid has yet to be analysed 
for IMP-1. 
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The Active Site 
In general, each resonance of the active site displayed two distinct peaks that 
simplified to a single resonance after incubation at 37 °C for a few weeks. One 
explanation for the peak multiplicity could be that the enzyme was measured in metal-
limiting conditions with no exogenous zinc present. This raises the possibility of there 
being a slow equilibrium between a mono- and di-zinc form of IMP-1 under NMR 
conditions. It is consistent with observations that after ageing some enzyme may 
denature and precipitate, releasing zinc ions into the solution. A small increase in 
exogenous zinc concentration may shift the equilibrium to the purely di-zinc form, 
leading to the loss of cross-peaks of the mono-zinc form. This explanation of peak 
heterogeneity is contradicted by the observation that enzyme purified under metal-
limiting conditions still maintained ICP-OES metal analysis results of approximately 2 
metal ions per protein molecule.* 
A more plausible explanation for the peak doubling attributes the effect to 
multiple active-site conformations. Flexibility of the active site of MβLs is well-
documented and presumed to assist in substrate promiscuity.109,110 A genuine possibility 
is the existence of two distinct active-site conformations in solution without inhibitor, 
and exchange between these two states that is slow with respect to the ms – µs timescale 
could explain the peak doubling observed for these residues. In this case, the loss of one 
conformation by ageing has interesting implications for the biological activity of the 
enzyme. 
If the peak doubling arises from alternative conformations of the active site, it 
would be interesting to assess the peak doubling in the presence of an inhibitor or 
substrate. It would also be interesting to monitor these resonances in the presence of 
excess zinc, as the exchange of metals described in section 2.4.4 may be reflected in the 
NMR spectra. An activity assay comparing fresh and aged protein would also be 
informative. 
Notably, the spectrum of [FeZn]IMP-1 generally displayed a much smaller 
degree of peak multiplicity than the [ZnZn] form. This indicates that the presence of 
 
* The NMR experiments in this work were performed at 37 °C. It is not known whether this temperature encourages 
the release of any of the active site metals. Purifications were typically performed at 4 °C, potentially increasing the 
enzyme’s ability to retain the metals even in a metal-limiting environment. 
 106 
iron in the active site discourages either metal loss or active site mobility, however, 
direct comparison of the active-site resonances was not possible due to excessive line 
broadening by PRE. In future, the active-site resonances of the gallium-substituted 
enzyme could be analysed for peak doubling. 
Missing NMR Cross-Peaks 
The fact that cross-peaks from the C-terminal helices were missing in 3D NMR 
experiments recorded with long constant-time evolution times is most readily attributed 
to line broadening due to conformational mobility. Interestingly, X-ray crystallography 
analysis of the C-terminal helices did not indicate significantly higher B-factors than 
elsewhere in the protein structure, suggesting that the low-temperature measurements 
froze out the lowest-energy conformation. NMR relaxation studies could be performed 
to confirm and quantify the mobility of these residues. It is unclear, however, whether 
and how this mobility would impact the activity of the enzyme. 
Gallium as a Diamagnetic Reference for Iron 
The use of [GaZn]IMP-1 as a diamagnetic reference for [FeZn]IMP-1 relied on 
some fundamental assumptions.216-223 Firstly, it is essential that the gallium ion occupy 
the same metal-binding site as iron in the in vivo [FeZn] form. In view of the ionic 
radius and charge state of gallium, this assumption appears reasonable and was shown 
to be true. Additional evidence, however, pointed to the possibility that gallium (and 
iron) can also occupy the other metal-binding site when the protein is expressed in the 
cell-free system. This would explain the additional cross-peak heterogeneities observed 
in cell-free samples that made it more difficult to assign PCSs even in singly-labelled 
samples. Therefore, the PCS measurements used only the strongest cross-peak for each 
residue. 
Secondly, it was assumed that the [GaZn] form would have nearly identical 
structural and mobility characteristics as the [FeZn] form. Indeed, the 15N-HSQC cross-
peaks produced by the [GaZn] form were a much better diamagnetic reference than the 
[ZnZn] form, even if not perfect for all amino-acid residues. The remaining small 
differences in structure or mobility between [GaZn] and [FeZn] forms would add some 
error in the fit of the PCS Δχ-tensor. 
To the best of my knowledge, this is the first example of a gallium-substituted 
metallo-enzyme being produced in cell-free protein synthesis, the first gallium-
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substituted metallo-β-lactamase and the first example of a gallium-substituted enzyme 
that does not require prior de-metallation to form an apo-enzyme. 
2.7.2 Characterisation of the Iron in [FeZn]IMP-1 
Oxidation State of Iron 
The oxidation state of the iron bound to IMP-1 was investigated by several 
methods, all of which supported the presence of Fe(III) in the active site. Treatment of 
the enzyme with a reducing agent altered the visible spectrum, causing a red shift in 
absorbance. Treatment with an oxidising agent had no significant effect. This was 
corroborated by NMR analysis and expression of protein using the cell-free protein 
synthesis method. If a ferrous salt was provided to the cell-free reaction, a very lightly 
coloured protein was obtained and the NMR spectra were distinctly different from 
samples of either [ZnZn]IMP-1 or [FeZn]IMP-1 made in vivo. If a ferric salt was 
provided to the cell-free reaction, the deep purple colour was evident in the preparation 
and the NMR spectra were closely similar to those of typical samples prepared in vivo. 
This suggests that the IMP-1 protein can incorporate both iron(II) and iron(III), and that 
the protein maintains the oxidation state of the iron for at least the time it takes to purify 
and measure an NMR spectrum of a sample from a cell-free protein synthesis reaction 
in buffers without reducing agents. This indicates that the oxidation state of the iron in 
IMP-1 depends on the environmental conditions when the iron is incorporated into the 
protein. In oxidative extracellular conditions, ferric iron would be expected to be the 
predominant iron species in the bacterial periplasm, where IMP-1 is folded.231  
Determination of the Iron-Binding Site 
As Fe(III) has a relatively small ionic radius and a high electronegativity, it was 
expected that the unpaired electrons of the nitrogen ligands of the Zn1 site should be 
favourable for the formation of stable complexes.232 The identification of the Zn1 site as 
the Fe(III) binding site was supported by anomalous X-ray diffraction data and multiple 
NMR experiments. 
Anomalous X-Ray Diffraction Scattering 
Unexpectedly, the maximal anomalous scattering signal was observed in the Zn1 
site at both the iron and zinc ion edges, raising the possibility that iron binds at either 
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metal site. Correcting the metal-site occupancies from the electron density scattering 
data (independent of the anomalous scattering signal), however, produced an excellent 
match with theoretical predictions, supporting the conclusion that, at least in the single 
crystal, iron exclusively populates the Zn1 site. 
NMR Analysis of [FeZn]IMP-1 using PREs 
PRE effects resulted in significantly different peak intensities in 15N-HSQC 
spectra of [ZnZn] and [FeZn] enzymes, which correlated clearly with the distance from 
the active-site metal ions, identifying the active site as the paramagnetic centre. The 
PREs were, however, not sufficiently accurate to discriminate between the two metal-
binding sites, which are only about 3 Å apart. To achieve the necessary accuracy of 
measurement, PREs would need to have been measured for nuclear spins less than 10 Å 
from the metal.7,11 In view of the small number of amide protons in this distance range 
and the fact that flexible loops (as present in the active site of IMP-1) easily lead to 
bigger PREs than expected, PREs were of limited value for identifying the iron-binding 
site. Nonetheless, the PREs conclusively located the metal in the active site and 
demonstrated that there was no other iron-binding site elsewhere in the protein. 
NMR Analysis of [FeZn]IMP-1 using PCS 
A grid search to find the metal positions that produce the best Δχ-tensor fits also 
located the paramagnetic metal in the active site. Furthermore, the grid search 
pinpointed the paramagnetic metal to a position located about 1.3 Å and 3.9 Å from the 
Zn1 and Zn2 sites respectively. Δχ-tensor fits restricted to either metal-binding site also 
confirmed the Zn1 site as the better fitting site. 
To my knowledge, this is the first time PCSs have been used successfully to 
pick the paramagnetic centre in a choice between two metal-binding sites that are 
located within 4 Å of each other. This result highlights the accuracy with which PCSs 
can determine structural features in biological macromolecules. 
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A Single Iron-Binding Site? 
All data collected on [FeZn]IMP-1 in this work confirm the Zn1 site as the 
primary binding site for iron. 
Firstly, the ICP-OES results indicated that, even protein expressions in the 
presence of an excess of iron resulted in only a single iron ion per protein molecule.* 
Strictly speaking, this result does not imply that only one site can bind iron, as the 
possibility remains that only one site at a time incorporates iron. Arguably, the ICP-
OES data do not even exclude the possibility that an [FeFe]IMP-1 species exists, as 
long as there was also an equal amount of [ZnZn]IMP-1 present in the sample. 
However, this scenario disagrees with the NMR spectra of a sample containing one 
equivalent each of iron and zinc, which was largely devoid of cross-peaks assigned to 
[ZnZn]IMP-1. 
Secondly, the anomalous X-ray scattering experiment matched theoretical 
predictions at the zinc ion edge after the adjustment of the occupancies of the two metal 
sites. For a significant population of zinc in the Zn1 site, the zinc ion edge anomalous 
signal would have been expected to be stronger in the Zn1 site and weaker in the Zn2 
site. This confirms that iron can exist in the Zn1 site. Observation of iron in the Zn2 site 
may require different crystallisation conditions. 
Finally, the paramagnetic NMR spectra of [FeZn]IMP-1 provided key diagnostic 
evidence of only a single iron-binding site. Even though signals from residues close to 
the active site were largely unobservable due to PREs, distant residues displayed single 
cross-peaks due to a single PCS. If iron had also been present at the Zn2 site, this would 
have produced a distinctly different Δχ-tensor and, hence, different PCSs. By the same 
argument, slow exchange of iron between the Zn1 and Zn2 sites would have produced 
two distinct cross-peaks for most of the NMR spectrum of [FeZn]IMP-1, even at 
distances far from the active site. This was observed for [FeZn]IMP-1 samples produced 
in vivo, and is the strongest evidence for a single preferred iron-binding site.† 
 
* Among many measurements, a single ICP-OES result indicated the presence of more iron than zinc (Figure 2-28), 
which may be attributed to the loss of zinc rather than the excess of iron. Unfortunately, quantification of the metal-
to-protein ratio was not possible for this sample. 
† This result is based on the NMR spectra of [FeZn]IMP-1 using the typical in vivo synthesis, harvest and purification 
method described in sections 2.9.2 and 2.9.6. Periplasmic expressions of 15N-labelled [FeZn]IMP-1 were of too low a 
yield for detailed analysis by NMR. 
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Notably, peak doubling was observed for [FeZn]IMP-1 samples produced by 
cell-free synthesis. It is not clear whether this reflects multiple metal-binding sites or 
(more likely) an artefact of the significantly higher concentration of iron available in the 
cell-free reaction mixtures than in vivo. Ultimately, the main point of interest would be 
the situation in the periplasm. As the protein yields are relatively low in periplasmic 
expressions, sensitive methods such as EPR and XAFS experiments would be beneficial 
to characterise the environment of iron in the active site and identify any small 
populations of iron in the Zn2 site or di-iron active sites. These techniques have 
previously been performed successfully on iron forms of glyoxalase II.233 
Spin State of Iron 
The iron in the Zn1 site has a slightly distorted tetrahedral coordination 
geometry, for which crystal field theory predicts very low splitting energies.234 Its 
coordination involves three imidazole-nitrogen ligands (histidine) and a water oxygen 
ligand, all of which create moderate ligand field strengths. Finally, the iron(III) ion is a 
d5 ion, so has very high mean electron pairing energies. This strongly suggests that the 
iron(III) in the enzyme is high-spin. 
High-spin iron(III) is fully consistent with the paramagnetic NMR data, where 
high-spin iron(III) is expected to have slower electron relaxation rates than low-spin 
iron(III) or iron(II), and therefore significantly stronger PREs24,28 – evidenced in IMP-1 
by the large radius (12 Å) around the metal site for which no cross-peaks could be 
observed in the 15N-HSQC spectrum of [FeZn]IMP-1. 
High-spin iron(III) typically has a negative Δχax component,22,25,235 whereas low-
spin iron(III) usually has a positive Δχax component.22,235-237 Consistent with this notion, 
the sign of the Δχ-tensor was determined to be negative for [FeZn]IMP-1 in the present 
work. 
2.7.3 Structural Comparison of [FeZn]IMP-1 to [ZnZn]IMP-1 
CD Spectroscopy 
The CD spectra in the far-UV region of both the [FeZn] and [ZnZn] proteins are 
almost identical, indicating that the backbone structure is preserved between the two 
forms. Even in the near-UV region, differences between the two forms were minimal, 
pointing to only minor conformation or environmental changes in the aromatic side 
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chains. The structural similarity of [FeZn]IMP-1 and [ZnZn]IMP-1 was confirmed by 
the X-ray crystal structure. 
X-Ray Crystal Structure 
Of particular importance to this study was the ability to directly compare the 
[FeZn]IMP-1 structure with two structures of [ZnZn]IMP-1 at high resolution and with 
ligands bound to the active site. Only a single IMP-1 structure had been co-crystallised 
with citrate (4F6Z109), but this structure was not suitable for comparison due to an active 
site mutation (C158G). Of the remaining wild-type enzyme structures, the succinic acid 
derivate in 1JJE120 (1.8 Å resolution) has very similar coordinating atoms and was 
initially chosen for comparison. Although the ligand is slightly bigger than citrate, 
structural alignments showed that the ligand binds to the metal ions in a very similar 
way. In contrast, the ligand bound in 1DD6182 is much larger than citrate and has a 
sulfur atom in place of the bridging-water or hydroxide ion ligand. This structure is also 
of slightly lower resolution (2.0 Å). Given these differences in ligand properties, it was 
surprising to find that the backbone RMSDs indicate greater similarity of the 
[FeZn]IMP-1 structure to 1DD6 than 1JJE. 
The inter-metal distance was practically the same in 1DD6 (3.60 Å) and 1JJE 
(3.56 Å), despite the different bridging ligands. In contrast, the metal-metal distance 
was larger for the [FeZn]IMP-1 structure (3.80 Å). This inter-metal distance is the 
largest of any of the published crystal structures of IMP-1 with two metal ions. 
All of the distances from the protein ligands to the metal of the Zn1 site were 
subtly smaller in [FeZn]IMP-1 than in 1DD6, by up to 0.13 Å. This is consistent with 
Fe(III) having a smaller ionic radius than Zn(II). In contrast, the differences in metal-
ligand distances for His77 and His79 were insignificant for the Zn1 site between 
[FeZn]IMP-1 and 1JJE, while the distance for His139-Nε2 was larger (Δ=+0.13 Å). This 
small distance change is readily explained by a slight opening in 1JJE of the αβ/βα-
sandwich constituting the two main subdomains. As expected, the distance between the 
coordinates of the metal and the sulfur ligand was greater in 1DD6 (Δ=+0.24 Å) than 
the distance from the metal to the oxygen of the ligand in either [FeZn]IMP-1 or 1JJE. 
The Zn1 site in 1DD6 has a slightly distorted tetrahedral geometry, specifically 
in the displacement of the sulfur ligand. The Zn1 coordination geometry is similar in 
[FeZn]IMP-1 and 1JJE, with a subtle displacement of the side-chain of His77. In 
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contrast, the Zn2 site has different coordination geometries due to the different number 
of coordinating atoms provided by the bound active-site ligands, making structural 
comparisons for this site uninformative. 
Using the coordinates of Ala53, Gly120 and Leu205 to define the opening angle 
of the αβ/βα-sandwich, the 1JJE structure is more closed in comparison to the 
[FeZn]IMP-1 and 1DD6 structures. Gly120 is located at the hinge of the opening angle. 
If such a hinge motion occurs in solution, it would explain many of the subtle structural 
differences observed between 1JJE and 1DD6. It could also be biologically important, 
enabling promiscuity of the active site by expanding the range of substrates that can be 
accommodated in the catalytic region. The hinge is more open in the [FeZn]IMP-1 
structure, similarly to 1DD6, which explains the significantly smaller RMSD values 
after alignment of [FeZn]IMP-1 to only the N- or C-terminal regions of 1JJE. 
Analysis of the packing density showed very little difference in the efficiency of 
internal packing between the three crystal structures. The presence of a unique cavity 
large enough to fit a water molecule underneath the metal-binding site in the 
[FeZn]IMP-1 structure was interesting and could result from subtle changes in amino-
acid side-chain conformations in response to the smaller ferric metal ion. 
It is important to note that the structural differences highlighted are very subtle 
and the significance of these comparisons is limited by the resolution and quality of the 
solved crystal structures and by the presence of different active-site ligands. For 
example, the 2.3° difference in the αβ/βα-sandwich opening-angle could be attributed to 
crystal packing effects, as the structures compared had different space groups, different 
unit cell measurements and different numbers of monomers per unit cell. The 
diffraction-component precision index (DPI)210 for the [FeZn]IMP-1 structure was 
0.11 Å, suggesting that differences greater than 0.11 Å (such as the inter-metal distance) 
are significant. Clearly, any structural difference between [FeZn]IMP-1 and 
[ZnZn]IMP-1 is minor and near the limit of detection at the resolution of the crystals 
structures available. 
Structure Comparison by NMR Spectroscopy 
The similarity in chemical shifts between [FeZn]IMP-1 and [ZnZn]IMP-1 
provides evidence for a very similar three-dimensional structure of the two forms of the 
enzyme. Nonetheless, not all chemical shift differences could be explained by PCSs 
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induced by the paramagnetic iron. This may point to a small difference in the structure 
and/or mobility between the two forms. 
The problem of non-PCS-like shift differences prompted the use of a [GaZn] 
species, which indeed presented a better diamagnetic reference for [FeZn]IMP-1. To 
elucidate any structural differences induced by a triply versus doubly charged metal ion, 
future NMR experiments could employ the diamagnetic [GaZn] form for detailed 
comparison with the [ZnZn] form. 
Are There Any Significant Structural Differences? 
The chemical shift changes observed by NMR suggest that the [FeZn] form may 
be structurally more different from the [ZnZn] form than indicated by the X-ray crystal 
structural comparison. 
Firstly, NMR experiments identified at least two distinct conformations of the 
protein residues close to the active site of [ZnZn]IMP-1, although only one of the 
conformations remained after incubation for a week at 37 °C. Clearly, the chemical 
environment in the catalytically relevant area changes with time. All available crystal 
structures of IMP-1, including the one solved in this work, involved crystallisation at or 
above room temperature over the course of several weeks. By the time crystals form, 
the single crystal may contain an enzyme population that was not even present in the 
fresh solution. It is thus always possible that the structural similarity between the [FeZn] 
and [ZnZn] forms in the single crystal is a crystallisation artefact. 
Secondly, the resolution of 1.8-2.0 Å of the presently solved and previously 
available X-ray structures is not sufficient to interpret very small differences in inter-
atomic distances, and one must be careful not to over-interpret the coordinates.238 The 
influence of different ligands, space groups and unit cell dimensions is also difficult to 
assess. While the NMR chemical shifts and cross-peak multiplicities observed in 
solution with fresh protein preparations suggested that [ZnZn] and [FeZ] forms differ, 
albeit subtly, the NMR data are more difficult to interpret in structural terms. 
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2.7.4 Enzyme Stability Comparison of [FeZn]IMP-1 and [ZnZn]IMP-1 
Thermal Stability 
The [FeZn] form of IMP-1 melts approximately 1.4 to 1.9 °C lower than the 
[ZnZn] form, but this does not necessarily indicate that the [FeZn] form is less stable at 
ambient temperature. Firstly, the CD spectra recorded of both species at 90 °C differed 
significantly, were potentially complicated by precipitation or aggregation and were not 
consistent with expectations for a completely unfolded random coil protein. Secondly, 
the thermal treatment was irreversible, making it difficult to obtain accurate melting 
temperatures. Regardless, the thermal stability of the two forms is similar. 
Along with the imperfect isosbestic points in both the [ZnZn]IMP-1 and 
[FeZn]IMP-1 melt, fitting sigmoid functions to different regions of the CD spectrum 
suggested at least a two-step denaturation pathway. This denaturation pathway of 
[FeZn]IMP-1 is different as evidenced by the change in isosbestic point at 202 nm. It is 
not clear whether the earliest unfolding event is reversible. Previous studies on the 
thermal stability of [ZnZn]IMP-1 utilised differential scanning calorimetry (DSC) 
measurements.205,239 The best way of comparing the stability of the [ZnZn] and [FeZn] 
forms at ambient temperature would be a denaturation experiment using increasing 
amounts of urea. 
Exogenous Metal Exchange 
The metal ions of IMP-1 are bound very tightly, and both are functionally 
important.194,240 The enzyme retains two metal ion equivalents even during long size-
exclusion and ion exchange chromatography separations in metal-limiting conditions. 
Therefore, it was surprising to find just how rapidly cadmium was able to exchange into 
the active site of both [FeZn] and [ZnZn] forms of IMP-1. 
Remarkably, cadmium replaced both iron and zinc after treatment of 
[FeZn]IMP-1. As the present study identified the iron to occupy the Zn1 site, this result 
suggests that cadmium exchanges with either metal-binding site. Lack of selectivity for 
the metal-binding site has been reported for other doubly-charged ions such as 
Co2+,203,239 but Cd2+ has previously been reported to occupy the Zn2 site exclusively.203 
The evidence presented by Siemann et al.203 was based on their observation that only a 
single equivalent of cadmium was ever observed exchanging into their protein sample – 
a result replicated in the current work. An alternative explanation, however, would be 
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that the presence of a cadmium ion in IMP-1 prevents binding of a second cadmium ion 
as Cd2+ has a larger ionic radius (0.97 Å) than Zn2+ (0.74 Å) or Fe3+ (0.64 Å). 
Interestingly, addition of an excess of cadmium resulted in an exchange of one 
cadmium for a zinc in the [ZnZn]IMP-1 sample in less than 5 minutes. This facile metal 
exchange is unexpected in view of the high metal affinity of IMP-1. Siemann et al.203 
also noted this ‘unusual kinetic lability’ and compared the rapid exchange to 
metallothioneins, a class of enzymes capable of rapid transfer of tightly bound zinc ions 
to acceptor proteins. Remarkably, compared to this family of metal-transfer enzymes, 
IMP-1 shows about 10 times faster exchange rates.203 
Although cadmium also exchanged into the [FeZn] form, only half a 
stoichiometric equivalent was found per protein molecule after the 5-minute treatment. 
As expected, the addition of zinc to the [ZnZn] sample hardly changed the metal content 
of the enzyme, but zinc treatment did dilute the iron bound to the [FeZn] form. Like the 
cadmium exchange, this addition of zinc was incomplete after 5 minutes. The fact that 
the presence of Fe3+ in the active site of the enzyme slows the metal-ion exchange 
process has potentially broad implications for the stability or activity of the 
enzyme.194,203-205,239,240 
It is proposed that, for future studies of IMP-1, more successful substitution of 
other ions into the active site may be possible via the metal-ion induced exchange 
process, making this method preferable to attempting the formation of the apo-enzyme, 
as per the currently typical procedure for metallo-enzymes.194,204,205,239,240 
The Effect of Metal Substitution on IMP-1 Stability 
At least two unfolding events were detected using the thermal CD denaturation 
experiment for both [ZnZn] and [FeZn] forms of the enzyme. The attempts to remove 
the metal ions demonstrated that the presence of metal ions in the active site stabilises 
the enzyme and keeps it soluble. It is thus tempting to associate the two unfolding 
events with the sequential loss of the two metal ions prior to a fast denaturation of the 
apo-enzyme as per scheme (2.4): 
 (2.4) 
where M denotes a site occupied with a metal ion, and X denotes a site without a metal 
ion. Both IMP-1 (current work) and BcII241 (class B1) have been shown via X-ray 
[M1M2]P(aq)
slow−−−￿￿ −
1
[M1X2]P(aq) ￿−2
slow−−￿ [X1X2]P(aq)
fast−−→
3
[X1X2]P(s)
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crystallography to lose metal from the Zn2 site under crystallisation conditions, so it is 
reasonable to assume that this site loses its metal first during thermal denaturation. 
Attempts to refold precipitated protein have been unsuccessful,203,240 implying 
that step 3 is irreversible, at least in the typical refolding conditions used so far. 
Previous works have described near full recovery of activity after partial de-
metallation205,239 suggesting that step 1 is readily reversible, although others describe 
this step as being irreversible,240 so it would seem the conditions used are important. At 
least two groups194,205 describe the recovery of activity after complete de-metallation, 
suggesting that step 2 is also reversible. In the present work, irreversible denaturation 
(step 3) always seemed to predominate the reverse pathway (step 2). 
In the scenario of sequential metal loss, stabilisation of the [M1X2]P 
intermediate by metal substitution with a tighter binding ion could drastically increase 
the likelihood of the protein remaining folded in vivo. This would increase the chances 
for a partially de-metallated enzyme to regain a second catalytic metal ion and recover 
full activity. Equilibria between forms at different stages of de-metallation would also 
impact on the enzyme stability at different pH values. It is quite possible that the [FeZn] 
form is more stable over a different pH range than the [ZnZn] form. 
2.7.5 Functional Comparison of [FeZn]IMP-1 and [ZnZn]IMP-1 
The enzymatic activity at pH 7.5 against benzylpenicillin (a penam) is higher for 
[ZnZn]IMP-1, with a kcat value 3.5 times faster and a Km value almost 5-fold lower than 
for [FeZn]IMP-1. This yields a 17-fold higher kcat/Km for [ZnZn]IMP-1 under the tested 
conditions. This is a significant difference, but it also shows that the enzyme is still 
active in the [FeZn] form.  
A more rigorous study of the relationship between pH and the activity of the 
different forms of IMP-1 could yield important results, but the activity differences 
probably also depend on the substrate. It would also be interesting to quantify any effect 
the 37 °C treatement that was required for crystal formation would have had on the 
activity of the enzyme. 
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2.7.6 General Discussion 
An Iron-Binding IMP-1 Species 
Iron has been found in metallo-β-lactamases previously. In particular, inactive 
iron species have been reported for members of class B3 (L1242,243 and GOB-18242,244) 
following expression in the cytosol of E. coli. It is well documented that bacteria 
concentrate zinc and iron ions in the cytosol even under metal-limiting conditions,244,245 
whereas the metal content of the periplasm is largely dependent on the extracellular 
environment and ion pumps that deplete the region of metal ions.243,245 ICP-OES metal 
analyses of E. coli cytosol and periplasmic soluble fractions indicate that the 
concentration of zinc and iron is approximately 45 µM in metal-limiting conditions, and 
while iron concentrations increase three-fold in the cytoplasm in response to the 
addition of 100 µM iron, zinc concentrations are relatively stable even in the presence 
of excess zinc.127,243 It is thus not surprising to find iron in the active site of IMP-1 
metallo-β-lactamase even when the protein is expressed under conditions of relatively 
low concentrations of iron and high concentrations of zinc. 
It is important to remember, however, that in the wild metallo-β-lactamases are 
translocated to the periplasmic space in a metal-free unfolded state,127,242,243,246 and 
therefore fold in a metal ion environment that is very different to the cytosol. For the L1 
and GOB-18 enzymes, isolation from periplasmic extracts yielded exclusively active 
zinc(II)-bound enzymes.231,242,243,246 In fact, the secretion mechanism of unfolded 
metallo-β-lactamases led to the proposal that the secretory machinery may play an 
important role in determining the metals that are ultimately taken up by a given apo-
enzyme.231,243 In metal-limiting conditions, periplasmic extracts typically contain less 
than 1 µM zinc or iron, however, both metals are concentrated to close to 1.23 mM zinc 
and 2.83 mM iron after the addition of 100 µM metal to the media.243,247 Expression of 
IMP-1 in the periplasm did not yield pure [ZnZn]IMP-1, and actually increased the 
likelihood for iron to be substituted into the active site. Even under conditions known to 
favour the [ZnZn] form during intra-cellular expression, up to 25% of the product was 
the [FeZn] species. 
The fact that iron successfully competes for the active site of IMP-1, even when 
zinc is supplied in 20-fold excess, can be put in context partially by metal stability 
predictions. The Irving-Williams bivalent metal stability series248,249 does not describe 
the relationship between Zn2+ and other metals except for copper(II), but suggests that 
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the larger ionic radius and smaller ionic charge of Zn2+ makes zinc(II) complexes less 
stable than iron(III) complexes, whereas the stability of zinc(II) and iron(II) complexes 
should be comparable. For example, pyridine complexes of Fe3+ are more stable than 
those of Zn2+.247 In the oxidising environment of the periplasm, a strong preference for 
iron(III) over zinc(II) is not unexpected. 
Iron-Binding in the Metallo-β-Lactamase Superfamily 
The metal binding specificity of IMP-1 is not unusual in the context of the entire 
metallo-β-lactamase superfamily where at least three families of the superfamily 
exclusively bind iron. Members of a fourth family (glyoxalase II) have been reported to 
bind zinc, iron and manganese. Like group 3a metallo-β-lactamases, this family has a 
dinuclear metal-binding site, with the Zn1 site coordinated by three histidines. The Zn2 
site differs, however, as its coordinating residues are a histidine and two aspartates. The 
two active-site metals of glyoxalase II are bridged by a catalytic water/hydroxide ion, 
but differ from IMP-1 in that an oxygen atom from an aspartate residue constitutes an 
additional bridging ligand. An additional ligand, from either a bound inhibitor or the 
solvent, coordinates each of the zinc ions, providing both metals with six ligands in 
distorted octahedral coordination geometries (Figure 2-68). 
 
Figure 2-68 Comparison between the active-site metals and side-chains of coordinating residues in A) IMP-1 
(1JJE)120 and B) human glyoxalase II (1QH3)250. Zinc ions are depicted as grey spheres with a 50% reduced radius 
compared to the ionic radius for better visibility of the amino-acid side-chains. The bridging water/hydroxide ion and 
bound inhibitors are not shown. Nitrogen, oxygen and sulfur atoms are shown in blue, red and yellow, respectively. 
The human wild-type glyoxalase II has been observed with 0.7 equivalents of 
iron and 1.5 equivalents of zinc per protein molecule, but was originally assigned as a 
pure zinc enzyme.233,250 Data published on the glyoxalase II from Arabidopsis thaliana 
in 2003, however, showed significant levels of iron, zinc and manganese in protein 
recombinantly expressed in the cytoplasm of E. coli.233 As in the present work on 
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IMP-1, the degree of substitution was dependent on the environmental availability of 
the different metal ions, with conventional expression media yielding approximately 
0.8 ± 0.2 equivalents of iron per protein molecule.233,241 Higher iron availability did not 
yield greater than 1 equivalent of iron per protein molecule, and reduction of the iron 
content was achieved by supplementing the expression media with 250 µM of the 
competing metal. For the iron-containing species, EPR measurements identified an 
Fe(III) spin in an environment consistent with a [Fe(III)Zn(II)] metal centre. An 
[Fe(III)Fe(II)] form was also identified. 
Why Has Iron Not Been Found in IMP-1 Before? 
Identification of which metal is present in a metallo-protein has traditionally 
been achieved by isolating the protein, forming the apo-enzyme and subsequently 
identifying which metals can recover maximal activity in vitro. The original work on 
IMP-1133 applied such a protocol and indicated a 100% loss of activity after treatment 
with EDTA, and a 54% recovery of activity after treatment with zinc. This result has 
been put in question by more recent work where EDTA has been proven to be highly 
inefficient in removing metals from the active site of IMP-1.79 Divalent cations other 
than zinc were tested for recovery of activity, but iron(III) was not tested.133,138 
The first thorough biochemical analysis of IMP-1 in 1999 assayed several metal 
ions, including zinc, cadmium, cobalt, calcium, copper, manganese and nickel, but not 
iron.79 This may be attributed to the limited iron sensitivity of the ICP-MS technique251-
253 used for metal analysis.* 
Since the initial reports of IMP-1 as a zinc-binding enzyme, most studies of 
IMP-1 have utilised purification buffers with at least 10 µM zinc salts.† As zinc readily 
occupies both binding sites, the iron form of the enzyme was easily missed. Previous 
purification protocols employed long size-exclusion and dialysis steps in the presence 
of zinc salts, during which any population of [FeZn]IMP-1 could have been converted 
to the [ZnZn] form. Anecdotal reports from others working with this enzyme described 
 
* Argon from the plasma and oxygen from the sample matrix combine to form 40Ar16O+ with an atomic mass 
equivalent to the main isotope of iron, 56Fe. ArOH+ is also formed, equivalent to the next-most abundant iron isotope. 
Commercial research and development of ICP-MS instrumentation has only recently started to address this 
problem.251,253,254 The method of metal ion quantification in the present study (ICP-OES) does not suffer from this 
limitation. 
† In fact, even early work by Watanabe et al. and Laraki et al. employed exogenous zinc in the purification 
buffers.79,133 
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a purple colour present in their enzyme preparations, which dissipated over the course 
of size exclusion chromatography in 500 µM ZnCl2.255 Again, this points to metal 
exchange during protein purification. The problem associated with large amounts of 
metal being present during purification, with respect to establishing the wild-type 
composition and activity, has been discussed previously.241,256,257 It is finally beginning 
to be recognised that the traditional practice of oversupplying a single metal ion in 
metallo-enzyme preparation can cause experimental artefacts.256,257 
The Metals in the Active Site of IMP-1 in vivo 
One or Two Metals? 
Previously, several class B1 metallo-β-lactamases have been purified with only 
a single metal present, and there is still some disagreement over the degree of metal 
saturation in vivo.241,258,259 A common argument is that the saturation of the metal-
binding sites may be an artefact of the expression and purification of metallo-β-
lactamases in the presence of excess zinc. In the present study, IMP-1 was expressed 
with excess metal present, but was purified under metal limiting conditions. In 
practically all preparations, almost two equivalents of metal were observed per protein 
molecule. This supports the notion of IMP-1 having very tight metal binding affinity, 
and that once the metals are incorporated into the enzyme they are not easily 
released.79,203 This is also consistent with data collected on BCII (another B1 MβL) that 
showing the metal binding is cooperative260 
In the native environment, the enzyme is located in the periplasm in the presence 
of siderophores and the metal ion concentration fluctuates with environmental 
conditions. As IMP-1 has been shown to be less active in the mono-metal form,194 it is 
advantageous for the enzyme to bind its metal cofactors tightly. 
 [ZnZn]IMP-1, [FeZn]IMP-1 or Both? 
It is clear that IMP-1 can exist and is active in either [ZnZn] or [FeZn] form. In 
the native environment of bacteria, however, the pool of metals available for enzyme 
binding is limited. Under these conditions, the metal affinity of the enzyme relative to 
the gamut of other metal-binding proteins can determine the uptake of specific metals in 
the enzyme.231,241 In the case of clinically relevant metallo-enzymes, the metals 
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available in the pathological environment also govern the metal species present in the 
enzyme. Unfortunately, this is particularly difficult to assess. 
Compelling evidence has been collected over the last two decades showing 
[ZnZn]IMP-1 exists in clinically relevant infections, but there is little evidence for or 
against the existence of [FeZn]IMP-1 in the clinical environment. It thus remains 
unclear whether the [FeZn] form is a laboratory artefact or whether it is an essential 
feature of IMP-1 to retain at least partial activity under unusual environmental 
conditions. The latter idea is supported by the discovery of several examples of zinc-
dependent enzymes over the last decade, which had to be reclassified as cambialistic or 
even iron-dependent enzymes in vivo.257,261,262 
One example of a cambialistic enzyme is LpxC from E. coli that has been shown 
to use either iron or zinc cofactors in vivo.261,262 The enzyme was originally classified as 
a Zn2+-dependent deacetylase, as metal chelators reversibly inhibit it, and it contained 
Zn2+ when purified under aerobic conditions. Unfortunately, the original research did 
not evaluate the ability of Fe2+ to activate LpxC. The mis-assignment of the native metal 
cofactor as only Zn2+ has been attributed to the aerobic purification of these enzymes, 
leading to the oxidation of Fe2+ to Fe3+ and subsequent substitution with Zn2+ at the 
active site.261,262 Consistent with the current study, the ratio of iron to zinc in the 
enzyme was found to depend on the iron to zinc ratio in the cell lysate, implying that the 
metal co-factors in the enzyme depend on the relative metal abundance in the 
environment.257,262 
Another example is MshB from mycobacteria. This enzyme prefers an Fe2+ 
cofactor in anaerobic or low zinc environments, whereas it prefers Zn2+ in aerobic or 
high-zinc environments.257,263 The ability to switch between co-factors under changing 
environmental conditions is likely an important feature of metallo-enzymes that carry 
out critical cellular functions, such as the antibiotic resistance provided by metallo-β-
lactamases. 
2.7.7 Future Prospects using High-Throughput Paramagnetic NMR 
The present work determined the backbone NMR resonance assignments for 
most of IMP-1, identified conditions for the controlled formation of [ZnZn] and [FeZn] 
forms in vivo, and established [GaZn]IMP-1 as a suitable diamagnetic model of the 
[FeZn] enzyme. This presents a firm basis for future paramagnetic NMR studies on 
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IMP-1. In addition, the development of high-yielding in vivo and cell-free protein 
expression systems and a rapid purification procedure open the door to high-throughput 
experiments. 
While high-spin iron(III) is mostly regarded as a problematic cofactor for high-
resolution protein NMR,28 in the case of IMP-1 it provides interesting possibilities for 
high-throughput ligand screening using NMR. As it has been shown that the [FeZn] 
form is catalytically active with an almost identical structure, it is a good model for the 
[ZnZn] protein. 
In the case of a weakly binding fragment suitable for fragment based drug 
design (low mM to high µM binding affinity), the small molecule would enter and leave 
the active site in the fast-exchange regime of the NMR time-scale. In a sample with 
excess ligand, this would result in NMR signals averaged between the narrow signals of 
the unbound ligand and the significantly broadened signals from the bound ligand. 
Comparison with samples without protein would highlight any attenuated signals as 
arising from ligands that closely approach the active site. Such measurements could be 
performed without perdeuteration using only small amounts of protein (nM 
concentrations), which is ideal for a high-throughput procedure. 
In the case of a tightly binding, drug-like fragment (low µM to nM binding 
affinity), the exchange of the ligand in and out of the active site is likely to be slow on 
the NMR time-scale, implying lifetimes of seconds or longer. In this case, the signals 
from any bound compound would be broadened beyond detection by PRE from the 
paramagnetic iron centre. At the same time, the presence of the ligand in the active site 
would change the electronic environment at the paramagnetic centre, resulting in a 
change of the Δχ-tensor and, hence, different PCSs. Monitoring a few NMR ‘reporter’ 
signals from elsewhere in the protein could identify this change. Unnatural fluorinated 
amino acids264 incorporated in the protein outside the active site are an attractive option 
as a reporter signal. This would provide unique and sensitive NMR nuclei in the protein 
that could be measured using simple 1D NMR experiments, without the need for 
expensive protein isotope labelling. More protein sample would be required in this 
regime (µM concentrations), however, due to the stability of IMP-1, it would be 
possible to recycle the protein by passing it through a short desalting column. 
Even though NMR is inherently a linear process, limiting the applicability to 
high-throughput protocols, small libraries of fragments could be tested simultaneously 
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to increase parallel thoughput in either of the above cases. Along with automated NMR 
sampling and processing systems, this method provides a potentially powerful method 
for drug-lead identification. 
2.8 Conclusion 
An [Fe(III)Zn(II)]IMP-1 variant was identified and structurally characterised. 
X-ray diffraction analysis revealed only subtle differences when compared to the 
[ZnZn] form of the enzyme, but NMR analysis suggests subtle differences in structure 
and/or mobility between the two species. Paramagnetic NMR and anomalous X-ray 
scattering techniques were successfully used to identify the preferential iron-binding 
site as the Zn1 site. While initial activity assays indicate that the [ZnZn] form is more 
active at pH 7.5, the [FeZn] variant still shows significant catalytic activity. 
The discovery of the iron-substituted variant has clinical implications for the 
design of inhibitors intended for IMP-1, as a drug developed solely against 
[ZnZn]IMP-1 might not be as effective against [FeZn]IMP-1. 
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2.9 Experimental Methods 
2.9.1 Constructs and Bacterial Strains 
The blaIMP1 gene in pET-47b(+) was generously donated by A/Prof. G. Schenk 
(University of Queensland) and was used unchanged for in vivo over-expression (Figure 
2-69). This construct was not suitable for cell-free expression due to the presence of the 
lac operon repression system, therefore the gene was also subcloned into pETMCSI263 
with an N-terminal expression MASMTG tag for cell-free protein synthesis (Figure 
2-70).* In order to remove any competition for the active site metals, neither construct 
included a His6 purification tag. The DNA sequence encoding the native N-terminal 
signal peptide (MSKLSVFFIFLFCSIATAA) responsible for transport of the protein to 
the periplasm was appended via overlapping PCR and restriction digest ligation onto the 
5’ end of the gene in pET-47b(+) for periplasm expression studies. 
 
Figure 2-69 pET47(b) with blaIMP-1. The gene without the N-terminal signal peptide (purple) is inserted between 
NdeI and XhoI restriction sites, removing the N-terminal His6 tag from the vector. A stop codon is inserted prior to 
the thrombin cleavage site and the STag coding sequence. The lac operon repression system is present (lacO and lacI 
- red) making this vector unsuitable for in vitro expression. Antibiotic selection is by kanamycin (green) making it 
suitable for in vivo activity assays of IMP-1. Figure generated using SerialCloner265 and SnapGene Viewer266. 
 
* Cloning of the MASMTG construct into pETMCSI was performed by Dr R. Qi (RSC, ANU) prior to the 
commencement of this PhD project 
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Figure 2-70 pETMCSI with blaIMP-1. The gene (purple) is inserted between NdeI and EcoRI restriction sites. The 
N-terminal signal peptide is removed, and a MASMTG T7 expression tag is appended to the N-terminus. The lacI 
and lacO repression system is not present. Antibiotic selection is by ampicillin (green), making it not ideal for in vivo 
assays of the IMP-1 protein. Figure generated using SerialCloner265 and SnapGene Viewer266. 
2.9.2 Cytosolic Protein Synthesis 
Highest yields of soluble protein were obtained by using a high cell density 
expression system based on the method by Sivashanmugam et al.,192 with a number of 
key modifications. In brief, 50 mL of LB media202 with either 100 mg/L ampicillin or 
50 mg/L kanamycin was inoculated with a scraping from a -80 °C DMSO stock of 
BL21(DE3)recA strain containing either pETMCSIII or pET47b(+) with the blaIMP1 
gene (section 2.9.1) and incubated in a 125 mL flask with shaking at 37 °C for eight to 
twelve hours to an OD600 of 0.2 to 0.5. This culture was used to inoculate 1 L of 
antibiotic LB media in a 2 L baffle flask, which was subsequently incubated at 37 °C 
with fast shaking (> 200 rpm) for 12 to 16 hours to an OD600 of 5 to 8. The cells were 
then harvested by gently centrifuging at 1,700 g for 10 minutes and resuspended gently 
in 200 mL of room temperature defined minimal media consisting of 50 mM Na2HPO4, 
25 mM KH2PO4, 10 mM NaCl, 5 mM MgCl2, 0.1 mM CaCl2, 0.5 × Me Mix198 (25 µM 
FeCl3, 10 µM CaCl2, 5 µM MnCl2, 5 µM ZnCl2, 1 µM CoCl2, 1 µM CuCl2, 1 µM NiCl2, 
1 µM Na2SeO3, 1 µM H3BO3), 0.25 × RPMI 1640 vitamin mix (Sigma), 1% glucose, 
0.1% NH4Cl, pH 8.2 with either 50 mg/L kanamycin or 100 mg/L ampicillin in a 2 L 
baffle flask. Either 500 µM ZnSO4 or FeCl3 was added to the defined minimal media for 
generation of either [ZnZn]IMP-1 or [FeZn]IMP-1, respectively (section 2.3.3). 
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The pH of the resuspended culture was measured and adjusted directly with 
dilute NaOH or KOH to between 8 and 8.4. The culture was then incubated at 25 °C for 
one to two hours with fast shaking (> 200 rpm). Protein production was induced by the 
addition of 1 mM IPTG and incubated with fast shaking (> 200 rpm) for 20 to 22 hours 
at 25 °C. Cells were harvested by centrifuging at 4,730 g for 15 minutes, then 
resuspended in 15 mL of 50 mM HEPES (pH 7.5) buffer. 1 unit of DNase I (NEB) per 
200 mL culture was added, and cells were lysed by a minimum of two slow passes 
through a French pressure cell (12,000 psi). The lysate was centrifuged at 32,000 g for 
one hour and then clarified by filtration through a 0.45 µm syringe filter unit (Millipore) 
prior to purification. 
For 13C- or 15N-labelled protein for NMR, the glucose and/or ammonium 
chloride was supplied in labelled form and was otherwise treated identically. For 
2H/13C/15N-labelled samples, single colonies were selected from 70% deuterated 
minimal media plates for optimal expression in deuterated minimal media culture. The 
above protocol was then implemented, with all media consisting of solids being first 
dissolved into 100% D2O and sterilised by filtration through a 0.22 µm pore size filter. 
Deuterated glucose was not used. As the protein cannot be successfully refolded, proton 
back-exchange onto the amides was achieved by incubating the protein in H2O-based 
buffers during purification. 
2.9.3 Periplasmic Antibiotic Plate Assay 
Rich LB202 media agar plates supplemented with 50 mg/mL kanamycin were 
spread with a solution of IPTG to a final concentration of 1, 0.5, 0.25 or 0 mM IPTG. 
Once dry, the plates were spread with 200 µL from a 5 mL rich media overnight culture 
of BL21DE3(recA) containing the pET47b(+) plasmid with blaIMP1 with or without the 
N-terminal signal peptide (section 2.9.1). Four filter paper disks were placed onto each 
plate, and 20 µL of 1, 10, 100 or 200 mg/mL ampicillin was pipetted onto each disk. 
The plates were incubated for 16 hours at 37 °C. 
2.9.4 Periplasmic Protein Synthesis 
For overexpression of periplasmic protein, a similar protocol was used as for the 
cytosolic expression (section 2.9.2) with the exception that, in an attempt to reduce the 
overload on the native E. coli membrane transport proteins, only 0.5 mM IPTG was 
used for induction. 
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After expression, cells were harvested by centrifugation at 4,730 g for 
15 minutes. The medium was retained as the medium fraction and the cells were 
resuspended in 5 mL of chilled 500 mM sucrose, 100 mM Tris·Cl, pH 8.0 and 
incubated on ice for 1 to 1.5 hours. Sphereoblasts were removed by centrifugation at 
30,000 g for 30 minutes and the supernatant was collected as the periplasmic fraction. 
The spheroblasts were then resuspended in 5 mL of chilled 500 mM sucrose, 100 mM 
Tris·Cl, pH 8.0. 1 unit of DNase I (NEB) was added and the spheroblasts were 
processed through a French pressure cell (12,000 psi). The lysate was centrifuged at 
32,000 g for one hour and the supernatant collected as the cytosolic fraction. 
2.9.5 Cell-Free Protein Synthesis 
Protein was synthesised with single or selectively isotope-labelled amino acids 
using a dialysis-fed cell-free protein synthesis system.267 Cell-free extracts were 
reduced with NaBH4 for labelling with single amino acids prone to PLP-cofactor-
dependant aminotransferase activity.268 N-acetyl-glutamate was used in place of the 
glutamate of the buffer system when labelling glutamate.215 In an attempt to control the 
metal ion content of the enzyme, additional 10 µM zinc, 110 µM iron(II) chloride, 
110 µM iron(III) chloride or 110 µM gallium(III) sulfate (220 µM gallium) was added 
to the outer buffer. Typical yield of purified protein was approximately 0.8 mg/mL of 
reaction mixture. 
2.9.6 Protein Purification 
Clarified lysate or 50-fold diluted crude cell-free mixture was loaded onto either 
a 35 mL or 5 mL SP Sepharose cation exchange column pre-equilibrated with 50 mM 
HEPES, pH 7.5. The protein was washed with one column volume of buffer, followed 
by a one-column volume wash using buffer with 100 mM NaCl. Bound protein was 
eluted in a single peak using a linear gradient from 100 to 500 mM NaCl over five 
column volumes. Pure protein was concentrated using a 30 kDa cut-off ultrafiltration 
device (Millipore), and desalted by one or two passes through a PD-10 or NAP-5 
column pre-equilibrated with the desired buffer system via gravity flow. Protein 
intended for crystallography trials was also run through a 300 mL S300 or S200 
Sepharose gel filtration column in 10 mM HEPES pH 7.0, 100 mM NaCl to ensure 
greater than 99% purity. 
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For higher-throughput cell-free protein synthesis samples, a purification method 
that could be run in parallel was implemented.* Amicon Pro Affinity Concentrators 
(Millipore) with Sepharose SP cation exchange resin was used. The concentrator was 
washed with a high-salt buffer (50 mM HEPES, pH 7.5, 500 mM NaCl), followed by 
five washes with a low salt buffer for equilibration (50 mM HEPES, pH 7.5). The cell-
free protein samples were diluted 1 in 10 in low salt buffer and then incubated for 
30 minutes (30 °C) with shaking, prior to spinning off residual liquid. Protein was 
eluted using the high-salt buffer. 
2.9.7 Protein Storage 
Purified protein in MES or HEPES buffer at pH 6.5 to 7.5 containing a 
minimum of 100 mM NaCl was successfully stored frozen for long periods at -20 °C 
only after snap freezing in liquid nitrogen. Otherwise, protein stored at 4 °C would often 
precipitate slightly once, but would remain stable at 4 °C for months after removal of 
precipitant by centrifugation. NMR samples kept in 20 mM MES pH 6.5, 100 mM NaCl 
were stable and gave almost identical NMR spectra even after over 12 months of 
storage at 4 °C. 
2.9.8 Presumptive Test for Iron 
To ascertain the presence of iron, two qualitative tests were performed. 
Colourless potassium thiocyanate reacts with Fe3+ in solution to form 
[Fe(NCS)(H2O)5]2+, which has a strong blood-red colour. 20 µL of a 0.1 mM protein 
sample was treated with 40 µL of 0.2 M potassium thiocyanate. 
1,10-phenanthroline in complex with Fe2+ turns deep red, and in complex with 
Fe3+ turns light blue. 20 µL of 0.1 mM protein sample was treated with 40 µL of 0.1 M 
1,10-phenanthroline in 50% acetone and 10 µL of 0.5 M TCEP. 
2.9.9 Inductively Coupled Plasma Optical Emission Spectroscopy 
Quantitative metal analysis was performed on a Perkin Elmer Optima 2100 DV 
inductively coupled plasma optical emission spectrometer (ICP-OES). Protein samples 
 
* Dr C. T. Loh adapted the general protocol used for in vivo sample purifications for parallel purification of cell-free 
samples in consultation with the author. The final protocol was modified to increase yield by the author. 
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for analysis were exchanged into the analysis buffer (typically 50 mM HEPES, pH 7.5, 
100 mM NaCl) via passing through a PD-10 or NAP-5 size exclusion column. Due to 
foaming caused by nitric acid denaturation of protein, most accurate results were 
obtained by using masses for dilution factors rather than volumes. Depending on 
concentration, 500 to 3,000 mg of the eluent were mixed with 590 mg of 69% nitric 
acid in pre-acid washed glass or plastic ware and incubated for 20 minutes before 
dilution up to 10 g with Milli-Q grade water. The sample was then passed through a 
0.45 µm filter to remove insoluble denatured protein. A blank was also prepared by 
treating a buffer sample identically. 
The instrument was calibrated prior to each run with 0.5, 1.0, 2.0, 5.0 and 
10.0 mg/mL solutions of either CCS4 or CCS6 ICP-MS Standard (Inorganic Ventures). 
A linear standard curve was generated having an R2 ≥ 0.9999. Wavelengths for analysis 
were chosen for best sensitivity and minimal overlap with other peaks (Table 2-21). 1.0 
or 2.0 ppm quality controls were measured every 5 to 10 samples to ensure minimal 
calibration shift. 
Table 2-21 Wavelengths used for ICP-OES analysisi 
Element Wavelength (nm)  Element Wavelength (nm) 
Calcium 317.933  Iron 238.204 
Cadmium 228.802  Manganese 257.610 
Cobalt 228.616  Nickel 231.604 
Chromium 261.716  Selenium 196.026 
Copper 327.393  Zinc 206.200 
Gallium 417.206   
i optimised by microanalysis staff at RSC, ANU 
Results in mg/L would be converted into a molar concentration, then scaled to 
the dilution factor and protein concentration measured by absorbance at 280 nm on the 
pre-acid treated sample. Typical analysis for the [FeZn]IMP-1 yielded 0.99 iron ions 
and 1.01 zinc ions per protein molecule. Typical analysis for the [ZnZn]IMP-1 yielded 
0.04 iron ions and 1.98 zinc ions per protein molecule. Only insignificant trace levels of 
other metals were present in typical preparations. 
2.9.10 De-Metallation Trials 
Griffin Method 
50 mL of 27 µM IMP-1 were treated by four 12 hour dialysis steps against 1 L 
of 50 mM HEPES, pH 6.8 with 10 mM EDTA at 4 °C, followed by six 12 hour dialysis 
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steps against 1 L of Chelex* treated 50 mM HEPES, pH 6.8, 50 mM NaCl. The protein 
sample was then concentrated to 1 mL, had two 20-minute centrifugation steps at 
15,000 g applied to remove any precipitated protein, and was subjected to ICP-OES 
analysis for metal ions. 
Yamaguchi Method 
The reaction was performed in a 2 mL polypropylene tube that had been soaked 
in 1 M nitric acid overnight to remove any metal ions then washed with Milli-Q water 
20 times. 142.7 µL of 200 mM EDTA in 50 mM MOPS (pH 6.5), 1.0 M NaCl was 
added drop-wise to 428 µL of a 1.2 mM IMP-1 protein sample in 50 mM MOPS 
(pH 6.5), 1.0 M NaCl, 30% glycerol and incubated with stirring under nitrogen gas at 
30 °C for 48 hours. 
The sample was then cooled to 4 °C and two 20-minute centrifugation steps at 
15,000 g applied to remove any precipitated protein. The supernatant was passed 
through a PD-10 column pre-equilibrated with 50 mM MOPS (pH 6.5), 1.0 M NaCl, 
30% glycerol to remove all EDTA. The protein sample was subsequently concentrated 
to 1 mL, had two 20-minute centrifugation steps at 15,000 g applied to remove any 
precipitated protein, and was subjected to ICP-OES analysis for metal ions. 
2.9.11 Metal Ion Exchange 
20-fold molar excess of 0.1 M CdCl2, 0.1 M FeCl3 in 0.1 M HCl or 0.1 M 
ZnSO4 was incubated for 5.0 min at room temperature with either [FeZn]IMP-1 or 
[ZnZn]IMP-1 in 20 mM MES (pH 6.5), 100 mM NaCl. Excess metals were rapidly 
removed via two steps of desalting by eluting from a NAP-5 column directly onto a 
PD-10 column to ensure complete removal of all non-bound metal ions. Samples were 
analysed as per typical ICP-OES samples or mass spectrometry samples. 
2.9.12 UV/Vis Absorbance and Fluorescence Spectroscopy 
UV/Vis spectra were typically obtained on a NanoDrop ND-1000. Absorbances 
were measured on 2 µL samples. The inbuilt ‘Normalise’ function for A280 
measurements assumes the absorbance to be zero at 340 nm, which is not an appropriate 
 
* Chelex treatment was applied through a short column as per manufacturer (Bio-Rad) recommendations. 
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reference for the [FeZn]IMP-1 sample due to an additional absorbance in this range. 
Results, however, became less reliable when not using the normalisation function. To 
achieve reproducible results, A280 measurements were performed using the UV/Vis 
option, which normalises to the lowest absorption between 400 and 700 nm. 
Measurements were made at 1.0 and 0.1 mm pathlengths for concurrent normal and 
high absorbance measurements. 
Alternatively, a SPECTRAmax M2e spectrophotometer was used with a quartz 
cuvette for 10 mm pathlength absorbance and fluorescence measurements. 
2.9.13 Circular Dichroism 
Samples for CD analysis were measured on an Advanced Photophysics 
Chirascan Circular Dichroism instrument with Quantum Northwest TC 125 temperature 
control unit. Best results were obtained in chloride free 23 mM phosphate buffer, 
pH 7.0, 19 mM Na2SO4 (ionic strength = 0.1 M)269 made from the corresponding acids 
and bases in 50% D2O, and purged with nitrogen gas. Measurements were made in a 
Starna CD quartz cuvette with a 1 mm or 10 mm pathlength, and were averaged from 
three measurements. Thermal melts were run in a step-wise manner in 2-degree 
increments. Thermal equilibration of the sample was assumed after holding at each step 
prior to data acquisition for 30 seconds after the thermocouple on the cuvette holder had 
reached the desired temperature. 
Fitting of thermal denaturation curves was applied using KaleidaGraph 4.1270. 
Five wavelengths were assessed for each of the regions 186 to 198 nm, and 208 to 220 
nm. Each wavelength was fitted individually with the following equation,270  
 
(2.5) 
where Δε is the mean residue ellipticity, m1 is the left asymptote, m2 is the right 
asymptote, T is the temperature, Tm is the denaturation temperature, and dx is the slope 
at T = Tm. 
2.9.14 Activity Assay 
Activity assays were performed in a multicomponent buffer of 25 mM MES, 
25 mM HEPES, 25 mM CHES and with a constant ionic strength of 100 mM (NaCl).269 
Acetate and citrate buffers were avoided due to the potential for competition in the 
∆￿ = m1 +
m2 −m1
1 + e−(
T−Tm
dx
)
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active site. Constancy of the pH was assured by measurement of the buffer sample prior 
to and after the assay using a microsample pH meter. 
Benzylpenicillin substrate (Fluka, ≥ 98% penicillin G sodium salt) was prepared 
from dry powder as a 4 mM stock in multicomponent buffer at the pH of the assay. 
Hydrolysis of benzylpenicillin was assayed at 235 nm. Up to 16 concentrations of 
substrate (31.25 µM to 2 mM) were used for fitting Michaelis-Menten kinetics curves. 
Protein concentrations of approximately 0.5 to 15 nM were used for [FeZn]IMP-1. 
The assays were performed on a SPECTRAmax M2e spectrophotometer with 
200 µL per well of a Thermo Scientific Nunc 96 Well UV transparent plate. Substrate 
and protein solutions were incubated at 37 °C for 10 min prior to rapid mixing and 
measurement. Initial velocities were measured from initial linear rates (typically from 
20 to 100 seconds), using SoftMax Pro software with R-values greater than 0.98. 
Michaelis-Menten constants were obtained via fitting the function (2.6) using 
KaleidaGraph software270 (yielding R-values greater than 0.95).270 
 
(2.6) 
An accurate Δε value was not determined for benzylpenicillin in the plate assay 
format, meaning that it was not possible to determine an accurate kcat value for either 
enzyme. To obtain an approximate value for kcat, it was assumed that the [ZnZn]IMP-1 
enzyme was as active as that reported by Iyobe et al.142 for IMP-1 in subtly different 
conditions (461 s-1). The kcat value for [FeZn]IMP-1 was then scaled by the same factor 
to yield an approximate (but accurate relative to [ZnZn]IMP-1) kcat value. It is worth 
noting that the determined Km for [ZnZn]IMP-1 in this work was within the margin of 
error reported by Iyobe et al.142 
2.9.15 X-ray Protein Crystallography 
Automated Crystal Condition Screening Runs 
Six commercial crystallisation screens from Hampton Research were trialled: 
Peg/Ion (HR2-139), Grid Screen Salt (HR2-248), Crystal Screen (HR2-130), Peg RX 
(HR2-086), Salt RX (HR2-136), Index (HRR-134). Each screen of 96 conditions was 
set up in an Intelli-Plate 96-3 plate using a Genomic Solutions Cartesian Honeybee 
Vmax[S]
Km + [S]
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Nano Dispensor. Typically, 50 µL reservoir solution was used with 0.5 µL of reservoir 
and 0.5 µL of 25 to 10 mg/mL protein per sitting drop. 
Plates were incubated at 4, 18 or 28 °C for several weeks. Crystal conditions 
were attempted for both [FeZn]IMP-1 with and without the N-terminal MASMTG cell-
free expression tag. Crystal conditions were also attempted in the presence of FeCl3. 
Manual Crystal Condition Screen 
Manual screens were performed around previously published conditions and 
around conditions identified from the automated run. Typically, 1 µL of 15 to 
32 mg/mL protein with 1 µL of reservoir liquid per hanging drop was used over 500 to 
1,000 µL mother liquor. 
Plates were incubated at 4, 18 or 28 °C for several weeks. Crystal conditions 
were attempted for both [FeZn]IMP-1 with and without the N-terminal MASMTG T7 
expression tag. Crystal conditions were also attempted in the presence of FeCl3 or an 
inhibitor (captopril).123-125 
Microseeding was applied by breaking up unusable crystals, pipetting up and 
down the total hanging drop solution from a partially successful crystallisation 
condition. The microcrystal suspension was then recovered and serial-diluted into the 
appropriate reservoir solution. The diluted solution was then used in place of the 
reservoir liquid in the hanging drop as per the above procedure. 
2.9.16 X-ray Diffraction and Structure Refinement 
X-ray scattering experiments were performed on the MX1 beamline at the 
Australian Synchrotron, Victoria, Australia.* Crystals were found to be in the P1 space 
group, so 360° acquisition of scattering data was required for anomalous difference 
measurements. 
The CCP4271 workspace was used to determine the X-ray diffraction structure.† 
iMosflm was used to process the raw image files, followed by analysis of the cell 
content by Mathews_coeff which gave probabilities of 28 and 57% for 4 and 5 
 
* Diffraction experiments were carried out by Dr P. Carr (RSC, ANU) in consultation with Dr C. Jackson (RSC, 
ANU) and staff from the Australian Synchrotron. 
† The structure was solved and refined by Dr P. Carr (RSC, ANU) in consultation with the author. 
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molecules per asymmetric unit respectively. Phaser272 was then used for molecular 
replacement to search for 4 molecules of chain A from PDB 2DOO183 per asymmetric 
unit. Several rounds of refinement were applied using REFMAC5273 and Coot.211 The 
structure of citrate was taken from the PDB (1C5R209). Average B factors were 
calculated using BAVERAGE. 
Anomalous scattering experiments were performed at 7,162.0 eV (iron ion edge) 
and 9,660.0 eV (zinc ion edge). 360° data were acquired for 9,660.0 eV, and 1,080° data 
were acquired for 7,162.0 eV. BDFMs (Bijvoet difference Fourier maps)274 were 
calculated using FFT.275 The intensities of the anomalous peaks (e/Å3) at the Zn1 and 
Zn2 site were determined using Coot.211 
2.9.17 Protein Structure Analysis and Image Rendering 
All protein 3D structures were analysed using PyMOL software.276,277 Structural 
alignments between homologous sequences were carried out on backbone atoms (name 
CA+C+N+O) by minimising the RMSD iteratively with the ‘align’ command. Reported 
RMSD values were calculated using the ‘rms_cur’ command between backbone atoms 
after the iterative ‘align’ command. All RMSD values were only calculated for 
backbone atoms unless otherwise stated. Angles and distances were either measured 
between 3 points using the ‘get_angle’ and ‘get_distance’ commands or manually 
calculated from the PDB file mathematically. 
Electron or anomalous scattering density maps were exported from CCP4 with 
‘.map.ccp4’ file extensions, and imported into PyMOL. Figures of isosurface lobes 
depicting the magnitude of PCS due to the Δχ tensor were generated in PyMOL using 
density maps generated by Numbat.30 Figures with coloured scales utilised the 
‘data2bfactor.py’ script278 and the inbuilt ‘spectrum’ command. All 3D protein 
structures shown in figures were rendered using PyMOL’s inbuilt ray-tracing rendering 
engine. 
Volume and cavity calculations were performed using Voronoia software.212 
Chain A of the PDB aligned structure was exported from PyMOL as a PDB without 
water molecules or active site ligands, and imported into Voronoia. Packing density was 
then calculated including heteroatoms (metals) and surface atoms with the ProtOr 
radii.279 Due to the small differences being measured, a grid distance of 0.01 Å was 
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used. The resultant .vol files were then processed, again in Voronoia, to calculate the 
number of cavities (that can fit a 1.4 Å sphere), and other packing statistics. 
2.9.18 NMR Acquisition, Processing and Analysis 
All spectra were acquired on either a 600 or 800 MHz Bruker NMR 
spectrometer with AVANCE II console and TCI cryoprobe. Cell-free samples were 
measured in a 3 mm tube or a 5 mm Shigemi tube. In vivo samples were measured in a 
5 mm tube or a 5 mm Shigemi tube. All NMR experiments were performed in 20 mM 
MES, pH 6.5, 100 mM NaCl at 310 K. 
Aged NMR samples were incubated at 37 °C for one to three weeks either in the 
NMR magnet or in an air incubator in NMR buffer inside a 5 mm NMR tube. The 
samples were recovered and centrifuged to remove any precipitant and the pH was 
measured prior to NMR measurement. The NMR buffer was not exchanged or refreshed 
unless the pH shifted. 
Calibration of chemical shift was calculated using the water signal and the 
Fortran script ‘calibrate’ that implements the chemical shift referencing described by 
Wishart et al.280 The correction was applied during conversion of raw Bruker-type ser 
files using bruk2pipe281 scripts. Raw data were then processed with nmrPipe,281 and 
analysed using ccpNMR Analysis v2.3.1 software.282,283 Typical processing scripts 
applied linear prediction in all indirect dimensions doubling the number of points in the 
indirect dimensions. 
Chemical shift perturbations using a weighted distance score were calculated in 
ccpNMR Analysis v2.3.1 using the equation:283 
 (2.7) 
Evidence of PREs was defined by measuring the peak height of the 
paramagnetic and diamagnetic samples separately. A distant resonance (Glu65 at > 
26 Å) was used as a normalisation resonance with an assumed null PRE. Evidence of 
PREs was shown as the ratio of the normalised paramagnetic intensity divided by the 
diamagnetic intensity. 
The solved X-ray crystal structure of [FeZn]IMP-1 determined in this work was 
used for Δχ-tensor fitting. Only backbone amide proton shifts were used for Δχ-tensor 
fitting. Python scripts were written to complete the grid search based Δχ-tensor fits. 
￿
∆δ21H + (0.15×∆δ15N)2
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First, the script calculated a grid of metal positions at a defined resolution over the 
protein and then a pyParaTools34 fit for each metal position was applied using the 
T1M1FM protocol. Any points that did not converge were excluded from further 
processing. The scripts then wrote out a pdb file of the grid points with the χ2 value in 
the B factor column and the Δχax component in the occupancy column. This ‘grid’ pdb 
file was then overlaid with the protein structure in PyMOL and visually analysed using 
a colour gradient scaled to the RMSD score. Alternatively, the grid pdb file was 
imported into Microsoft Excel and the RMSD value plotted against the distance from 
the Zn1 or Zn2 sites. Two grid searches were performed. A coarse grid with a spacing of 
1 Å between points covered the entire protein and a fine grid with a spacing of 0.1 Å 
was calculated within the region of 5 Å from the two metal sites. 
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3 Cell-free protein synthesis with 2H/15N/13C-labelled 
amino acids in H2O for the production of 
perdeuterated proteins with 1H in the exchangeable 
positions 
3.1 Introduction 
3.1.1 Perdeuteration 
NMR studies of proteins larger than 20 kDa are hindered by low signal-to-noise 
due to fast relaxation rates caused by slow molecular tumbling. In addition, the larger 
number of signals results in spectral overlap. Short T2 relaxation times also cause 
significant line broadening, which increases the overlap problem. Some of the spectral 
overlap can be resolved by using multi-dimensional NMR experiments at high magnetic 
field strengths, however, long pulse sequences are required to exploit the available extra 
resolution. For magnetisation to persist during longer pulse sequences, perdeuteration is 
often requisite. Replacing all non-exchangeable protons with deuterium nuclei increases 
the relaxation times by reducing dipole-dipole relaxation. Consequently, the signal-to-
noise ratio is increased and high-resolution constant-time experiments are possible. 
A common method of isotope-labelling for NMR is to overexpress the protein of 
interest in bacteria that are cultured in defined media with 13C-labelled glucose and 
15N-labelled ammonium chloride. A high percentage of deuteration is possible by 
simply replacing the H2O in the media with D2O, however, to achieve near complete 
deuteration, deuterated glucose must also be used. For optimal yields, the bacteria need 
to be adapted to grow under deuterated conditions by increasing the D2O content for a 
series of growth generations and/or selecting optimally expressing colonies from D2O 
agar plates.192 If the purpose is to record NMR experiments such as 15N-HSQC, HNCA, 
or HNCO spectra, protons must be back-exchanged onto the backbone amides. This can 
be achieved by denaturing and refolding the protein in an H2O based buffer, which 
enables solvent access and spontaneous proton exchange throughout the entire protein. 
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The proton back-exchange step poses a problem for proteins such as IMP-1 
(chapter two) that cannot be refolded in good yield. Hence, exchange of the backbone 
amide hydrogens is only possible for amino acids that are solvent accessible. An 
alternative method for perdeuteration is described in this chapter. By using a cell-free 
protein-synthesis expression system in H2O with 2H/13C/15N-labelled amino acids, 
perdeuterated samples of IMP-1 can be prepared, where all amide hydrogens are 
protons rather than deuterons right from the start and back-exchange is unnecessary. 
3.1.2 Cell-Free Protein Synthesis 
Cell-free protein synthesis has become an economical and useful technique of 
protein production for NMR purposes. The technique uses cellular extracts rather than 
live cells to express the protein of interest. Escherichia coli based S30 extracts are 
commercially available or can be made by lysing cultured cells through a French 
pressure cell, followed by centrifuging at 30,000 g to remove cellular debris and 
genomic DNA. Final preparation of the extract is performed via dialysis against a PEG 
solution to concentrate the extract and remove any small molecules.267 
Typical yields of about 1 mg of protein per mL of reaction mixture are obtained 
in the constant-feed cell-free protein synthesis system described by Apponyi et al.267 
This system has an inner reaction mixture inside a small dialysis bag immersed in an 
outer feed buffer. The inner reaction buffer contains the target DNA with a T7 
promoter, the cellular S30 extract, tRNA and a eukaryotic ATP regeneration system 
(creatine kinase). Supplying T7 RNA polymerase is no longer required if BL21(DE3) 
cells induced with IPTG have been used to prepare the S30 extract. The outer feed 
buffer is typically 10 times the volume of the inner reaction mixture and constantly 
replenishes the inner reaction mixture with small molecules and cofactors such as salts, 
amino acids, ATP, ribonucleotides and folinic acid. It also provides the benefit of 
diluting any inhibitory molecules formed during the reaction. 
Of particular relevance to perdeuteration are enzymatic conversions between 
amino acids.284 Enzymatic metabolism of the labelled amino acids in an H2O 
environment has the potential to dilute the deuterium labelling with protons.285 In the 
cell-free protein synthesis system, a large number of enzymes responsible for catalysing 
amino-acid transformations in vivo are inactivated, typically by the loss of cofactors. 
Further inactivation of these enzymes can be achieved by the addition of inhibitors of 
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specific metabolic reactions,286 but unfortunately these inhibitors are often expensive. 
Alternatively, bacterial strains have been genetically modified to suppress certain 
conversion pathways,287 however, these auxotrophic cell lines are often less viable and 
therefore give lower protein expression yields. 
Fortunately, chemical treatment of the entire cellular S30 extract with NaBH4 
has been identified as a low-cost method to almost completely suppress amino-acid 
conversions.268 The key reaction is reduction of the Schiff base (aldimine) formed in 
pyridoxal 5’-phosphate (PLP) dependant enzymes.288 These enzymes include all 
transaminases and many other enzymes responsible for decarboxylations, racemization, 
eliminations and replacement of α-amino groups.288 While these enzymes are not 
required for protein synthesis, they catalyse the conversion between amino acids in vivo, 
so inhibition of these pathways is beneficial for maintaining specific isotope labelling in 
cell-free protein synthesis reactions.268 
3.2 Results 
3.2.1 Synthesis of Perdeuterated IMP-1 
To improve the NMR spectral resolution of IMP-1 (the topic of Chapter Two), 
production of a 2H/13C/15N-labelled protein was attempted as per section 2.9.5. As the 
protein could not be refolded, back-exchange of 1H onto the exchangeable sites was 
attempted simply by performing all purification steps in H2O-based buffers. From the 
peaks measured in a 15N-HSQC spectrum of the sample, it was evident that complete 
back-exchange had not occurred (Figure 3-1). Complete back-exchange was still not 
achieved in a 2H/13C/15N sample stored at 4 °C in a H2O buffer for over 1 year (data not 
shown).  
In an attempt to obtain more complete back-exchange of 1H onto the 
exchangeable positions, a 2 mL cell-free protein synthesis expression of IMP-1 with 20 
uniformly 2H/13C/15N-labelled amino acids (20AA) was performed. *  The protein 
expressed with high yield and was purified. The expression yielded 1.8 mg of 
concentrated, purified protein (Figure 3-2).  
 
* All cell-free protein synthesis reactions for this chapter were performed by Dr C.-T. Loh in consultation with the 
author 
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An expression was also trialled using the cheaper algal amino-acid mixture 
(AlgalAA), supplemented with the four amino acids missing from the mixture (Asn, 
Gln, Cys and Trp). This sample, however, produced only poor yields (Figure 3-2). 
 
Figure 3-1 A) [15N,1H]-HSQC spectrum of 13C/15N-labelled IMP-1 and B) [15N,1H]-TROSY spectrum of 2H/13C/15N-
labelled IMP-1. Both samples were prepared using in vivo methods. Although the peak shape is narrower in the 
perdeuterated sample, many peaks are weak or missing, indicating incomplete back-exchange of 1H. Even storage of 
the perdueterated sample at 4 °C in an H2O buffer for over 1 year did not significantly increase the amount of back 
exchange (data not shown). 
 
 
Figure 3-2 15% SDS-PAGE of total (T) and soluble (S) fractions from cell-free expressions of IMP-1 using either 20 
individual 2H/13C/15N-labelled amino acids (20AA) or the algal amino-acid mixture supplemented with cysteine, 
asparagine, glutamine and tryptophan (AlgalAA). Control samples were performed using 20 individual unlabelled 
amino acids. 
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3.2.2 NMR Analysis 
 [15N,1H]-TROSY spectra were recorded for both of the 20AA and AlgalAA 
perdeuterated samples (Figure 3-3). It was evident that the cell-free protein synthesis 
method produced high quality spectra and that all the backbone resonances observed for 
a 1H/15N-labelled in vivo sample were present without the need for refolding. While the 
AlgalAA sample produced enough protein for 2D NMR, it required 10 hours to record 
the spectrum in Figure 3-3B due to the low yield of protein from the cell-free extract. In 
contrast, the 20AA sample gave well-resolved and high-signal-to-noise NMR spectra 
after only 30 minutes. 
A TROSY-HNCA experiment was performed on the 20AA sample. To assess 
the extent of Cα protonation, the standard Bruker pulse sequence (trhncaetgp2h3d) was 
modified to remove the proton decoupling pulse during the Cα evolution time. The 
strongest and most resolved peak for each amino-acid type was identified and the 
degree of proton substitution at the Cα position was determined by integration of the 
two 3D satellite peaks arising from the 1JHC coupling. Percentage protonation estimated 
for each amino-acid type is listed in Table 3-1. 
 
Figure 3-3 [15N,1H]-TROSY spectra of perdeuterated IMP-1 prepared by different cell-free reactions. A) Spectrum of 
the 20AA sample recorded in 30 min. This spectrum shows all the peaks observed in the 1H/15N-labelled sample 
prepared in vivo in H2O. B) Spectrum of the AlgalAA sample recorded in 10 hours. This spectrum also displays a 
complete set of cross-peaks, but the low protein yield obtained in the cell-free reaction affected the NMR sensitivity. 
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Table 3-1 Percentage proton substitution onto Cα 
Amino Acidi 1D traceii % 1Hαiii Etezady-Esfarjaniiv % Su
v 
Alanine 
(A98) 
 
< 3 high 0.4 
Cysteine 
(C158) 
 
8 high N.D. 
Aspartic acid 
(D6) 
 
< 3 very high 2.1 
Glutamic acid 
(E150) 
 
< 3 very high 3.0 
Phenylalanine 
(F63) 
 
< 3 high 4.2 
Glycine 
(G120)vi 
 
< 3 high 1.0 
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Amino Acidi 1D traceii % 1Hαiii Etezady-Esfarjaniiv % Su
v 
Histidine 
(H19) 
 
< 3 low N.D. 
Isoleucine 
(I9) 
 
< 3 medium N.D. 
Lysine 
(K54) 
 
7 medium N.D. 
Leucine 
(L4) 
 
< 3 medium N.D. 
Methioninevii N.D. - low N.D. 
Asparagine 
(N122) 
 
13 very high 0.5 
Proline 
(P95)ix 
 
< 3 N.D. N.D. 
 144 
Amino Acidi 1D traceii % 1Hαiii Etezady-Esfarjaniiv % Su
v 
Glutamine 
(Q113) 
 
< 3 very high 3.0 
Arginine 
(R92) 
 
< 3 medium N.D. 
Serine 
(S117) 
 
14 high 1.0 
Threonine 
(T96) 
 
6 low N.D. 
Valine 
(V16) 
 
6 medium N.D. 
Tryptophan 
(W124) 
 
< 3 high 4.0 
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Amino Acidi 1D traceii % 1Hαiii Etezady-Esfarjaniiv % Su
v 
Tyrosine 
(Y68) 
 
< 3 high N.D. 
i Amino acid measured indicated in parenthesis 
ii 1D traces (blue solid line) were selected to emphasise satellite peaks and were often not directly through the centre 
of the main peak. This means that substitution may appear exaggerated in the 1D traces. For reference, the red solid 
1D trace is equivalent to 10% of the blue trace, and the dashed blue line is twice the estimated noise level. Vertical 
scale is relative between peaks. 
iii Percentage of protonation on the Cα of each amino acid as estimated by volume measurement of Cα satellites in the 
TROSY-HNCA spectrum. All amino acids were supplied with 97 to 99% deuteration, so any result below 3% is 
insignificant. 1JCα-Hα coupling constants for all significant protonation samples were about 125 ± 15 Hz (spectral 
resolution of 20 Hz). 
iv Degree of protonation of the Cα as reported by Etezady-Esfarjani et al.285 
v Percentage of protonation on the Cα of each amino acid as reported by Su et al.268 for amino acids treated with 
reduced S30 extract. These values do not include the contribution to protonation present in the commercially 
available amino acids (up to 3%). N.D.: Not detected or reported.  
vi Glycine Cα peaks are negative in sign in the Bruker trhncaetgp2h3d NMR experiment. The 1D trace has been 
inverted to facilitate comparison. 
vii No methionine signals were observed for IMP-1 in the TROSY-HNCA NMR experiment 
ix
 The proline signal for Pro95 was observed via the i-1 peak of Thr96 
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3.2.3 Cost analysis 
The costs of the different labelled materials as advertised by CIL289 are listed in 
Table 3-2. From this table it can be calculated that the labelled components for a 
100 mL in vivo 2H/13C/15N-labelled IMP-1 sample for NMR using the method described 
in section 2.9.2 would cost approximately US$540 with 13C-labelled glucose or US$800 
using 2H/13C-labelled glucose. Conversely, the labelled components used for the sample 
prepared via cell-free synthesis with individual 2H/13C/15N-labelled amino acids would 
have cost a little under US$505 ($252 per mL). 
Table 3-2 Cost of isotope labelled components required for perdeuteration of proteins (Jan 2014) 
Component Product code Amount (g) Costi 
in vivo 
15N ammonium chloride NLM-467-1 1.0 $48 
13C glucose CLM-1396-1 1.0 $194 
2H/13C glucose CDLM-3813-1 1.0 $454 
2H2O DLM-4-99-1000 1000.0 $680 
cell-free protein synthesis components 
2H/13C/15N L-alanine CDNLM-6800 0.25 $1,099 
2H/13C/15N L-cysteine CDNLM-6809 0.25 $1,643 
2H/13C/15N L-aspartic acid CDNLM-6803 0.25 $722 
2H/13C/15N L-glutamic acid CDNLM-6804 0.25 $785 
2H/13C/15N L-phenylalanine CDNLM-6811 0.25 $1,529 
2H/13C/15N glycine CDNLM-6799 0.25 $474 
2H/13C/15N L-histidine:HCl:H2O CDNLM-6806 0.25 Not advertisedii 
2H/13C/15N L-isoleucine CDNLM-6807 0.25 $1,213 
2H/13C/15N L-lysine:2HCl CDNLM-6810 0.25 $1,529 
2H/13C/15N L-leucine CDNLM-6808 0.25 $1,097 
2H/13C/15N L-methionine CDNLM-6798 0.25 Not advertisedii 
2H/13C/15N L-asparagine:H2O CDNLM-6802 0.25 $1,485 
2H/13C/15N L-proline CDNLM-6812 0.25 $1,560 
2H/13C/15N L-glutamine CDNLM-6805 0.25 $1,559 
2H/13C/15N L-arginine:HCl CDNLM-6801 0.25 $1905 
2H/13C/15N L-serine CDNLM-6813 0.25 $1,097 
2H/13C/15N L-threonine CDNLM-6814 0.25 $1,675 
2H/13C/15N L-valine CDNLM-6817 0.25 $1,097 
2H/13C/15N L-tryptophan CDNLM-6816 0.25 $2,888 
2H/13C/15N L-tyrosine CDNLM-6815 0.25 $1,560 
i cost in US$ on 13 January 2014 
ii prices for histidine and methionine are not listed on the CIL website. For cost analysis estimates, these were 
overestimated to be $4,000 for 0.25 g. 
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3.3 Discussion 
3.3.1 Cell-Free Protein Synthesis 
Labelling with 20 Individual 2H/13C/15N Amino Acids 
Isotope labelling with the 20 individual 2H/13C/15N-labelled amino acids (20AA) 
produced almost the same yields as an unlabelled control. This confirms that amino 
acids labelled with 2H, 13C or 15N do not compromise the protein synthesis system if it 
is based on a conventional S30 extract treated with NaBH4. In contrast to in vivo 
systems, where optimal yields depend on using bacteria that have been conditioned to 
grow in D2O, the S30 extract does not need to be conditioned to perform optimally with 
deuterated amino acids. 
Supplemented Algal Amino-Acid Mixture 
Even after supplementing the algal amino-acid mixture with asparagine, 
glutamine, cysteine and tryptophan (AlgalAA), this approach resulted in poor protein 
yields. This is most likely due to the cell-free protein synthesis reaction running out of 
one or more amino acids. The amino-acid composition of the algal amino-acid mixture 
is listed in Table 3-3. 
It is worth noting that the algal amino-acid mixture had an amino-acid content of 
only 77.4%,* so that the final concentration of amino acids present in the cell-free 
protein synthesis reaction was in fact lower than initially anticipated. From Table 3-3, it 
can be seen that 7 of the 16 amino acids in the algal amino-acid mixture were supplied 
at less than 80% of the minimal amino-acid concentration recommended by Apponyi et 
al.,267 and at least 5 were present at less than 55% of the recommendations. 
As the S30 extract is treated with NaBH4 to limit proton exchange particularly 
onto the Cα or Cβ atoms, the cell-free S30 extract cannot rely on residual PLP-cofactor-
dependent transaminase activity to correct for any imbalance of amino-acid 
concentration. Supplementing the mixture by adding individual amino acids so that no 
single amino acid is limiting could potentially rectify this, however, since the key 
 
* Algal amino-acid mixture (CDNLM-2496-0) certificate of analysis for lot PR-19646, CIL 
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motivation for using the algal amino-acid mixture is to avoid the high cost of 
purchasing individual amino acids, this is clearly not ideal. 
Future experiments should take the issue of limited amino-acid availability into 
account by increasing the amount of algal amino-acid mixture supplied to the cell-free 
protein synthesis reaction by at least 1.6 fold to 2.5 mg/mL of reaction and feed 
buffers.* This increase would provide all the amino acids except for methionine and 
phenylalanine at greater than 80% of the Apponyi et al.267 recommendations (Table 
3-3). These two amino acids could be supplemented along with the four missing amino 
acids. 
It is worth noting that the use of algal amino-acid mixture without 
supplementation may well be useful for uniform labelling of 13C/15N samples not 
requiring deuteration, as the PLP enzymes would not need to be inhibited and 
interconversion between amino acids by the transaminases could be allowed to occur 
freely. This has been previously discussed by Yokoyama et al. who found that by 
performing a cell-free protein synthesis reaction with additional 15N-labelled 
ammonium acetate, (13C/)15N-labelled indole, sodium sulfide, PLP and acetyl coenzyme 
A, they could express proteins from the algal amino-acid mixture without needing to 
add the four missing amino acids.290 Using this system they were able to recover yields 
of uniformly 13C/15N-labelled protein close to that obtained using individual amino 
acids, at approximately 15% and 38% cost saving for uniformly 15N- and 
13C/15N-labelled samples, respectively. 
  
 
* It is noted that solubility issues arise when making amino-acid stocks. Dissolving 27.5 mg of algal amino-acid 
mixture directly in 10 mL of the premade feed buffer prior to pH adjustment rather than making the amino acids in a 
separate stock can resolve this. 
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Table 3-3 Amino-acid content in the algal amino-acid mixture 
Amino Acid Molar%i Mass%ii mmol/giii Conc. 
(x 1.6)iv 
Apponyiv 
Alanine 11.6 9.7 0.78 1.18 (1.89) 1.00	  
Cysteinevi - - - 1.00 0.35	  
Aspartic acid 9.7 12 0.65 0.99 (1.58) 1.00	  
Glutamic acid 8.8 12 0.59 0.89 (1.43) 1.00	  
Phenylalanine 1.5 2.4 0.10 0.16 (0.25) 0.35	  
Glycine 7.8 5.5 0.53 0.80 (1.28) 1.00	  
Histidine 0.8 1.1 0.05 0.08 (0.13) 0.15	  
Isoleucine 3.4 4.3 0.23 0.35 (0.56) 0.15	  
Lysine 8.1 11.1 0.54 0.82 (1.32) 1.00	  
Leucine 7.2 8.9 0.49 0.74 (1.18) 1.00	  
Methionine 1.5 2 0.10 0.15 (0.24) 1.00	  
Asparaginevi - - - 1.00 0.35	  
Proline 3.0 3.3 0.20 0.31 (0.49) 0.15	  
Glutaminevi - - - 1.00 1.00	  
Arginine 4.3 7 0.29 0.44 (0.70) 0.35	  
Serine 5.0 4.9 0.34 0.51 (0.81) 1.00	  
Threonine 5.6 6.2 0.38 0.57 (0.91) 0.15	  
Valine 5.0 4.9 0.34 0.51 (0.81) 1.00	  
Tryptophanvi - - - 1.00 0.05 
Tyrosine 2.6 4.3 0.17 0.26 (0.42) 0.05	  
i Molar ratio of amino acids present in lot PR-19646 for the algal amino-acid mixture (CDNLM-2496-0). 
ii Mass ratio of amino acids present in lot PR-19646 for the algal amino-acid mixture (CDNLM-2496-0). 
iii mmol of amino acid per gram of algal amino-acid mixture. Calculated with a correction applied for amino-acid 
content (77.4%) of the mixture, and increased amino-acid masses due to isotope labelling. 
iv Concentration in mM of amino acid present in the algal amino-acid cell-free reaction performed in this work. This 
was equivalent to 1.5 mg/mL of reaction and feed buffer. Concentration in parenthesis refers to the concentration 
using 2.5 mg of algal amino-acid mixture per mL of reaction and feed buffer, as recommended in this work. 
v Recommended amino-acid concentration in mM in Apponyi et al.267 
vi The amino acids cysteine, asparagine, glutamine and tryptophan were not present in the algal amino-acid mixture 
and were supplied independently at 1 mM concentration 
3.3.2 NMR Analysis 
NMR analysis of the Cα protonation via the 1JHC satellites in the 
TROSY-HNCA experiment indicated that the cell-free reaction still allowed proton 
exchange at the Cα position of some amino-acid types. The degree of deuterium 
labelling in the 2H/13C/15N-labelled amino acids supplied by CIL are reported to be 97% 
to 99%. Therefore, satellite peaks with volumes of 3% of the main peak could not be 
regarded as significant and do not indicate metabolism by the cell-free extract. This 
applies for the amino acids alanine, aspartic acid, glutamic acid, phenylalanine, glycine, 
histididine, isoleucine, leucine, proline, glutamine, arginine, tryptophan and tyrosine 
(methionine was not observed). However, the integration of the satellite peaks suggests 
some additional degree of Cα protonation for the remaining amino acids. 
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Integration of the satellite peaks of threonine (T112), valine (V16) and lysine 
(K54) suggested a Cα protonation level of 6%, 6% and 7%, respectively, corresponding 
to about 3-4% proton substitution beyond the 1H contamination reported by the 
manufacturer. Cysteine (C158) was measured to have 8% Cα protonation, but this 
measurement is not reliable due to the poor signal-to-noise ratio of the single cysteine 
peak in the IMP-1 spectrum. Serine (S117) and asparagine (N122) displayed higher 
levels of protonation of the Cα position at 14% and 13%, respectively. 
Significant discrepancies between a previous study of Cα protonation level268 
and this work were unexpected and may be attributed to small differences in methodical 
approach. Even though careful quantitative NMR measurements are possible, the poor 
signal-to-noise ratio of the cross-peaks of some residues and the limited spectral 
resolution of the indirect 13C dimension compromised the accuracy of the integral 
method used in this chapter. In the report by Su et al.,268 proton substitution was 
determined by performing a mock cell-free protein synthesis reaction using an amino-
acid mixture without DNA present, but the mock reaction was performed for only half 
the time of a regular experiment and therefore potentially underestimated the degree of 
protonation. In addition, the earlier work used 13C-1H cross-peaks of the residual 
50 mM HEPES buffer from the cell-free protein synthesis reaction as internal reference 
to determine the concentration of the protonated amino acids, which could be less 
accurate than the direct comparison with the 15N-13C-cross-peak of the Cα-2H groups 
used in the present work. Finally, peak overlaps prevented the individual measurement 
of glutamate, lysine and arginine concentrations. It was assumed that lysine and 
arginine showed no significant protonation,285 but in this present work proton 
substitution of lysine exceeded that of glutamic acid. Serine and tyrosine peaks also 
overlapped in the previous study by Su et al., preventing explicit assessment of these 
amino acids. Finally, no 13C-HSQC peaks were observed for cysteine, histidine, 
isoleucine, leucine, proline, threonine or valine. 
A better method in future studies could run a similar mock cell-free protein 
synthesis reaction for the full experimental time, followed by freeze-drying of the outer 
medium and redissolving in a minimal amount of D2O. This concentrated sample could 
then be assessed by quantitative 1D 13C-NMR without proton decoupling. Integration of 
the satellite peaks and comparison with the centre peak would give an independent 
percentage of proton substitution. If the resolution of the directly detected 13C 
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experiment is insufficient, the amino acids could be separated by HPLC prior to NMR 
measurement. 
Perdeuterating IMP-1 using the cell-free protein synthesis protocol described in 
this chapter produced higher quality spectra with narrower peak shapes than the in vivo 
sample even though the in vivo sample produced a more concentrated protein sample 
(Figure 1 of the attached application note). This can be attributed to the additional line-
broadening arising from incomplete deuteration of the side-chain carbons in the in vivo 
sample, due to the use of uniformly 13C-labelled glucose rather than 2H/13C-labelled 
glucose. 
Regardless of the discrepancies between the Su et al. study291 and the present 
work, it is clear that the NaBH4 treatment of the cell-free S30 extract significantly 
reduces the extent of amino-acid metabolism, effectively minimises proton substitution 
at the Cα position, and produces higher levels of perdeuteration than in vivo expressions 
in D2O that use 13C-labelled glucose. 
3.3.3 Cost Analysis 
Although the initial cost of purchasing the individual 2H/13C/15N-labelled amino 
acids for the cell-free protein synthesis system may appear high, it is in fact comparable 
to the cost of labelled components in an efficient, high-yielding in vivo expression 
system. Considering the benefits of the cell-free protein synthesis system, such as 
simplified purification and improved time-efficiency, perdeuterating proteins for NMR 
via cell-free protein synthesis is an economically viable and indeed attractive 
alternative. 
It should be highlighted that the cost analysis performed in this chapter only 
compared the isotope-labelled materials, ignoring the costs associated with all other 
aspects of in vivo expression or the cell-free protein synthesis (such as generating the 
S30 extract). This simplification is reasonable though, as the most significant cost in 
either system is the isotope-labelled materials. 
If the previously discussed problems with the algal amino-acid mixture could be 
resolved by simply increasing the amount of mixture provided to the cell-free synthesis 
reaction, this would further reduce costs and simplify the preparation of cell-free stock 
solutions. Using 2.5 mg of algal amino-acid mixture per mL of the reaction and feed-
buffer solutions, along with supplementing 0.05 mM tryptophan, 0.1 mM methionine, 
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0.1 mM phenylalanine, 0.35 mM cysteine, 0.35 mM asparagine and 1 mM glutamine, 
would cost $92/mL,* a potential saving of 63% compared to using individual amino 
acids alone. 
Finally, it is noted that CIL also offer a ‘20 amino-acid mix for cell-free’ 
(catalogue number CDNLM-6784-0.5) at an advertised price of US$2887 per 0.5 g. 
This mixture is similar to the algal amino-acid mixture in as much as the majority of the 
amino acids are derived from an algal source. Communication with CIL confirms that 
this mixture has all 20 amino acids in the molar ratio listed in Table 3-4. If 33 mg of this 
amino-acid mixture could be used per mL cell-free reaction (including 10 mL feed 
buffer), only three of the amino acids would be present at less than 80% of the 
recommended amount. Supplementing this mixture with less than 0.1 mM 
phenylalanine, 0.25 mM glutamine and 0.7 mM methionine would bring it to within 
20% of the recommendations by Apponyi et al.267. Costs associated with this would 
equate to $238/mL,† which is slightly cheaper than the system based on individual 
amino acids. 
  
 
* $50 for 27.5 mg of algal amino-acid mixture ($907 per 0.5 g), $3 for 0.2 mg of tryptophan ($2888 per 0.25 g), $6 
for 0.4 mg of methionine (~$4000 per 0.25 g), $2 for 0.4 mg of phenylalanine ($1529 per 0.25 g), $7 for 1 mg of 
cysteine ($1643 per 0.25 g), $7 for 1.2 mg of asparagine ($1485 per 0.25 g), $17 for 3.5 mg of glutamine ($1559 per 
0.25 g) 
† $190 for 33 mg of the ‘cell-free’ amino-acid mix ($2887 per 0.5 g), $2 for 0.4 mg of phenylalanine ($1529 per 
0.25 g), $6 for 0.9 mg of glutamine ($1559 per 0.25 g) and $40 for 2.5 mg of methionine (overestimate of $4000 per 
0.25 g) 
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Table 3-4 Amino-acid composition of the ‘20 amino-acid mix for cell-free’ 
Amino Acid Molar%i Mass%ii mmol/giii Conc.iv Apponyiv 
Alanine 11.6 8 0.677 2.05 1.00 
Cysteine 1.9 3.3 0.111 0.34 0.35 
Aspartic acid 10 9.9 0.584 1.77 1.00 
Glutamic acid 10 11.2 0.584 1.77 1.00 
Phenylalanine 1.4 1.7 0.082 0.25 0.35 
Glycine 7.4 4.2 0.432 1.31 1.00 
Histidine 0.8 0.9 0.047 0.14 0.15 
Isoleucine 3.4 3.5 0.198 0.60 0.15 
Lysine 7.4 8.6 0.432 1.31 1.00 
Leucine 7.2 7.5 0.420 1.27 1.00 
Methionine 1.6	   1.8 0.093 0.28 1.00	  
Asparagine 5.6	   5.6 0.327 0.99 0.35	  
Proline 3.4	   3 0.198 0.60 0.15	  
Glutamine 4.1	   4.6 0.239 0.73 1.00	  
Arginine 4.2	   5.7 0.245 0.74 0.35	  
Serine 4.8	   3.8 0.280 0.85 1.00	  
Threonine 5.7	   5.2 0.333 1.01 0.15	  
Valine 4.8	   4.5 0.280 0.85 1.00	  
Tryptophan 2.3	   3.6 0.134 0.41 0.05	  
Tyrosine 2.4	   3.3 0.140 0.42 0.05	  
i Molar ratio of amino acids present in lot PR-19629 of the ‘20 amino-acid mix for cell-free’ (CDNLM-6784-0). 
ii Mass ratio of amino acids present in lot PR-19629 of the ‘20 amino-acid mix for cell-free’ (CDNLM-6784-0). 
iii mmol of amino acid per gram of ‘20 amino-acid mix for cell-free’. Calculated with a correction applied for amino-
acid content (83.4%) of the mixture, and increased amino-acid masses due to isotope labelling. 
iv Concentration in mM of amino acid present for a cell-free protein synthesis reaction supplied with 3 mg/mL ‘20 
amino-acid mix for cell-free’ (i.e. 33 mg for a 1 mL reaction with a 10 mL feed buffer). 
v Recommended amino-acid concentration in mM in Apponyi et al.267 
3.4 Conclusions 
This work shows that using the cell-free protein expression method for the 
production of perdeuterated proteins for NMR is of particular value for proteins that are 
difficult to refold. While the direct cost of 2H/13C/15N-labelled amino acids for the cell-
free protein synthesis experiment initially appears prohibitive, a considered cost 
analysis finds this method economically on par with other methods. A brief analysis of 
costs associated with the use of supplemented amino-acid mixes suggests the potential 
for further significant savings, but a more thorough experimental investigation is 
required to confirm this. 
The cell-free protein synthesis system described here takes less time, simplifies 
product purification and produces more completely deuterated amino-acid side-chains 
while the backbone amides retain protons. Although particularly useful for proteins that 
are difficult to refold, this method could also be recommended for perdeuterating any 
protein for NMR. 
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3.5 Methodology 
3.5.1 Protein Synthesis 
The construct used for expression of the IMP-1 metallo-β-lactamase protein 
included an N-terminal MASMTG expression tag in the pET47b(+) vector as described 
in section 2.9.1. 
Protein synthesis by in vivo methods was performed as per section 2.9.2. Cell-
free protein synthesis followed the protocol of Apponyi et al.267 with the addition of 
NaBH4 treatment to inhibit PLP-cofactor dependant enzymes,268 and supplying the 
reaction with 10 µM ZnSO4 to promote the formation of the [ZnZn] form of IMP-1. 
The amino acids used were either individual 2H/13C/15N-labelled amino acids, 
part of a 2H/13C/15N-labelled amino-acid mixture (algal amino-acid mix) or amino acids 
at natural isotopic abundance. Control and individual 2H/13C/15N-labelled amino acids 
were supplied to the cell-free protein synthesis reaction at 1 mM concentration each. 
The algal amino-acid mixture was supplied at 1.5 mg/mL (inner and outer buffers) and 
supplemented with 1 mM cysteine, asparagine, glutamine and tryptophan. All labelled 
amino acids and amino-acid mixtures were purchased from Cambridge Isotope 
Laboratories (CIL). 
Protein samples were purified via a short (10 mL) cation exchange column as 
per section 2.9.6. 
3.5.2 NMR Acquisition and Analysis 
NMR experiments were performed on a Bruker 800 MHz NMR Spectrometer 
with TCI cryoprobe. Samples were measured in 20 mM MES buffer (pH 6.5), 100 mM 
NaCl in a 5 mm Shigemi tube. 
NMR spectra were processed using nmrPipe software281 with a cosine 
apodisation function and no linear prediction. Integration of satellite peaks was 
performed on 3D spectra, using ccpNMR Analysis v2.2.2.282,283 Peaks were centred 
using Lorenzian peak fitting and the volume measured using the truncated box sum* 
 
* The truncated box sum adds points consecutively within a given range (box) from the peak centre unless the 
intensity begins to rise again (i.e. due to an overlapping peak). 
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(box width 1H: 50 Hz, 13C: 120 Hz, 15N: 120 Hz). The volume of each satellite was 
added and then a percentage of total protein calculated as per: 
 
(3.1) 
To maximise the accuracy of the measurement, only the most intense and 
resolved peak for each amino-acid type was measured. 
3.5.3 Cost analysis 
The estimated cost of uniform labelling in vivo was based on the use of 500 mL 
D2O, 1.0 g of glucose and 0.1 g of ammonium chloride. This is enough for a 100 mL 
expression media with 400 mL starter culture, but does not include the labelled 
materials for adapting the bacteria to D2O growth, or any other materials required. 
The estimated cost of uniform labelling in the cell-free system was based on the 
use of 1 mM of each amino acid in a total volume of 22 mL. The mass was calculated to 
account for counterions and isotope labelling; for example, the mass of L-lysine:2HCl is 
approximately 220 g/mol (128 g/mol + 20 g/mol for the labels + 2 x 36.5 g/mol for 
2HCl), so to attain 22 mL of a 1 mM solution, less than 4.8 mg is needed, which equates 
to a total cost of $29.60. In the case of two amino acids where an exact price was not 
available, an overestimate of $4,000 per 0.25 g was used. Calculations did not include 
the costs associated with making the S30 extract or any other materials required. 
3.6 Reproduction of the Submitted Application Note 
Carruthers, T.; Loh, C.-T.; Otting, G. (2013) Cell-free protein synthesis with 
2H/15N/13C-labeled amino acids in H2O for the production of perdeuterated proteins with 
1H in the exchangeable positions. Application Note for CIL 
Dr  C. T. Loh was responsible for preparing and performing the cell-free 
synthesis reaction. I was responsible for the generation of genetic material for cell-free 
synthesis, providing recommendations for modifications to the cell-free protein 
synthesis for IMP-1, protein purification, NMR acquisition and analysis, and figure 
generation for the final manuscript. Prof. G. Otting wrote the manuscript, with editing 
advice provided by all authors.  
￿
(Vsatellites)￿
(Vall)
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Cell-free protein synthesis with 2H/15N/13C-labeled amino acids in H2O for the 
production of perdeuterated proteins with 1H in the exchangeable positions 
 
Thomas Carruthers, Choy-Theng Loh and Gottfried Otting 
 
Research School of Chemistry, Australian National University, Canberra, ACT 
0200, Australia 
 
 
Perdeuteration is essential for NMR studies of big and immobile proteins (> 40 kDa) to slow 
down the relaxation rates of the remaining 1H NMR signals. Uniformly 2H/15N/13C-labeled 
proteins are typically produced by growing E. coli in minimal medium with 13C-glucose as the 
only carbon source, 15N-ammonium salts as the only nitrogen source, and perdeuteration 
achieved simply by making up the medium with D2O instead of water. As the resulting 
protein product is uniformly labeled with 2H, observation of the backbone amides by 1H NMR 
requires prior 2H-1H back-exchange of the amide hydrogens. This poses a dilemma for 
proteins that do not tolerate 2H-1H back-exchange. For example, the hydrogen-exchange of 
amide deuterons buried in the interior of the protein depends on local (for some amides even 
global) unfolding of the protein to expose the amides to the solvent. Proteins for which back-
exchange is difficult include the large class of proteins that cannot be reversibly denatured 
(usually leading to precipitation) and proteins of limited stability that don’t tolerate long 
incubation times. Here we illustrate the finding that back-exchange is redundant if the protein 
of interest is produced by cell-free synthesis from perdeuterated amino acids in H2O. 
Importantly, the costs associated with cell-free synthesis compare favorably with those of 
in vivo expression.  
A brief description of cell-free protein synthesis 
Cell-free protein synthesis uses a cell extract rather than live cells to produce the protein of 
interest in a coupled transcription-translation reaction. Using cell extracts has numerous 
advantages: (i) cell extracts are depleted of the DNA from the original organism so the 
synthesis machinery only produces the target protein encoded by the DNA that is supplied to 
the reaction mixture; (ii) the process of preparing the cell extract inactivates a number of 
enzymes that perform chemical transformations between amino acids in vivo, therefore 
metabolic conversions between different amino acids are suppressed; (iii) the chemical 
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environment in which the protein synthesis proceeds can readily be controlled and modified; 
and (iv) proteins can be produced from linear DNA amplified by PCR making it very easy to 
introduce mutations by site-directed mutagenesis.1 Cell-free protein synthesis became an 
important tool in NMR spectroscopy in 1999 when Kigawa and co-workers established 
conditions for high-yield protein expression.2 Cell extracts can readily be prepared from 
E. coli by breaking the cells, centrifugation, and collection of the supernatant. In our hands, 
homemade S30 extracts routinely sustain the production of about 1 mg of protein per ml of 
reaction mixture. The protocol involves the use of a dialysis system in which the reaction 
mixture containing the S30 extract is placed in a dialysis bag and immersed in an outer buffer 
that supplies low-molecular weight compounds to sustain the protein synthesis reaction, such 
as amino acids, nucleotides, and ATP. The target DNA is added to the reaction mixture 
together with any other macromolecules that aid in protein production, such as tRNA and 
RNA polymerase. The DNA can be the same plasmid DNA that directs the protein expression 
in conventional in vivo systems or it can be PCR-amplified DNA.  Detailed protocols for the 
preparation of S30 extracts and cell-free reactions that we have established in our laboratory 
have been published.3 
 
Cell-free synthesis of perdeuterated proteins in H2O 
Producing perdeuterated proteins by cell-free synthesis from perdeuterated amino acids in 
H2O can be compromised by undesired residual activity of metabolic enzymes in the cell 
extract. For some amino acid types, these metabolic activities can substitute some of the 
carbon-bound deuterons by protons. The effect is most pronounced for hydrogens in the -
position and can be attributed to enzymes requiring the pyridoxal 5’-phosphate (PLP) 
cofactor. The cell-free synthesis method offers the crucial advantage that this 2H-1H exchange 
can be suppressed in a straightforward manner by treating the S30 extract with NaBH4 to 
reduce PLP and its adducts with the protein.4 This leads to irreversible inactivation of the PLP 
enzymes, none of which are required for protein production.  
 
 
Analysis by NMR spectroscopy 
Figure 1 shows a comparison between two [15N,1H]-TROSY spectra of 2H/15N/13C-labeled 
metallo- -lactamase from Klebsiella pneumonia (IMP-1), where one sample was prepared 
in vivo in E. coli using a minimal medium with D2O (Figure 1A), while the other sample was 
prepared by cell-free synthesis in H2O, supplying all amino acids in 2H/15N/13C-labeled form 
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(Figure 1B). Clearly, more cross-peaks can be observed for the sample prepared by cell-free 
synthesis. IMP-1 is a metallo-enzyme that we have been unable to refold following 
denaturation. The protein is also prone to precipitation during NMR measurement, making 
prolonged incubations for 2H-1H back-exchange of amide hydrogens unpractical. As an added 
benefit of using highly perdeuterated amino acids, the cross-peaks in Figure 1B tend to be 
narrower than those in Figure 1A. We attribute this effect to incomplete perdeuteration in the 
sample prepared in vivo, as we used uniformly13C-labeled glucose rather than 2H/13C-labeled 
glucose. 
 
Cost and yield  
The protein sample of Figure 1B was prepared in a 2 ml reaction mixture in an outer buffer of 
20 ml. Each of the labeled amino acids was supplied at a final concentration of 1 mM, i.e. the 
amino acids were supplied in total quantities ranging from 1.6 mg (glycine) to 4.7 mg 
(lysine:2HCl). For such small quantities of amino acids, the total cost of the amino acids from 
CIL ended up being significantly less than the pro-rata cost for accessing the 800 MHz NMR 
spectrometer to measure a 3D HNCA spectrum for backbone resonance assignment. 
Regarding the protein yield, purification by chromatography via an SP column, buffer 
exchange, and concentrating of the sample produced a total of 1.8 mg of purified IMP-1, 
corresponding to a 0.4 mM solution in a volume of 0.15 ml that was measured in a 5 mm 
Shigemi tube. The initial yield after synthesis was significantly higher but the protein is prone 
to degradation, precipitating heavily during the purification and concentration steps.  
 
Final remarks 
Cell-free protein synthesis offers additional advantages beyond those discussed here (for a 
review see, e.g., ref. 5). It has long been established that cell-free synthesis is the technique of 
choice for sample preparations in which only one or several amino acids are isotope labeled, 
because the amino acids are used sparingly and isotope scrambling is suppressed (see, e.g., 
ref. 6). As only a small fraction of the amino acids is incorporated into the final protein 
product, further dramatic improvements in protein yield are conceivable. Unfortunately, algal 
hydrolysates do not produce good protein yields in our hands, so that, counter to intuition, the 
purchase of the 20 individual amino acids is more economical. Even so, comparing only the 
cost of labeled compounds needed for the production of uniformly isotope labeled proteins, 
cell-free synthesis readily competes with in vivo preparations. 
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4 The Set-Up, Optimisation and Operation of an In-
House Built Para-Hydrogen Producing Rig 
4.1 Introduction 
The dihydrogen molecule can form two spin isomers with different nuclear spin 
configurations. The αα, ββ and αβ+βα nuclear configurations are referred to as the 
triplet state, or ortho-hydrogen (oH2), and rapidly interconvert with each other.292 The 
αβ-βα state is termed the singlet state, or para-hydrogen (pH2), and is more stable than 
oH2 as it has access to a lower energy rotational state.292 pH2 is invisible in typical 
NMR experiments as the two nuclear spins are antiparallel. 
Two mechanisms of conversion between oH2 and pH2 are known, chemical 
exchange of hydrogen nuclei and paramagnetic relaxation.293,294 The chemical exchange 
mechanism scrambles the nuclear spin alignment, requiring the molecular bond between 
the two hydrogen atoms to be broken.294 In contrast, the magnetic mechanism relaxes 
the spin states when the atoms of the hydrogen molecule experience significantly 
different magnetic fields. This is often achieved by the use of a paramagnetic catalyst, 
such as activated charcoal, or ferric chloride,292,295 however, there are numerous 
examples of other paramagnetic metals being used to catalyse this process.293,294 At 
room temperature, 25% of hydrogen gas consists of pH2, whereas the lower energy pH2 
state is favoured at low temperatures (Figure 4-1).296  
The hyperpolarisation effect of pH2 was predicted by Bowers and Weitekamp in 
1986,297 and proved by the same authors a year later.298 This effect can theoretically 
provide up to 3.5 × 103-fold NMR signal enhancement for 50% pH2 enrichment,298 and 
has provided mechanistic insight into short-lived intermediates that would otherwise be 
impossible to observe.292,299 
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Figure 4-1 Temperature dependence of the percentage of pH2 in equilibrium. A black, red and blue cross marks the 
phase transition temperatures of liquid nitrogen, solid nitrogen and liquid helium, respectively. Values are taken from 
Harkness and Deming.300 
In the simplest example of pH2-induced hyperpolarisation (or PHIP), both atoms 
of a single hydrogen molecule are added to a double bond via a hydrogenation reaction. 
The two hydrogen atoms must remain coupled and become magnetically inequivalent 
for the hyperpolarised signal to be observed.292,301-303 Alternatively, the hydrogen atoms 
can be made non-degenerate by forming a metal dihydride.304 Hyperpolarisation can 
then be transferred to another molecule of interest via a temporary association with the 
metal complex in a system termed NMR-SABRE (NMR signal amplification by reverse 
exchange).304-308 
Protons originating from pH2 only populate the αβ and βα spin states (Figure 
4-2). As a consequence, very large population differences exist in the energy level 
diagram, which is the basis behind the hyperpolarization. In the presence of a high 
magnetic field this difference generates four hyperpolarized transitions. In contrast, in 
the absence of a high magnetic field the coupling between the spins is strong, so only 
the lower energy level of either αβ or βα is populated and two transitions are possible.299 
This presents two experimental outcomes for hydrogenation reactions with pH2. 
In the first case, where hydrogenation is carried out at high magnetic field such as in the 
probe of an NMR magnet, antiphase multiplets are observed. This has been termed the 
PASADENA experiment (Parahydrogen And Synthesis Allow Dramatic Enhancement 
of Nuclear Alignment).298,301 In the second case, where hydrogenation occurs in low 
magnetic field, the two multiplets are in-phase but have opposite sign. This has been 
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calleded the ALTADENA experiment (Adiabatic Longitudinal Transport After 
Dissociation Engenders Net Alignment).309 Experimental results from both effects are 
shown in Figure 4-3. 
 
Figure 4-2 Energy diagram (i) and simulated NMR spectrum (ii) description of standard BOLTZMANN population 
distribution, PASADENA and ALTADENA experiments. Line thickness indicates spin state population. If the 
hydrogenation occurs at high magnetic field the PASADENA effect is observed, where the two spin states αβ and βα 
are equally populated and give rise to four transients. In the absence of a strong magnetic field the ALTADENA 
effect occurs, where only the lower of either αβ or βα is populated. This gives rise to only two transitions. 
 
 
Figure 4-3 Experimental A) PASADENA and B) ALTADENA spectra. When hydrogenation occurs at high 
magnetic field, two antiphase multiplets are observed for HA and HB with high sensitivity. However, if the 
hydrogenation occurs in the absence of a magnetic field, the multiplets experience high signal intensity gains but 
have opposite sign. Figure adapted from the supplementary information of Kotunov et al.302 
Contrast agents for MRI labelled with 13C can also be hyperpolarised and enable 
high-resolution images to be acquired in short times. Bhattacharya et al. described a 
system in which a 13C-labelled precursor was hydrogenated with pH2 in the stray 
magnetic field of an MRI machine, followed by the transfer of the polarisation to 13C 
via a radiofrequency pulse sequence.310,311 This hyperpolarisation was sufficiently long-
lived to enable fast purification from the catalyst, injection into a rat model and 
subsequent 3D measurements. Later work in the same group demonstrated in vivo 
imaging of hyperpolarised 1-13C-succinate and 1-13C-maleate, and identified 13C-
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glutamate and 13C-glutamine metabolic products of succinate as potential biomarkers 
for a rapid MRI based brain tumour assay.312 
To increase the hyperpolarisation spin lifetime, the hyperpolarised nuclei can be 
treated with a series of spin echoes or stored at zero magnetic field to remove the 
difference in resonance frequencies of the two spins. Alternatively, the singlet state can 
be stored if the two spins are made magnetically equivalent, such as in the case of pH2. 
Warren et al.313 described an interesting example for the system shown in Figure 4-4. 
Acetone was used to shift the equilibrium to the right and the degenerate 13C nuclei 
were able to store the hyperpolarisation until it was recovered via an injection of water, 
restoring the magnetic inequivalence of the 13C nuclei. 
 
Figure 4-4 Equilibrium between 3,3-dihyroxybutan-2-one and biacetyl. In acetone, biacetyl is more stable and the 
13C spins are degenerate, storing hyperpolarisation for long periods. The addition of water favours the monohydrate, 
breaking the degeneracy and allowing the hyperpolarisation to relax. 
Recently, methods for continuous feeding of hyperpolarised gas to an NMR 
sample have been described.314,315 By using gas-permeable membrane tubing typically 
used for degassing solvents or for gas exchange in clinical dialysis instruments, 
hyperpolarised xenon or hydrogen gas was added continuously to an NMR sample, 
enabling the acquisition of 2D NMR spectra.314 Along with the SABRE 
method,305,306,316 this presents the possibility of continual hyperpolarisation transfer to 
large biomolecules via transient pH2-metal-protein complexes over the duration of a 
long multidimensional experiment. This would have obvious benefits for protein NMR, 
including higher signal-to-noise ratios as is required for non-uniform sparse sampling 
pulse sequences. 
The work in this chapter is primarily concerned with refining an in-house built 
pH2 rig to generate optimal yields for future hyperpolarisation experiments. 
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4.2 Results 
4.2.1 Initial Design 
Dr D. Shishmarev, Prof. G. Otting, Mr M. Hill, and Mr D. Bansner at the 
Research School of Chemistry, ANU performed the initial design of the pH2 rig prior to 
my involvement. Figure 4-5 shows a schematic of the initial system design. 
 
Figure 4-5 Initial design of the pH2 producing rig. 
The system was designed to utilise a copper reaction chamber containing an 
activated charcoal catalyst, which is cooled to liquid nitrogen temperature to effect the 
conversion of oH2 to pH2. 
4.2.2 Improvements to Rig 
The first iteration of the rig raised a number of safety concerns and had practical 
issues with regard to pH2 generation. 
Safety 
Three safety concernws associated with the initial version had to be addressed. 
Firstly, any cylinder containing flammable gas such as hydrogen should be protected 
from the possibility of flashbacks, where an ignited gas-front burns along the gas line 
and into the gas cylinder. This risk can be addressed by incorporating a ‘flashback 
arrestor’ into the line close to the cylinder. The flashback arrestor forces any flame 
 166 
rushing along the gas line through a fine mesh of flame resistant material, which 
dissipates heat and thus extinguishes the flame. Most quality flame arrestors also have a 
backflow prevention valve to stop a pressure wave from reaching the cylinder, and a 
heat sensitive cut-off valve that physically cuts off the flow to the cylinder if a flashback 
occurs. Whilst the risk associated with flashbacks in the pH2 system would be low in 
general operation, the original protocol of conditioning the pH2 rig for initial use and for 
post-use warming recommended the use of heat guns, introducing an ignition source. 
This problem was addressed by incorporating a BOC flashback arrestor (model B0304) 
into the system just after the pressure regulator on the gas cylinder. 
The second safety modification was to adjust the orientation of the pressure 
relief valve outlet. This vent was orientated upwards to direct any hydrogen gas towards 
the intake of the fume hood and away from the hood opening. While hydrogen gas is 
lighter than air, the gas given off by the pH2 rig out of this relief valve is still close to 
liquid nitrogen temperatures and exiting the rig at 690 kPa (100 psi) pressure. With the 
initial orientation of the valve outlet, hydrogen gas was escaping the fume hood, as was 
evident from the way the outlet gas disturbed the nitrogen vapour given off by the 
nitrogen Dewar. A change of orientation of the pressure relief valve outlet made a 
significant difference to the flow within the hood, and no more hydrogen gas was 
observed leaving the opening of the fume hood. 
A third safety concern arose with the two NMR tube attachment points. It turned 
out to be practically impossible for a single user to hold both tubes against the rig while, 
at the same time, manipulating gas taps. This resulted in an incident where a tube flew 
off and exploded on impact with the base of the fume hood, propelled by the positive 
pressure in the tube. To prevent this from happening again, a wire arrest support was 
designed to allow the tube to come off the rig in the case of overpressure without 
becoming a dangerous projectile. The final iteration of this rig was designed to have a 
single NMR tube attachment, enabling the user to hold the NMR tube for the duration 
of its fill while adjusting the gas taps. 
Pressure Leaks 
The most significant problems hampering the usability of the rig resulted from 
gas leaks during either high- or low-pressure operation. The rig is required to be gas 
tight from 690 kPa (100 psi) to 20 Pa (0.003 psi) at temperatures ranging from -196 °C 
to +150 °C. This is difficult to achieve and gas leaks occurred from several of the joints 
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and the taps, especially after a number of heat/cool cycles. Tightening the joints in situ 
rectified most of these issues, however, a number of joints had to be remade by the 
workshop technical staff (M. Hill) due to sheering of the soft copper thread before a 
suitable seal was established.  
One of the biggest leaks occurred at the cap that sealed the reaction chamber. No 
leaks were detected at room temperature at either high- or low-pressure, but little to no 
pH2 could be obtained. It was subsequently discovered that the hydrogen gas cylinder 
was still releasing gas into the rig (the sound of gas passing through the flame arrestor 
could be detected) even after the system had come to a ‘cold’ equilibrium, indicating the 
presence of a significant leak. The leak turned out to have arisen from freezing of the 
rubber O-ring sealing the top of the reaction chamber when the reaction chamber was 
cooled to liquid N2 temperatures. Attempts were made to keep the top of the chamber 
warm using heated reticulating water, but this posed the potential problem of water 
freezing in the warming tube and also caused much faster rates of liquid nitrogen boil-
off, to the extent that the rig could not be left unattended for even 10 minutes. 
Redesigning the opening to the reaction chamber to incorporate an indium wire seal 
analogous to those used in cryogenic systems rectified the problem. 
Other Modifications 
Further modifications were made to render the system more usable. The 
majority of the glass section was removed from the rig and the remainder simplified and 
redesigned. This removed the glass cold trap, the 500 mL glass storage vessel, and a 
large length of glass tubing, which reduced the amount of gas wasted during purging of 
the system and made the pH2 yields more reproducible. 
It was also noted that initial designs used nitrogen gas to purge the rig prior to 
hydrogen treatment. However, as any residual nitrogen from purging would dampen the 
generation of pH2,294 this was modified to an argon purge. 
The rig was raised on supports and clamped to the fume hood to enable a 
laboratory jack to be included under the liquid nitrogen Dewar. This allowed the Dewar 
to be lowered away from the copper reaction chamber so that a warm-up of the system 
did not necessitate the boil-off of all the liquid nitrogen. 
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A cold trap was incorporated to protect the vacuum pump from any moisture 
that was pulled off the activated charcoal during conditioning. The cold trap used either 
liquid nitrogen or a dry ice/ethanol bath after purging with argon gas.* 
A tap was introduced into the line prior to the NMR tube attachment glassware 
to enable purging of the low-pressure side without requiring the attachment of an NMR 
tube. Also, the NMR tubes initially constructed were too heavy for a normal airlift to 
eject the sample from the magnet, due to the large valve. This was temporarily 
addressed by attaching a fly line to the sample so it could be pulled out manually, and 
eventually a smaller tap was used (similar to a Young tap NMR tube), which proved 
light enough for the normal airlift. 
Finally, a vacustat was included after the cold trap to assess the gas-tightness of 
the system and to identify leaks. This line was removed and placed in a gas bubbler 
when purging with a stream of gas (steps 7 and 9 in the following protocol). 
4.2.3 Final Design and Method of pH2 Generation 
The final optimised design of the system is schematically described in Figure 
4-6. A protocol for reproducible pH2 generation based on recommendations from Prof. 
B. Messerle (School of Chemistry, UNSW) was developed with this rig and is as 
follows: 
 
* Argon gas freezes at liquid nitrogen temperatures, so a dry ice/ethanol bath is recommended. 
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Figure 4-6 Final design of pH2 generating rig. Taps are numbered 1 to 11 and referred to in text. Pressure regulators 
are designated A (on the gas cylinder) and B (in the rig). While the storage vessel is constructed from stainless steel, 
the inside is coated with Teflon to prevent the gas being exposed to the metal surface. The vacustat or gas bubbler is 
attached to the vacuum line with tap 11 as required. The cold trap is used with either liquid nitrogen or dry 
ice/ethanol as required (see text). 
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Conditioning Catalyst 
The copper reaction chamber contains 500 g of activated carbon (granular Darco 
4-12 mesh – Sigma). It is recommended the yield of pH2 be assessed by the simple 
NMR experiment described in section 4.2.4 every time the rig is set up and to 
recondition the catalyst if the yields are sub-optimal. Reconditioning is also necessary if 
the pressure of the reaction chamber drops to atmospheric pressure. In this case, steps 5 
to 10 should be sufficient and, because of the fragility of the indium seal, should be 
attempted prior to discarding and replacing the charcoal. Throughout this section, gas 
taps are indicated as being open (in bold) or closed (in superscript), such that (1 2 3 4 5 6 
7 8 9 10 11) would state taps 1 and 3 are open, and taps 2 and 4-11 are closed. 
1. The catalyst is initially conditioned by dismantling the reactor from the 
tubing with spanners and opening the top of the reactor with an Allen key. 
Care should be taken to recover the indium seal wire from the top of the 
reactor for either recycling or appropriate disposal. The activated charcoal 
can then be recovered from the reaction chamber and disposed of. The 
reaction chamber is subsequently cleaned thoroughly with water and rinsed 
several times with acetone prior to drying in an oven overnight. 
2. After removing all rubber O-rings, removable glassware sections should also 
be washed with water, rinsed with acetone and dried. O-rings should be 
inspected and replaced if stretched or brittle. 
3. 500 g of activated charcoal (granular Darco 4-12 mesh – Sigma) is then 
replaced in the reaction chamber, and the chamber with charcoal is dried 
again in a glassware oven overnight. 
4. The apparatus is then reassembled, with care taken to ensure all O-rings are 
in good condition and properly positioned. A fresh section of indium wire 
(or the recycled indium after being redrawn into a wire and rinsed with dilute 
hydrochloric acid*) is placed around the opening of the reaction chamber in 
the groove, slightly overlapping at the end. The top of the reaction chamber 
is then placed carefully on top, fixed to the chamber by the Allen bolts, and 
 
* Indium metal forms a protective oxide layer over time and can be safely and easily handled. However, bare 
elemental indium metal exposed after treating with HCl will readily ‘dry weld’ to itself. This is useful for creating 
indium O-rings, but users should take care when handling the freshly etched metal so that it does not need to be re-
drawn into wire. 
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gently tightened as indicated in Figure 4-7. The bolts need to be tightened 
only ‘two finger’ tight initially, and progressively tighter over several 
‘cycles’. Slow, even tightening ensures the indium wire melts into the cap 
properly to form a cryogenic seal. Several rounds of retightening should be 
applied over the next few days as the indium reshapes into a cryogenic seal. 
 
Figure 4-7 Order of tightening of Allen bolts on the reaction chamber. Gentle, evenly distributed pressure is 
important for a proper seal to be established. 
5. All impurities that reduce pH2 formation, including oxygen, nitrogen and 
water, must be removed from the catalyst. This is done by closing the system 
and heating the reaction chamber to between 100 °C and 145 °C* under 
vacuum for a minimum of 4 hours. An insulated lab heating tape can be 
used† with a thermocouple or thermometer attached to the copper reaction 
chamber. A liquid nitrogen cold trap is used to protect the vacuum pump at 
this stage, and a stream of nitrogen gas or compressed air is applied to the 
copper tube wrapped around the outside top of the reaction chamber to 
reduce the temperature at the indium seal. A heat gun may be used to heat 
the rest of the copper tubing in the rig to assist removal of contaminants 
from these parts. (1 2 3 4 5 6 7 8 9 10 11) 
6. After 4 hours, the pressure should be measured on the vacustat. Pressures 
near 20 pa (0.003 psi) should be achievable when the vacuum is only open to 
the high-pressure side. Pressures of 100 pa (0.015 psi) or higher indicate a 
 
* The melting point of indium is 156.6 °C 
† Care needs to be taken to ensure the electrical safety of the heating tape. Many laboratory heating-tapes are 
designed for use on glass or ceramic tubes or columns and so may not be sufficiently insulated for use on a 
conductive surface such as copper. Best practice would also include attaching a ground line from the apparatus to the 
power supply or fume hood. A residual current device (RCD) protected circuit is also recommended. 
1
3
5
7
2
4
6
8
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significant leak somewhere in the rig or that the vacuum pump needs 
servicing. This issue needs to be resolved before going further. (1 2 3 4 5 6 7 8 
9 10 11)  
7. The apparatus is then taken off vacuum and the cold trap is removed from 
the liquid N2 bath (1 2 3 4 5 6 7 8 9 10 11). The vacustat is disconnected from 
the vacuum line and a gas bubbler is attached. The apparatus, still under 
heating, is then filled with argon gas, and then purged for a minimum of 
1 hour with a slight flow. This is achievable by opening tap 8 and setting 
pressure regulator B to just above atmospheric pressure or until a slow 
steady stream of bubbles is present in the gas bubbler (1 2 3 4 5 6 7 8 9 10 11). 
8. After one hour, the apparatus is then evacuated again as per step 5 for a 
minimum of one hour, with the exception that: a) the liquid N2 bath must be 
replaced with a dry ice/ethanol bath, as argon solidifies at liquid N2 
temperatures, and b) the glass side is also evacuated (1 2 3 4 5 6 7 8 9 10 11). 
Checking with the vacustat again is advisable, although pressure tightness is 
less important for the low-pressure side, so a measurement of 50 to 100 Pa 
(0.0075 to 0.015 psi) is acceptable. 
9. The apparatus is then taken off vacuum, and the heating tape removed. The 
system is then filled with high purity H2 gas and purged as in step 7 for a 
minimum of 1 hour (1 2 3 4 5 6 7 8 9 10 11). 
10. From now, a positive pressure of about 275 kPa (40 psi) must be maintained 
on the high-pressure side of the apparatus. This ensures that any minor leaks 
do not let moisture or oxygen into the reaction chamber. If the pressure 
drops to close to atmospheric pressure, reconditioning is likely to be 
necessary. 
Generating pH2 
To generate pH2, the following steps are taken 
11. Ensure tap 1 is open and tap 2 is closed, then attach an ultra-pure hydrogen 
cylinder and set regulator A to 500 kPa (75 psi). Keep the cylinder open to 
the reaction chamber for cooling (1 2 3 4 5 6 7 8 9 10 11). 
12. Place a pre-cooled 5 L liquid N2 Dewar with about 250 mL of liquid 
nitrogen onto a laboratory jack and raise it around the reaction chamber. This 
minimises liquid nitrogen boil off to just that required to cool the reaction 
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chamber. Half-fill the Dewar with liquid nitrogen in situ using another vessel 
and wait for the rapid boiling to cease. Continue to incrementally add liquid 
nitrogen to the Dewar until full, waiting for the rapid boil off to end after 
each top up. Once the Dewar is full, and not vigorously boiling, the 
apparatus can be left for up to 30 minutes without significant warming 
occurring. Gas will flow into the reaction chamber as it cools due to thermal 
contraction of the gas and absorption into the activated charcoal. 
13. After 30 minutes, evacuate the storage vessel and the low-pressure side of 
the rig (1 2 3 4 5 6 7 8 9 10 11). Close off the vacuum and close off the 
cylinder from the reaction chamber (1 2 3 4 5 6 7 8 9 10 11), then open the 
reaction chamber to the storage vessel to store some pH2 gas for purging (1 2 
3 4 5 6 7 8 9 10 11). Next, close off the storage vessel and the reaction chamber 
and then reopen the cylinder to the reaction chamber (1 2 3 4 5 6 7 8 9 10 11). 
14. After 30 to 60 minutes pH2 will have formed in the reaction chamber. Close 
regulator B. Purge the system with the gas stored in the storage vessel by 
venting it into the system and then evacuating once more (1 2 3 4 5 6 7 8 9 10 
11) At this stage set regulator B to the pressure desired for the NMR sample 
and leave it set for the entire run. Then evacuate again (1 2 3 4 5 6 7 8 9 10 11) 
and then close off the vacuum (1 2 3 4 5 6 7 8 9 10 11). 
15. Freeze an NMR sample inside the tube in liquid nitrogen and then evacuate 
the tube by attaching it to the low-pressure side and opening up the tube to 
vacuum (1 2 3 4 5 6 7 8 9 10 11). Close tap 9 and 10, thaw the sample, and 
repeat several times to de-gas the NMR solvent of any oxygen or nitrogen. 
16. After de-gassing the sample, freeze the NMR tube again. While frozen, 
purge the area in the tube above the sample a few times by evacuating 
(1 2 3 4 5 6 7 8 9 10 11) then adding pH2 (1 2 3 4 5 6 7 8 9 10 11), before finally 
closing tap 10 on the NMR tube with a dose of pH2 present. 
Warm-up and Preparation for Next Use 
Significant expansion occurs when the system warms to room temperature and, 
as a safety precaution, a pressure relief valve has been fitted and set to 689 MPa (100 
psi). This safety measure is only available to sections of the rig open to the reaction 
chamber. Care should be taken that no high-pressure gas will form as the system warms. 
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17. Set gas tap to (1 2 3 4 5 6 7 8 9 10 11). Ensure the pressure regulator B is still 
open. Turn off the hydrogen gas cylinder at regulator A, and on the cylinder. 
Disconnect the hydrogen gas cylinder. It is important to remove the NMR 
tube from the rig at this point, as the NMR tube attachment site is where 
excess gas will be vented if something goes wrong later. 
18. Slowly lower the liquid nitrogen Dewar from the reaction chamber until it 
can be removed completely. 
19. The pressure will increase steadily up to 689 MPa (100 psi) until the 
pressure relief valve opens and vents the hydrogen gas into the fume hood. If 
the pressure relief valve does not open (the pressure measured on the storage 
vessel goes higher than 100 psi), immediately vent the system by opening 
tap 7 (1 2 3 4 5 6 7 8 9 10 11), which will vent out the NMR tube slot. Do not 
leave the rig unattended before confirming that the valve has opened and the 
gas is venting. If the pressure relief valve is slow to open, do not use the rig 
until a qualified technician has serviced or replaced it. 
20. Once the valve has opened, set the taps to (1 2 3 4 5 6 7 8 9 10 11). Place an 
absorbent cloth or paper towel under the reaction chamber to minimize water 
spillage due to melting ice around the reaction chamber. The rig is safe to 
leave while it warms to room temperature. 
21. Check the rig at least every 2 weeks to ensure the H2 gas pressure remains 
above 275 kPa (40 psi). 
4.2.4 Assessment of pH2 Yield After Optimisation 
A simple 1D 1H NMR spectrum was acquired to determine pH2 yield similar to 
the experiment described by Bhattacharya et al.310 The spectrum is first set up using 
300 kPa of H2 gas at thermal equilibrium. 
The test sample is then compared at exactly the same pressure (by not adjusting 
the pressure regulator B) for a sample converted to pH2. The result for yield is shown in 
Figure 4-8. 
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Figure 4-8 1H NMR gas spectrum of detectible oH2 in thermal H2 gas (blue) and pH2 enriched H2 gas (red). The 
thermal peak almost exactly overlays with the pH2 enriched sample peak when multiplied by 0.67 (light blue). This 
indicates an increase in non-detectible pH2 concentration (with a concurrent decrease in concentration of detectible 
oH2) consistent with theoretical expectations for liquid nitrogen temperatures (Figure 4-1). 
The content of pH2 gas at liquid nitrogen temperature is close to 50% (Figure 
4-1). Hydrogen gas at room temperature contains 25% pH2, so a decrease of the oH2 
signal by 1/3 is expected. This is in excellent agreement with the integral of the curves 
in Figure 4-8, indicating that the pH2 rig, when operated following the procedure above, 
is generating optimal yields. 
4.3 Discussion 
4.3.1 Future Design Recommendations 
The design of the pH2 rig was optimised to produce close to theoretically 
obtainable yields of pH2 gas; nonetheless, recommendations can be made for 
subsequent improvements of the system, which would make it more flexible for 
experimental work. 
1. Most of the gas leak issues were due to joints developing leaks during 
multiple thermal cycles through temperatures between -196 °C to 100 °C. 
Any future design should avoid joints near the reaction area that is cooled by 
using continuous copper tubing or welded joints. In order to minimise 
differences in thermal conductivity and expansion, the use of different 
metals in the construction of the reaction chamber and adjoining regions 
should be avoided. 
relative
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2. The current reaction chamber is large and useful only for batch processing. 
A continuous feed system could be achieved by changing the large open 
reaction chamber for a long, thin copper tube filled with a fine activated 
charcoal powder and packed with glass wool. This tube could then be 
immersed in a liquid nitrogen Dewar (like the current system) with only 
minimal nitrogen loss as a lid could be added to the Dewar to reduce boil 
off. This could then be modified at a later point to be immersed in solid 
nitrogen (obtainable by placing liquid nitrogen under vacuum) or imbedded 
into a copper block attached to a liquid helium refrigeration system for 
higher pH2 yields (up to 75% and 99% pH2 enrichment respectively – Figure 
4-9). 
 
Figure 4-9 Potential helium cooled system to generate 99% pH2 samples. A long reaction tube packed with catalyst 
rather than a short large-diameter reaction chamber would facilitate continuous pH2 generation. 
3. To reduce the loss of usable pressure between the reaction chamber and the 
NMR tube, the tube diameter and length should be minimised between the 
reaction chamber and the outlet. 
4. The filters prior to and after the reaction chamber are made from stainless 
steel. The stainless steel filter seemed to have a minimal effect on pH2 yield, 
which is likely due to cooling of the filters by thermal conductivity (Figure 
4-10). For future designs where these filters may not be so close to the liquid 
nitrogen Dewar, these filters should be replaced by either copper or glass 
filters, as the iron in the stainless steel will provide a mechanism for back 
conversion to thermal H2. 
 177 
 
Figure 4-10 Evidence of liquid nitrogen cooling the reaction chamber and the two filters (seen on either side of the 
centre column highlighted by arrows). The fact that the two filters are also cooled may explain why the stainless steel 
did not have a detrimental effect on the pH2 yield as expected initially. The same filter further downstream from the 
reaction chamber could have a detrimental effect if it were not cooled. 
5. A bypass tube between tap 5 and regulator B would be beneficial, as it 
would enable the user to purge the glass section and perform control 
experiments with thermal H2. 
6. With a highly efficient pH2 gas generation system, ‘gas fed’ NMR 
experiments become feasible, where pH2 is constantly generated and fed 
directly into the sample tube via a gas permeable membrane while it is in the 
NMR magnet. Therefore, an ideal design would ensure no magnetic parts are 
present to hinder the placement of the rig close to the NMR magnet. It 
should also be small and not sensitive to vibration from movement on a 
trolley. If this is not feasible, a supplementary, non-magnetic rig that can 
hold several storage vessels may be a useful alternative. 
7. As the generation of pH2 is somewhat time consuming and wasteful of liquid 
nitrogen and hydrogen gas (due to purging), a verified method of storing pH2 
gas at suitably high pressure would be beneficial. This would require one of 
the following: 
a. the high-pressure side to be pressure tested to higher pressures, 
combined with a larger ‘pH2 friendly’ storage cylinder with no 
exposed steel parts; 
b. several smaller storage vessels like the one already used to be 
acquired and used either sequentially or in parallel with an 
appropriate pressure regulator and attachments; 
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c. a compressor with no metal parts exposed to the gas to recompress 
the pH2 into a cylinder with no exposed metal parts. 
These methods would need to be verified and a ‘shelf life’ determined for 
the stored gas. 
4.4 Conclusions and Future Work 
The pH2 rig has been optimised to work at close to theoretical yields for a liquid 
nitrogen system. This now paves the way for future experiments utilising 
hyperpolarisation with pH2 incorporation via hydrogenation reactions or systems like 
SABRE.304,305 Even though signal improvements of 3.5 × 103 may not be achievable in 
an aqueous environment, even a fraction of this gain would be greatly beneficial to 
biological NMR experimentation. 
Future work should investigate the stability of pH2 in aqueous environments and 
in the presence of water-soluble metal complexes that bind H2 reversibly at room 
temperature. These complexes may be able to transfer a portion of their hyperpolarised 
signal via NOE and other interactions to a protein molecule and give signal 
improvements for the solvent exposed surface. A continuous gas feed system akin to 
that described by Roth et al.315 and Baumer et al.314 would also be advantageous to 
enable longer multidimensional experiments to be acquired. Several gas exchange 
membrane samples from Membrana (Germany) have already been acquired for such a 
project. These membranes are usually used for blood dialysis and degassing solutions. 
They are expected to be suitable for constant-feed pH2 experiments. 
4.5 Experimental Methodology 
Simple single pulse-acquire 1D 1H NMR experiments were performed on a 
Bruker 600 MHz spectrometer at 298 K using 12 µsec pulse length. No lock was used 
and the sample was not shimmed. Without a lock or internal calibrant, the ppm value of 
the broad hydrogen gas peak is uncertain. The pH2 gas sample was ensured to have the 
same pressure as the thermal H2 gas sample by not adjusting regulator B between 
experiments.  
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5 Promotion of Mammalian Angiogenesis by 
Neolignans Derived from Soybean Extracellular 
Fluids – NMR Elucidation of Natural Products 
5.1 Introduction 
Natural product extraction can lead to the identification of novel compounds 
with biological activity. An essential part of the natural product discovery process is the 
structural elucidation of sometimes rather complex molecules. This elucidation is often 
hampered by limited product yields, however, sensitive techniques like mass 
spectrometry fragmentation analysis and comparison to known fragmentation libraries 
make it possible to identify many previously characterised natural products. When these 
methods fail, other techniques are required to determine the chemical structure of the 
isolated compound. 
This chapter describes the NMR structure elucidation of two naturally derived 
diastereomeric products extracted from soybean extracellular fluids that were found to 
exhibit pro-angiogenic properties. 
5.2 Results 
Three fractions separated via ultrafiltration and reverse phase HPLC from xylem 
sap (soybean) were found to have pro-angiogenic activity when tested using a modified 
rat aortic ring assay317,318.* One of the fractions was disregarded as it was found to lose 
pro-angiogenic activity after storage, indicating instability of the active compound. The 
other two fractions maintained activity even after long-term storage, and were 
designated FK1 and FK2. These compounds demonstrated bioactivity at micro to 
nanomolar concentrations. FK1 and FK2 both induced tube formation in the rat aorta 
 
* All natural product isolation, purification, mass spectral analysis and biological testing were performed by Dr F. 
Kordbacheh (RSB, ANU), Mrs A. Bezos (JCSMR, ANU), Prof. C. Parish (JCSMR, ANU), Dr C. Hocart (RSB, 
ANU) and Dr M. Djordjevic (RSB, ANU).  
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ring assay, however, FK2 also partially stimulated HUVEC* proliferation in the absence 
of bFGF†. 
FK1 and FK2 displayed identical mass spectra and UV absorbance spectra, 
implying that the two fractions were very similar compounds, possibly diastereomers. 
Large-scale extraction of 2000 mL of xylem sap was performed on 300 plants and 
yielded 458 µg of FK1 and 387 µg of FK2.  
The two purified isolates were presented to our group as lyophilysed products 
with the hope of structural elucidation after identification via mass spectrometry 
fragmentation analysis at the Research School of Biology (ANU) proved unsuccessful. 
Initial mass data (Agilent 6530 Accurate Mass LC-MS Q-TOF) implied a chemical 
formula of C20H22O6 (m/z 359), however, through the NMR structure elucidation 
process an extra proton signal belonging to the molecule of interest was found. It was 
proposed that the mass observed was in fact the [M-OH]+ peak, implying a formula of 
C20H24O7. Further MS studies in both positive and negative modes with a reduced 
nebulizer spray temperature finally detected the molecular mass peak (M+, m/z 376) 
along with fragmentation patterns consistent with previously reported data319,320 for the 
solved NMR structure (Figure 5-1). 
 
Figure 5-1 Structure of the natural product, guaiacylglycerol-8-O-4’(coniferyl alcohol) ether, with numbering as used 
in the text. Note the chirality of C-7 and C-8 is undefined, however the double bond C-7’–C-8’ was determined to be 
trans. 
Initial 1D 1H NMR spectra were recorded for both FK1 and FK2 products. FK1 
was determined to be more pure and of higher concentration, so initial structure 
determination was performed on this product. 13C-HSQC, 13C-HMBC, 1H-1H 
 
* Human umbilical vein endothelial cells (HUVEC) are used as a model of endothelial cells. 
† Basic fibroblast growth factor (bFGF) promotes angiogenesis 
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DQF-COSY, 1H-1H TOCSY and 1H-1H NOESY NMR spectra were then measured of 
FK1 and structural fragments were constructed as follows. Two methoxy resonances 
were identified in the 1H NMR spectrum at δ 3.68 (3H, s, H-10) and δ 3.70 (3H, s, 
H-10’). Two protons at δ 6.56 (1H, dt, J = 16.0, 1.0 Hz, H-8’) and δ 6.30 (1H, dt, 
J = 15.9, 6.0 Hz, H-7’) were identified in a trans double bond arrangement due to their 
3J coupling of 16.0 Hz, and were linked to a degenerate methelene group at δ 4.25 (2H, 
dd, J = 6.0, 0.9 Hz, H2-9’) via their 3J and 4J couplings, respectively. Proton signals at 
δ 4.07 (dd, 2J = 12.3 Hz, 3J = 2.8 Hz, 1H, H-9a) and δ 3.94 (dd, 2J = 12.3 Hz, 3J = 6.7 
Hz, 1H, H-9b) were linked through their 2J coupling and their shared carbon shift in the 
13C-HSQC spectrum, and were linked to a multiplet at δ 4.66 (m, 1H, H-8) via the 
DQF-COSY. An ABX aromatic coupling system was identified, and positioned the 
aromatic proton at δ 6.86 (dd, 3J = 8.1 Hz, 4J = 1.9 Hz, 1H, H-6) meta from δ 6.88 (d, 
4J = 2.0 Hz, 1H, H-2) and ortho to δ 6.74 (d, 3J = 8.1 Hz, 1H, H-5). Three further 
aromatic protons were identified and linked via the TOCSY cross-peaks, but needed 
correlations from the HSQC and HMBC spectra to resolve δ 6.97, (overlapped s, 1H, 
H-6’) as ortho to δ 6.97, (overlapped s, 1H, H-5’), and para to δ 6.98 (bs, 1H, H-2’). 
The HSQC and HMBC spectra were also used to resolve a solvent overlapped peak, 
Hδ 4.7 Cδ 72.54 (overlapped m, 2H, H-7, C-7) and link this resonance to Cδ 61.52 
(C-9). The methoxy group H3-10 was linked to H-2 via the NOESY spectrum and to 
Cδ 147.72 (C-3) via the HMBC spectrum, which was also linked to H-6 and H-5. 
Methoxy H3-10 was linked to H-2’ via the NOESY spectrum and to Cδ 149.22 (C-3’) 
via the HMBC spectrum, which was further linked to H-5’ and H-6’.  NOEs were 
observed between H-2’, H-5’ and H6’ to H-7’ and H-8’, linking these fragments, and 
was positioned by the HMBC correlation from H-7’ to Cδ 119.45 (C-6’) and Cδ 109.78 
(C-2’) as was H-8’ to Cδ 131.13 (C-1’). Finally, HMBC correlations between 6-H, 2-H 
and C-7 and further correlations between H-8 and Cδ 146.94 (C-4’) constructed the 
final compound. 
Assignments could easily be made for FK2 due to the similarity of the 13C-
HSQC cross-peaks to those of FK1 and 1H-1H couplings constants (Figure 5-2). It was 
then proposed that FK1 and FK2 were diastereomers, with undefined chirality of C-7 
and C-8. The compound identified (Figure 5-1) was proposed to be the previously 
described natural product guaiacylglycerol-8-O-4’(coniferyl alcohol) ether, of which 
there are four possible stereoisomers. The NMR spectra were found to be in agreement 
with previously reported chemical shifts and couplings.321 
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Figure 5-2 Overlay of 13C-HSQC spectra for the A) aliphatic and B) aromatic region, highlighting the similarity of 
spectra between FK1 (red/pink) and FK2 (blue/green). Along with coupling constants measured from 1D 1H NMR 
spectra, assignments were easily transferred from FK1 to FK2. Negative peaks (green and pink) indicate CH2 
resonances. 
A commercial sample of erythro-guaiacylglycerol-8-O-4’(coniferyl alcohol) 
ether* and an independently derived sample of threo-guaiacylglycerol-8-O-4’(coniferyl 
alcohol) ether (isolated from Bretshneidera sinensis)† were obtained. These were found 
to have almost identical spectroscopic and chromatographic properties to FK1 and FK2. 
 
* BOC Sciences, NY, USA 
† Kindly provided by Prof. Wei-Dong Zhang and Dr Shan Lei (Second Military Medical University, Shanghai, 
China) 
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Finally, erythro- and threo-guaiacylglycerol-8-O-4’(coniferyl alcohol) ether 
were chemically synthesized and assayed for bioactivity.* The synthesised compounds 
gave similar results to FK1 and FK2 in the bioassays, which confirmed the 
identification of FK1 and FK2 as the erythro- and threo-isomers of guaiacylglycerol-8-
O-4’(coniferyl alcohol) ether respectively. 
5.2.1 FK1 Chemical Shifts 
δ(1H, D20, 800 MHz) 6.88 (d, 4J=2.0 Hz, 1H, H-2), 6.74 (d, 3J=8.1 Hz, 1H, H-
5), 6.86 (dd, 3J= 8.1 Hz, 4J=1.9 Hz, 1H, H-6), 4.7 (overlapped m, 2H, H-7), 4.66 (m, 
1H, H-8), 4.07 (dd, 2J= 12.3 Hz, 3J= 2.8 Hz, 1H, H-9a), 3.94 (dd, 2J= 12.3 Hz, 3J= 6.7 
Hz, 1H, H-9b), 3.6824 (s, 3H, H3-10), 6.98 (bs, 1H, H-2’), 6.97 (overlapped s, 1H, H-
5’), 6.97 (overlapped s, 1H, H-6’), 6.56 (dt, 3J=16.0 Hz, 4J=1 Hz, 1H, H-7’), 6.31 (dt, 
3J=15.9 Hz, 3J=6.0 Hz, 1H, H-8’), 4.25 (dd, 3J=6.0 Hz, 4J=1.0 Hz, 2H, H2-9’), 3.7041 
(s, 3H, H3-10’) 
δ(13C, D2O, 201 MHz) 130.60 (C-1), 111.38 (C-2), 147.72 (C-3), 147.2 (C-4), 
115.42 (C-5), 121.13 (C-6), 72.54 (C-7), 83.56 (C-8), 61.52 (C-9), 55.69 (C-10), 
131.13 (C-1’), 109.78 (C-2’), 149.22 (C-3’), 146.94 (C-4’), 116.56 (C-5’), 119.45 (C-
6’), 130.61 (C-7’), 126.76 (C-8’), 62.29 (C-9’), 55.46 (C-10’) 
5.2.2 FK2 Chemical Shifts 
δ(1H, D20, 800 MHz) 6.94 (d, 4J=1.9 Hz, 1H, H-2), 6.85 (d, 3J=8.1 Hz, 1H, H-
5), 6.85 (overlapped dd, 3J= 8.1 Hz, 4J=1.7 Hz, 1H, H-6), 4.89 (d, 3J=5.5 Hz, 2H, H-7), 
4.61 (m, 1H, H-8), 3.59 (dd, 2J= 12.2 Hz, 3J= 6.0 Hz, 1H, H-9a), 3.77 (dd, 2J= 12.9 Hz, 
3J= 3.7 Hz, 1H, H-9b), 3.69 (s, 3H, H3-10 or 10’), 7.08 (d, 4J=1.8 Hz, 1H, H-2’), 6.87 
(d, 3J=8.64 Hz 1H, H-5’), 6.92 (dd, 3J=8.46 Hz, 4J=1.8 Hz 1H, H-6’), 6.59 (dt, 3J=15.9 
Hz, 4J=1.0 Hz, 1H, H-7’), 6.34 (dt, 3J=15.8 Hz, 3J=6.0 Hz, 1H, H-8’), 4.18 (dd, 3J=6.1 
Hz, 4J=1.2 Hz, 2H, H2-9’), 3.71 (s, 3H, H3-10’ or 10) 
δ(13C, D2O, 201 MHz) 110.75 (C-2), 115.48 (C-5), 119.59 (C-6), 72.43 (C-7), 
83.21 (C-8), 60.49 (C-9), 55.43 (C-10), 109.81 (C-2’), 115.42 (C-5’), 119.48 (C-6’), 
130.09 (C-7’), 126.70 (C-8’), 61.95 (C-9’), 55.43 (C-10’) 
  
 
* Chemical synthesis performed by J. Buckler (RSC, ANU) and Prof. M. Banwell (RSC, ANU) 
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5.3 Publication 
A journal article describing the complete project is currently in the late stages of 
drafting prior to submission hopefully in mid 2014. 
Kordbacheh, F.; Carruthers, T.; Buckler, J.; Bezos, A.; Hocart, C.; Banwell, 
M.; Parish, C.; Djordjevic, M. (in drafting – submission planned mid 2014) Promotion 
of Mammalian Angiogenesis by Neolignans Derived from Soybean Extracellular 
Fluids. 
5.4 Experimental Methodology 
NMR spectroscopy experiments were recorded on either a Bruker AVANCE 
800 or 600 MHz NMR spectrometer with TCI cryoprobe using D2O as the solvent at 
298 K. Spectra were analysed using Bruker TopSpin 2.1 software. 
1H NMR chemical shifts in parts per million (ppm) are reported using the HOD 
signal as an internal chemical shift reference (4.72 ppm at 298 K). 13C chemical shifts in 
ppm are referenced indirectly to the proton shift. 
1H. 1D proton NMR spectra were performed using a standard Bruker pulse 
program, zgpr, which included solvent suppression via pre-saturation. A total 
experiment time of 5 min was used with a t1max of 1.25 sec. 
1H-1H DQF-COSY.322 A phase-sensitive DQF-COSY spectrum was also 
measured using the standard Bruker sequence cosydfphpr, which includes a double-
quantum filter and pre-saturation. A total experiment time of 38 min was used with a 
t1max of 26 msec and a t2max of 104 msec. 
1H-1H TOCSY.323 A TOCSY spectrum was measured using the Bruker pulse 
program mlevphpp that was modified to include pre-saturation. A total experiment time 
of 19 min was used with a t1max of 13 ms, a t2max of 250 ms and a TOCSY mixing time 
of 60 ms. 
1H-1H NOESY.324,325 A NOESY spectrum was recorded using the Bruker pulse 
program noesygpphpp modified to include pre-saturation. A total experiment time of 
14.2 hours was used with a t1max of 39 ms, a t2max of 1.62 sec and a 500 msec NOE 
mixing time. 
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13C-1H HSQC.326-328 A 13C-HSQC spectrum was recorded using the standard 
Bruker pulse sequence hsqcedetgpsisp2.2. A t1max of 15.3 ms, a t2max of 152 ms and a 
total experiment time of 2.3 hrs was used. 
13C-1H HMBC.329 A 13C-HMBC spectrum was recorded using the standard 
Bruker pulse sequence hmbcetgpl2nd, which includes a two-fold low-pass J-filter to 
suppress one-bond correlations. A t1max of 10.1 ms, a t2max of 304 ms and a total 
experiment time of 8 hrs was used. 
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